# **BMJ** Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or payper-view fees (http://bmjopen.bmj.com).

If you have any questions on BMJ Open's open peer review process please email <a href="mailto:editorial.bmjopen@bmj.com">editorial.bmjopen@bmj.com</a>

# **BMJ Open**

Incidence of tuberculosis co-infection and its determinants among adult people living with HIV/AIDS at Afar Region government health facilities, northeast Ethiopia: A retrospective cohort study

Journal:	BMJ Open
Manuscript ID	bmjopen-2017-016961
Article Type:	Research
Date Submitted by the Author:	28-Mar-2017
Complete List of Authors:	Ahmed, Ausman; Jigjiga University, Department of Public health Mekonnen, Desalew; Addis Ababa University, Internal Medicine Yenit, Melaku; Melaku Kindie Department of Epidemiology and Biostatistics College of Medicine and Health Sciences Institute of Public Health, University of Gondar, Belayneh, Fanuel; Hawassa University Shiferaw, Atsede; University of Gondar, Department of Health Informatics
<b>Primary Subject Heading</b> :	Infectious diseases
Secondary Subject Heading:	HIV/AIDS
Keywords:	Incidence, TB, HIV/AIDS people, Northeast Ethiopia

SCHOLARONE™ Manuscripts

- 1 Incidence of tuberculosis co-infection and its determinants among adult people living with
- 2 HIV/AIDS at Afar Region government health facilities, northeast Ethiopia: A retrospective
- 3 cohort study
- 4 Ausman Ahmed<sup>1</sup>, Desalew Mekonnen<sup>2</sup>, Melaku Kindie Yenit<sup>3\*</sup>, Fanuel Belayneh<sup>4</sup>, Atsede
- 5 Mazengia Shiferaw<sup>5</sup>
- <sup>1</sup>Department of Public health, JigJiga University, JigJiga, Ethiopia
- 7 Department of Internal Medicine, Addis Ababa University, Ethiopia
- 8 <sup>3\*</sup>Department of Epidemiology and Biostatistics, University of Gondar, Gondar, Ethiopia
- <sup>4</sup>School of Public and Environmental Health, Hawassa University, Hawassa, Ethiopia
- <sup>5</sup>Department of Health Informatics, University of Gondar, Gondar, Ethiopia
- 12 Email addresses:
- 13 AA: soyra3362@yahoo.com
- 14 DM: <u>desalewm@yahoo.com</u>
- 15 MKY: <u>melaku98@gmail.com</u>
- 16 FB: <u>fanuelbelayneh@gmail.com</u>
- 17 AMS: <u>atsede.mazengia@yahoo.com</u>
- 19 \*Corresponding author
- 20 Melaku Kindie Yenit
- 21 Email: melaku98@gmail.com
- 22 Tell: +251-913002871
- 23 P.o.box: 196
- 24 University of Gondar

#### 1 Abstract

- 2 Background: Globally tuberculosis is the leading cause of death among people living with
- 3 HIV/AIDS, and most of the deaths occurred in resource limited countries. To be sure, data on the
- 4 incidence of tuberculosis is limited in Ethiopia.
- **Objective:** This study assessed the incidence of tuberculosis and its predictors among adults
- 6 living with HIV/AIDS in government health facilities of northeast Ethiopia.
- 7 Setting: A five year retrospective cohort study was conducted from May to June, 2015, on 451
- 8 adult HIV/AIDS infected individuals who enrolled in the chronic HIV Care Clinic of
- 9 Government health facilities of northeast Ethiopia.
- 10 Participants: A total of 451 HIV infected adults who newly enrolled in the chronic adult HIV
- care clinic, from July 1, 2010 with complete information were followed until May 2015.
- 12 Primary outcome measure: The primary outcome was the proportion of patients diagnosed
- with TB or TB incidence rate, which was measured using a retrospective cohort study
- **Results:** A total of 451 charts with complete information were followed for a total of 1377.41
- Person-Years (PY) of observation. The overall incidence density of tuberculosis was 8.6 per 100
- person-year observation. Previous TB disease (AHR=2.32, 95% CI=1.51-3.57), bedridden
- 17 (AHR=2.42, 95% CI = 1.05-5.59), and ambulatory functional status at the baseline (AHR=2.42,
- 18 95% CI=1.56-3.76), BMI<18.5kg/m<sup>2</sup> (AHR=1.62, 95 % CI =1.09-2.39), Not taking IPT
- 19 (AHR=6.96, 95% CI=2.53-19.08), and hemoglobin level below 10 g/dl (AHR= 2.54, 95%
- 20 CI=1.57-4.11) were determinants for the incidence of tuberculosis.
- 21 Conclusion: The incidence of TB disease among adults living with HIV/AIDS in the first and
- second years of follow-up was higher compared with subsequent years. Previous TB disease, not
- receiving IPT, low BMI, and low hemoglobin level and unable to work were found to be
- 24 determinants of the incidence of tuberculosis. Therefore, improving TB/HIV collaborative
- activities should be strengthened in the study setting.

# Strengths and limitations of this study

- The study which involved a five year follow up covered longer time than other similar studies and is expected to show the long term impact of HIV on TB.
- The study attempted to show the incidence of TB and its predictors among PLHIV using a five-year retrospective data
- The retrospective nature of the method prevented the inclusion of all possible factors that affect the incidence of tuberculosis.
- Some participants whose data were incomplete were excluded from the study because if such patients had TB they would undermine the findings of the study.
- Variables such as housing condition and household income were some of the plausible factors that were not measured in this study.

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright

Culture confirmation was not performed during the study period.

#### Introduction

TB is an infectious disease caused by the bacillus Mycobacterium tuberculosis. It typically affects the lungs (pulmonary TB), but it can also affect other sites (extra pulmonary TB). It has remained the major health problem globally. In 2015, TB was one of the top 10 causes of death worldwide and a leading cause of death among HIV positive people, ranking above HIV/AIDS as one of the leading causes of death from infectious diseases[1]. Out of the 1.4 million TB-caused deaths reported in 2015, 0.4 million occurred to HIV positive TB patients. Globally it was estimated that there were 10.4 million TB cases, including 1.2 million among HIV positive people[1]. Globally, nearly 78 million people have contracted HIV infection since the beginning of the HIV pandemic, and close to 39 million have died of AIDS related causes. Among these, TB was responsible for twenty-five percent of the deaths[2]. According to the WHO 2014 report, there were an estimated 1.1 million cases of TB co-infected with HIV[3], where the majority (90%) of the TB-HIV co-infected people were living in resource limited setting; like Ethiopia [4-6]. In the African region that has the highest TB/HIV burden, three-out of four TB patients knew their HIV status, and 70% of the TB patients known to be living with HIV in 2013 were started on antiretroviral therapy (ART). Sub-Saharan Africa is among the regions highly hit by the HIV epidemic and covers more than three-fourths (79%) of the burden of TB-HIV co-infections[7]. 

In Ethiopia, TB remains one of the leading causes of mortality and the third cause of hospital admission. In the last ten years, the number of new cases has increased from 55,000 to 100,000, and the increase in the number of tuberculosis cases is due to the rapid spread of HIV infection. According to the 2011 Ethiopian Demographic and Health Survey (EDHS) report, the prevalence of HIV in Ethiopia was 1.5%, and in Afar Region, where the study was conducted, it was 1.8%. Similarly, it was reported that the prevalence of TB was 211 per 100,000 of the population[8], and the global TB report indicated that Ethiopia ranked 10<sup>th</sup> among 22 TB high burden countries. Moreover, Ethiopia is one of the high TB/HIV burden countries, and the prevalence of TB/HIV co-infection was 15% in 2012[6, 7]. TB/HIV co-infection in the country is associated with diagnostic and therapeutic challenges and constitutes an immense burden in the health care system. The dual epidemics have drained resources and overburdened the limited health workforce[9]. Considering this challenge, the Ministry of Health designed a strategy to increase the

- 1 percentage of TB patients tested for HIV and vice versa. As a result, the percentage of TB
- 2 patients tested for HIV increased from 16 percent in 2007 to 92 percent in 2012, and the
- 3 proportion of HIV patients screened for TB from 25 percent in 2007 to 92 percent in 2012[10]
- 4 Though HIV increases the risk of developing TB, it is not the only determinant for developing
- 5 TB. Various reports indicated that socio-demographic[11, 12], clinical[13, 14], life style[14, 15]
- and environmental[16] factors were some of the determinants of the incidence of TB infection
- 7 among HIV positive individuals. Among the clinical factors, low CD4 count [17-21], low
- 8 hemoglobin level, diabetes and other opportunistic infections, and functional status showed
- 9 significant associations with the incidence of TB [20, 22-24]. However, IPT, ART, and CPT
- treatments reduce the risk of TB infection among HIV positive individuals [23, 25, 26]. In
- resource limited countries, such as Ethiopia, where there is poor access to health care, there are
- very few studies on the determinants of the incidence of TB among HIV infected people.
- 13 Therefore, this study assessed the incidence of active TB disease and its determinants among

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright

14 HIV positive people in northeast Ethiopia.

#### Methods

#### Study design and setting

- 17 A five year retrospective cohort study was conducted on HIV positive patients attending the
- 18 chronic HIV care clinics from July 2010 to June 2011, in selected government health facilities of
- 19 the Afar Regional State, northeast Ethiopia. The region is located in the north-eastern part of
- 20 Ethiopia and has a total population of 1,678,000, of whom only 289,000 live in urban and semi-
- 21 urban areas [27]. In the region, there are four hospitals, 40 health centers, and 15 private clinics
- providing health services. When HIV care service was first introduced to the region in 2006, 15
- 23 public health institutions were providing chronic HIV care and support to around more than
- 4,000 people living with HIV (PLHIV). Two health centers (Awash, and Samara) and three
- hospitals (Asayta, Abala, and Dubti General) were selected based on the availability of TB/HIV
- 26 clients. These health institutions were providing chronic HIV care and follow up for TB to about
- 27 85% of the patients living with HIV in the region.

# Study population and eligibility criteria

- 2 All HIV/AIDS patients who were 15 years and above and newly enrolled into HIV care in
- 3 selected government health facilities of Afar Region from July 2010 to June 2011 were the
- 4 population under study. These individuals, who enrolled into HIV care from July 2010 to June,
- 5 2011 were followed for five years, until May 2015. Consequently, a total of 503 people living
- 6 with HIV were registered during the period. Individuals with incomplete information, like
- 7 missing the date of enrollment and follow-up data, were excluded from the study. However,
- 8 individuals that were deleted for analysis were compared to the study groups and showed no
- 9 significant baseline demographic characteristics. In addition, those who died or were lost to
- 10 follow-up were considered as censored

# Measurements and study variables

The outcome variable in this study was the incidence rate of TB co-infection among HIV positive patients. An event of an incidence of TB in this study was considered as any form of TB that was not only diagnosed clinically or radio-graphically but also confirmed by laboratory examinations or by patients who have empirically started anti-TB treatment even after enrollment. TB was diagnosed using microscopic examinations of three sputum samples, chest xray, and fine needle aspiration of lymphadenopathy. Culture confirmation was not available in the study areas during the study period. When an individual became diagnosed with active TB, treatment was given based on the National TB Program, which WAS 8 months of treatment (currently 6 months). HIV positive individuals who were lost to follow-up, transferred, died, and who were not diagnosed for TB until the end of the follow-up period were considered as censored. Study variables, including socio-demographic and economic characteristics, such as age, sex, educational status, employment status, residence, religion, family size, marital status, and clinical characteristics, such as WHO clinical stage, baseline CD4 count, functional status, and history of TB, BMI, and hemoglobin level were reviewed. Functional status was measured at baseline, and a person was categorized as working if "he/she was able to perform usual work in or out of the house", ambulatory if "he/she was unable to perform work but able to perform activities of daily living" and bedridden if "he/she was not able to perform activities of daily living". CPT prophylaxis in this study was defined as a patient who took cotrimaxazole for longer than one month for a prophylaxis purpose. Substance use in this study was

- 1 considered as any substance used by the patient that is recorded on in-take form of the patient
- 2 chart.

# 3 Sample size and sampling procedure

- 4 All HIV/AIDS patients who were 15 years and above and enrolled newly into HIV care from
- 5 July 2010 to June 2011were the population under study. Sample size was calculated using the
- 6 single proportion formula, considering the following assumptions: 17% prevalence of TB among
- 7 HIV positive people in Jimma, Ethiopia[28], 95% level of confidence, 3.5 margin of error, and
- 8 3.3% expected incomplete record. Finally, the minimum sample size of 458 was obtained. Thus,
- 9 there were 503 PLHIV registered in the selected health facilities of chronic HIV care clinics, all
- of the 503 records were included in the study.
- In Afar Region, where the study was conducted, there are four hospitals, 40 health centers, and
- 15 private clinics providing health services to the community. Out of these health facilities, two
- health centers (Awash and Samara), and three hospitals (Asayta, Abala and Dubti General) were
- selected based on client flow and availability of TB and HIV follow-up services. In these
- selected health facilities, 503 HIV positive people were newly registered from July 2010 to June

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright.

- 16 2011. However, people living with HIV and registered in health facilities from July 2010 to June
- 17 2011 and had complete information were followed until May, 2015.

#### 18 Data collection tool and procedure

- Data were collected through chart reviewing, using the patient chart data extraction format by
- 20 nurses who took training on ART. All records of HIV/AIDS patients between July 2010 and
- 21 May 2015 were considered. Charts were retrieved by using patient medical record number and
- 22 ART registration numbers found on the database of the selected health facilities. Forms used for
- laboratory request, TB records, ART intake, and patient cards were reviewed. Data quality was
- 24 assured by using a pretested questionnaire and trained data collectors. Data completeness and
- consistency was checked by supervisors. The data clerk and case managers assisted the data
- 26 collectors by identifying charts.

## 27 Data Processing and Analysis

- 28 Extracted data were checked for completeness, coded, and entered into EPI-INFO version 7 and
- 29 exported to SPSS version 20 for further analysis. Statistical summary measures and incidence
- density were calculated. Magnitude was calculated and described by frequencies and tables.
- 31 Incidence density rate was calculated for the study period. Life table and log rank test was used

- 1 to estimate TB free survival among study participants and to compare different categories of
- 2 survival probability respectively. Time-to-event data that the study considered and survival
- 3 analysis were carried out, the cox proportional hazards model was fitted, and a life table was
- 4 used to estimate cumulative probabilities. Bi-variable and multivariate cox regression model was
- 5 used to identify the predictors of the incidence of TB. Variables with p-value less than 0.2 in the
- 6 bi-variable analysis were considered for the multivariate cox proportional hazard model. A 95%
- 7 confidence interval of hazard ratio (HR) was computed and variables having p-values less than
- 8 0.05 in the multivariate cox proportional hazards model were taken as significant predictors for
- 9 the outcome variable. Moreover, basic assumptions of cox proportional hazard model were
- 10 checked using the Schoenfield residuals test.

## 11 Ethical consideration

- 12 Ethical clearance was obtained from the Institutional Review Board (IRB) of the Institute of
- Public Health, the University of Gondar. A letter of permission was obtained from the Afar
- 14 Regional Health Bueuro (ARHO), and a written permission letter was sent to each selected
- health facilities. In addition, confidentiality was maintained by using only unique identification
- 16 codes rather than patient names and identifications.

# Results

#### Socio-demographic characteristics of PLHIV

- A total of 451 records of PLHIV who were enrolled at health facilities from July 1, 2010 to June
- 30, 2011 were reviewed and followed until 2015. A total of 451 HIV/AIDS patient charts with
- 21 complete information were analyzed in the study, while 24 charts were not included in the
- 22 analysis because they did not contain complete information. Out of the 451 patients that
- remained in the analysis, more than half, 267(59.2%), were females, and more than two-thirds,
- 24 297 (65.9%) were below the age of 35 years. The mean age (+SD) of the patients was
- 25 32.55(+7.48) years. Most of the respondents, 410 (90.9%), were urban residents, and 275
- 26 (61.0%) were Muslims (**Table 1**).
- 27 Almost half, 234(51.9%), of the participants were self-employed. Of the 130 (28.8%) patients
- recorded as substance users, 14 (5.0%) were tobacco users, 26 (20.0%) alcohol consumers, and
- 29 90 (75.0%) were using both of these. Only 76 (16.9%) of the patients had more than 5 family

- 1 members. Almost half, 212(47%), of the subjects never went to formal school. More than two-
- 2 thirds (68.1%) of the patients were currently or formerly married (**Table 1**).
- Table 1: Baseline characteristics of PLHIV who were enrolled for chronic HIV care at selected government health facilities in Afar Regional State, northeast Ethiopia from 2010-
- **2011**

Characteristics	Frequency	Percent (%)
Age (years)		
15-25	55	12.2
26-34	242	53.7
35-44	119	26.3
<u>≥</u> 45	35	7.8
Sex		
Male	184	40.8
Female	267	59.2
Marital status		
Single	144	31.9
Married	200	44.3
Divorced	77	17.1
Widowed	30	6.7
Residence		
Urban	410	90.9
Rural	41	9.1
Religion		
Muslim	275	61.0
Orthodox	165	36.6
Others	11	2.4
<b>Educational status</b>		
illiterate	212	47.0
Primary school	177	39.2
Above secondary	62	13.8
Family size		
1-3	216	47.9
4-5	159	35.3
>5	76	16.8
Occupation		
Self-employed	234	51.9
Governmental employed	45	10.0
Non-employed	172	38.1
Substance use		
Yes	130	28.8
No	321	71.2
Type of substance used		
Tobacco	14	5.0
Alcohol	26	20.0
Both tobacco and alcohol	90	75.0

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright.

#### Clinical characteristics of PLHIV

Out of the total 451 study participants with complete information for analysis, more than half (53.4%) had a baseline WHO clinical stage III and IV. The majority, 366 (81.2%), of the participants were enrolled with working functional status. The baseline median CD4 cell count was 285cell/µl with IQR of 178-383 ell/µl at the time of enrollment. Almost half, 218 (48.3%), of the participants were enrolled with BMI less than18.5 kg/m2, whereas more than half, 270(59.9%), of the study subjects had a baseline hemoglobin level below 12.5g/dl. During the five year retrospective follow up, most, 413(91.8%), of the participants were provided with CPT treatment, while only 94(20.8%) received IPT. Similarly, more than one-third (40.6% and 37%, respectively) of the respondents were initiated into ART therapy based on the patients' WHO clinical stage and CD4 cell count. More than one-third (37.7%) of the HIV/AIDS positive people took a combination of TDF, 3TC and EFV; likewise, one-fifth, 110(24.4%), of the patients took AZT, 3TC, and EFV. Another one-fifth, 96 (21.3%), of the patients changed their initial regimen, 92 due to substitution, 4 due to switching to second line treatment for HIV. Out of the 96 HIV/AIDS patients who changed their initial regimen, side effect and the development of TB were the major reasons for 50(52.08%) and 29(30.2%), respectively.(**Table 2**).

Table 2: Clinical characteristics of PLHIV on chronic HIV care at selected government health facilities of Afar Regional State, July 2010 to May 2015

variables	Frequency	Percent (%)
On ART		
Yes	215	47.7
No	236	52.3
WHO clinical stage		
I	62	14.1
II	138	31.3
III	172	39.0
IV	69	15.6
Functional status at baseline		
Working	366	81.2
Ambulatory	74	16.4
Bedridden	11	2.4
CD4 cell count (cell/ul)		
<100	44	9.8
100-200	124	27.5
201-349	125	27.7
>350	158	35.0
BMI (kg/m2)		
<18.5	218	51.7
≥18.5	203	48.3

Hgb level (g/dl)		
<12.5	270	59.8
<u>≥</u> 12.5	181	40.2
CPT use		
Yes	413	91.6
No	38	8.4
IPT use		
Yes	94	20.8
No	357	79.2
Initial regimen		
d4t-3TC-NVP	65	14.4
AZT-3TC-EFV	89	19.7
AZT-3TC-NVP	110	24.4
TDF-3TC-EFV	170	37.7
Others	17	3.8
History of TB		
Yes	74	16.4
No	377	83.6
Opportunistic infection (OI)		
Yes	34	7.5
No	417	92.5
Chronic illness		
Yes	35	7.8
No	416	92.2
Regimen change		
To First line	92	20.4
To Second line	4	0.9
Not changed	355	78.7
Reason for change		
Due to TB development	29	30.2
Due to side effect	50	52.1
Failure of treatment	4	4.2
Others	13	13.5
	ness index: CDA Cluster of differen	etiation: CDT_Catrimovazal

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright.

- AZT, Zidovudine; BMI, Body mass index; CD4, Cluster of differentiation; CPT, Cotrimoxazole
- 2 Preventive Therapy; D4T, Stavudine; EFV, Efaverenze; Hgb, Hemoglobin; IPT, Izonized
- 3 preventive therapy; NVP, Neverapine; OI, Opportunistic Infection; TB, Tuberculosis; TDF,
- 4 Tenofevir; 3TC, Lamavudine; WHO, World Health Organization

# The incidence of TB among PLHIV

- 7 Out of the total 451 HIV/AIDS patients, 119 (26.4%) developed active TB infection during the
- 8 follow-up period, while 332 were censored (40 patients were transferred out; 13 died; 21
- 9 dropped out, and 258 remained till the end of follow up.) Therefore, the overall TB incidence
- rate in the five year retrospective data was 8.64 cases per 100 Person-years of observation. The
- incidence of patients diagnosed with TB at the end of one year was 4.9 per 100 person-year

observation. The cumulative proportions of patients diagnosed with TB at the end of one year, two, three, and four years was 77%, 68.4%, 34.4% and 10.1%, respectively. The sum of the whole follow-up period for all 451 HIV / AIDS infected individuals was 1377.3 Person-years of observation. The minimum and maximum follow-up observation was 0.03 and 58.8 months, respectively. The median (IQR) follow-up period was 46.74 months of observation [IQR=15.95-52.42 months]. The median survival time was 54 months. Females constituted more than half, 67 (56.3%) of the total TB disease. Three-fourths, 91 (76.47%), of the cases were pulmonary TB. The majority, 114(96%) of the TB incidents occurred in the first one year of follow-up; 46 (38.6%) of the TB incidents within the first month of follow up, and 68 (57.14%) within the first year of follow up. The incidence of TB was 105 and 14 among urban and rural dwellers, respectively. The test of equality for survival distribution for different levels of different categories was performed with Kaplan Meier, using the long rank test. The association of differences was observed among the explanatory variables, like BMI and IPT. Baseline BMI had a significant difference for tuberculosis free survival. BMI <18.5 kg/m<sup>2</sup> had low TB free survival compared to those with BMI >18.5 kg/m<sup>2</sup> with the overall comparison result long rank of pvalue p<0.002 and for the IPT was p<0.0001 which shows a significant difference of TB free survival among patients provided with IPT (Figure 2 & 3). Out of the participants who developed TB, 41(34.5%) had history of TB, and 47(39.5%) were either ambulatory or bedridden at enrollment. One hundred fifteen (96.6%) of TB cases were not provided with INH prophylactic therapy. Ninety-five (79.9%) participants with incident cases of TB were enrolled with Hgb level below12.5g/dl.

Table 3: The incidence of tuberculosis stratified by socio-demographic characteristics of PLHIV on HIV chronic care at selected government health facilities of Afar Regional State,

**July 2010 to May 2015** 

Characteristics	Total	TB incidence	Person-Years observation
X7 00 11	N (%)	N (%)	(PY)
Years of follow-up	00(10.5)	(0(==4)	2.5.0
One year	88(19.5)	68(57.1)	35.07
Two years	41(9.0)	28(23.5)	54.73
Three years	32(7.0)	11(9.3)	76.66
Forth	89(19.8)	9(7.6)	322.67
Fifth	201(44.6)	3(2.5)	888.28
Age (years)			
15-25	55(12.2)	14(11.7)	158.81
26-34	242(53.7)	63(52.9)	739.05
35-44	119(26.3)	30(25.3)	384.1
≥45	35(7.8)	12(10.1)	95.45
Sex			
Male	184(40.8)	52(43.7)	536.9
Female	267(59.2)	67(56.3)	840.51
Residence	· (V	,	
Urban	410(90.9)	105(88.2)	1260.67
Rural	41(9.1)	14(11.8)	116.74
Marital status	, ,		
Single	144(31.9)	30(25.2)	435.14
Married	200(44.3)	52(43.7)	616.07
Divorced	77(17.1)	30(25.2)	184.5
Widowed	30(6.7)	7(7.9)	91.61
Educational status		,(,,,,,	71.01
Illiterate	212(47.0)	55(46.2)	683.8
Primary School	177(39.3)	49 (41.2)	510.54
Secondary and above	62(13.7)	15(12.6)	183.07
<b>Occupation</b>	-()	10(12.0)	165.67
Self-employed	234(51.8)	59(49.6)	741.68
Government-employed	45(10.1)	9(7.6)	121.45
Non- employment	172(38.1)	51(42.8)	514.28
Religion	172(30.1)	31(42.0)	314.20
Muslim	275(61.0)	70(58.8)	826.69
Orthodox	165(36.6)	47(39.5)	520.89
Others	11(2.4)	2(1.7)	29.83
Family size	11(2.4)	2(1.7)	29.63
1-3	216(47.9)	51(42.0)	668.68
4-5	159(35.3)	51(42.9)	484.74
<b>4-</b> 3 >5	` /	43(36.1)	
	76(16.8)	25(21.0)	223.99
Substance use	120(20.0)	12(25.2)	270.7
Yes	130(28.8)	42(35.3)	379.7
No	321(71.2)	77(64.7)	997.71

- 1 Table 4: the incidence of tuberculosis stratified by clinical characteristics of PLHIV on
- 2 chronic HIV care at selected government health facilities of Afar Regional State, July 2010
- 3 to May 2015

variables	Total	TB incidence	Person -year
	N (%)	N (%)	observation (PY)
History of TB	,	. ,	
Yes	74(16.4)	41(34.5)	164.74
No	377(83.6)	78(65.5)	1212.67
Opportunistic infection (OI)	•	, ,	
Yes	34(7.5)	19(16)	85.28
No	417(92.5)	100(84)	1292.13
Chronic illness			
Yes	35(7.8)	11(9.2)	106.28
No	416(92.2)	108(90.8)	1271.13
Functional status at baseline			
Working	366(81.1)	72(60.5)	1210.84
Ambulatory	74(16.4)	39(32.8)	145.92
Bedridden	11(2.4)	8(6.7)	20.65
$BMI (kg/m^2)$			
<18.5	218(48.3)	75(64)	626.46
≥18.5	203(45.0)	42(36)	750.95
Hgb level (g/dl)			
<12.5	270(60.0)	95(79.8)	731.63
≥12.5	181(40.0)	24(20.2)	645.78
CD4 cell count (cell/ul)			
<100	44(9.7)	22(18.5)	84.77
100-200	124(27.5)	40(33.6)	343.72
201-349	125(27.7)	29(24.4)	384.29
<u>≥</u> 350	158(35.0)	28(23.5)	564.63
On ART			
Yes	215 (47.7)	36 (30.3)	941.7
No	236(52.3)	83(69.7)	435.71
WHO clinical stage			
I	62(13.7)	7(6.0)	216.11
II	138(30.6)	29(24.4)	569.19
III	172(38.1)	59(49.6)	464.98
IV	69(15.3)	24(20.0)	187.13
Initial regimen			
d4t-3TC-NVP	65(14.4)	14(11.7)	223.56
AZT-3TC-EFV	89(19.7)	20(16.8)	296.28
AZT-3TC-NVP	110(24.4)	28(23.5)	349.17
TDF-3TC-EFV	170(37.7)	52(43.7)	461.71
Others	17(3.8)	5(4.3)	46.69
IPT use			
Yes	94(20.8)	4(3.4)	363.60
No	357(79.1)	115(96.6)	1013.81
CPT use	•		
Yes	413(91.6)	108(90.8)	1259.65
No	38(8.4)	11(9.2)	117.76

- 1 AZT, Zidovudine; BMI, Body mass index; CD4, Cluster of differentiation; CPT, Cotrimoxazole
- 2 Preventive Therapy; D4T, Stavudine; EFV, Efaverenze; Hgb, Hemoglobin; IPT, Izonized
- 3 preventive therapy; NVP, Neverapine; OI, Opportunistic Infection; TB, Tuberculosis; TDF,
- 4 Tenofevir; 3TC, Lamavudine; WHO, World Health Organization




Figure 1: TB free survival probability with BMI among PLHIV in Afar governmental health facilities, Northeast Ethiopia




Figure 2: TB free survival probability with IPT among PLHIV in Afar Governmental health facilities, Northeast Ethiopia

#### **Determinants of time to TB incidence**

2 In the bivariable cox regression analysis, baseline CD4 count, WHO clinical stage, substance

use, marital status, family size, opportunistic infection, history of TB, BMI, hemoglobin level,

and functional status were found to be the predictors for the incidence of tuberculosis at a p-

value of less than 0.2. Consequently, these variables were subjected to multivariate cox

regression analysis; finally history of TB, baseline functional status, baseline hemoglobin,

baseline BMI and IPT were found statistically significant determinants of TB free survival at a p-

value of less than 0.05.

9 Accordingly, the multivariate cox regression analysis indicated that people living with HIV

(PLHIV) and had history of TB were 2.32 times at higher risk of developing TB at any time

compared to PLHIV who had no history of TB (AHR=2.32, 95% CI: 1.51-3.57). PLHIV who

were at bed-ridden and ambulatory functional status at base-line were 2.42 times (each) at higher

risk of developing TB compared with PLHIV at working functional status (AHR=2.42, 95% CI:

1.05-5.59), and (AHR=2.42,95% CI:1.56-3.75), respectively. Similarly, PLHIV with baseline

BMI less than 18.5kg/m<sup>2</sup> were 1.62 times at higher risk of developing TB at any time compared

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright

with those with BMI greater than 18.5kg/m<sup>2</sup> (AHR=1.621, 95 % CI: 1.09-2.40). Individuals who

did not take Isoniazid prophylaxis therapy (IPT) were almost seven times at higher risk of

developing TB at any time compared to those who took IPT (AHR=6.96, 95% CI: 2.53-19.08).In

addition, PLHIV who were enrolled with baseline hemoglobin level (Hgb) less than 12.5 g/dl

were 2.54 times at higher risk of developing TB compared with those with Hgb level greater than

12.5 g/dl (AHR= 2.54, 95% CI: 1.57- 4.11) (Table-5).

Table 5: Cox regression analysis of the determinants of the incidence of tuberculosis among adult PLHIV on chronic HIV care at selected government health facilities of Afar Regional

State from July 2010 to May, 2015

Variables	Survival	status	Total	CHR(95%CI	) AHR(95%CI)**
	Event (TB)	Censored	<del>.</del>	•	,
Marital status					
Single	30	114	144	1.00	1.00
Married	52	148	200	0.94 (0.41-2.15)	1.16(0.69-1.94)
Divorce	30	47	77	1.15 (0.52-2.54)	1.31(0.76-2.28)
Widowed	7	23	30	1.90 (0.83-4.33)	1.55(0.63-3.79)
Family size				,	,
1-3	51	165	216	1.00	1.00
4-5	43	116	159	0.72 (0.83-1.16)	1.33(0.85-2.08)
>5	25	51	76	0.45(0.51-1.36)	1.54(0.90-2.63)
Substance use	23	<b>31</b>	70	0.15(0.51 1.50)	1.5 1(0.50 2.05)
Yes	42	88	130	1.37(0.95-2.01)	1.40(0.92-2.14)
No	77	244	321	1.00	1.40(0.92-2.14)
History of TB	, ,	277	<i>52</i> 1	1.00	1.00
Yes	41	33	74	3.47(2.38-5.07)	2.32(1.51-3.57)**
No	78	299	377	1.00	1.00
		299	311	1.00	1.00
<b>Opportunistic in</b> Yes	19	15	34	2.62(1.60,4.27)	1.27(0.72-2.23)
No E	100	317	417	1.00	1.00
Functional status		204	266	1.00	1.00
Working	72	294	366		1.00
Ambulatory	39	35	74	0.20(0.09-0.41)	2.42(1.56-3.76)**
Bedridden	8	3	11	0.74(0.34-1.57)	2.42(1.05-5.59)**
BMI (kg/m2)	7.5	1.40	210	1,00(1,04,0,60)	1 (0(1 00 0 00) ##
<18.5	75	143	218	1.80(1.24-2.63)	1.62(1.09-2.39)**
≥18.5	42	161	203	1.00	1.00
WHO clinical sta	_		60	1.00	1.00
I	7	55	62	1.00	1.00
II	29	119	138	0.28(0.12-0.65)	1.32(0.57-3.06)
III	59	113	172	0.49(0.29,0.84)	1.91(0.85-4.29)
IV	24	45	69	1.01(0.63-1.62)	1.91(0.78-4.65)
Hgb level (g/dl)					
<12.5	95	175	270	2.97(1.87-4.72	2.54(1.57-4.11)**
<u>≥</u> 12.5	24	157	181	1.00	1.00
CD4 count					
(cell/ul)					
<100	22	22	44	4.12(2.35-7.22)	1.33(0.68-2.61)
100-200	40	84	124	2.13(1.31-3.46)	1.56(0.89-2.73)
201-349	29	96	125	1.44(0.85-2.42)	0.93(0.53-1.62)
≥350	28	130	158	1.00	1.00
- IPT					
Yes	4	90	94	1.00	1.00
No	115	242	357	0.11(0.03-0.28)	6.96(2.53-19.08)**

<sup>4 \*\*</sup> Variable significant at p-value less than 0.05

- 1 AHR, Adjusted Hazard Ratio; BMI, Body mass index; CD4, Cluster of differentiation; CHR,
- 2 Crude Hazard Ratio; Hgb, Hemoglobin; IPT, Izonized preventive therapy; OI, Opportunistic
- 3 Infection; TB, Tuberculosis; WHO, World Health Organization

#### **Discussion**

5 TB and HIV remain the major public health problems in many parts of the world. Ethiopia is

- 6 among the TB high burden countries with an estimated annual incidence of 211cases per 100,000
- 7 people and a prevalence of 224 cases per 100,000 [29].TB is the most common cause of
- 8 morbidity and mortality among PLHIV. HIV infection increases the risk of TB, and it is
- 9 estimated that HIV infected individuals are 20-37 times at greater risk to developing TB in their
- 10 lifetime compared to non-infected individuals [30, 31].

- In this study, the overall incidence of TB among PLHIV was 8.64 cases per 100 person-year
- 13 (PY) observation. This finding is similar to findings reported from Gondar and Assela, Ethiopia,
- which is 7 cases and 7.9 cases per 100 PY observations [32, 33]. Similarly, the finding is

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright.

- consistent with that of a study in Tanzania and other Sub-Saharan countries which ranged from
- 7.6-8.2 per 100 PY [34, 35]. However, the incidence density of TB in this study is higher
- compared with those of studies conducted in Korea, Israel, and Malaysia [36-38]. The lower
- incidence of TB in the latter studies compared with this one might be due to the availability of
- 19 better preventive, diagnostic, and treatment setups and strategies for controlling TB in such
- 20 countries when compared with our study setting. In addition, low health care coverage, a high
- burden of HIV, and the fact that the study setting is unprivileged might explain the difference.
- Furthermore, late enrollment at health facilities due to late presentation of HIV infected people at
- health facilities increases the progression of latent infection to active TB after HIV chronic care.
- 24 It was noted that individuals with late presentation might get new infections or IRIS after
- 25 initiation into HAART, and IRIS related TB is commonly seen within the first six months of
- 26 initiation into HAART[39].
- 27 Out of the determinants of the incidence of TB infection in the multivariate cox regression
- analysis, the study revealed that history of TB, not using IPT, bedridden and ambulatory baseline
- 29 functional status, low hemoglobin level, and low BMI at baseline were found to be predictors of
- 30 the incidence of TB. Individuals who had history of TB had greater risk of developing TB

- 1 compared with those who had no history of TB treatment. Poor compliance for anti-TB treatment
- 2 at first episode, reactivation or re-infection of individuals with the existing diminished immunity
- 3 might be the reasons for higher incidence of TB among individuals with history of TB infection.
- 4 This finding is consistent with those of studies conducted in Uganda, Malaysia, and Israel [37,
- 5 38, 40].

- 6 PLHIV who did not take Isoniazid prophylaxis therapy (IPT) were found to be the predictors of
- 7 TB incidence. Individuals who did not take Isoniazid prophylaxis therapy (IPT) were almost
- 8 seven times at higher risk of acquiring TB at any time compared to those who took IPT
- 9 (AHR=6.96, 95% CI: 2.53-19.08). This might be due to the role of IPT in reducing the incidence
- of TB among people living with HIV. However, this fact, poor uptake, ambiguity, and fear of
- drug resistance might contribute to no-IPT use. The finding is consistent with those of studies in
- 12 Ethiopia, South Africa, and Brazil [41-43].
- Similarly, in this study, patients' functional status at baseline was found to be the predictor for
- TB incidence. Patients' ambulatory and bedridden functional status at baseline were 2.42 times
- at higher risk of developing TB compared with individuals with working functional status at
- baseline. This might be due to the fact that debilitated patients will be prone to malnutrition and
- lack of physical activity exposes them to many diseases, including TB. This finding is in line
- with those of other studies conducted in northwest Ethiopia [32].
- Out of the anthropometric variables, HIV patients with Body Mass Index (BMI) <18.5 kg/m<sup>2</sup> at
- 20 baseline were 1.62 times at higher risk of developing TB compared to individuals with
- 21 BMI≥18.5 kg/m<sup>2</sup> at base line. This finding was consistent with that of a study done in
- Tanzania[44], Ethiopia, and South Africa [34, 45]. The possible explanations might be that a low
- 23 BMI category is a proxy indicator for malnutrition, and malnutrition in HIV patients is
- associated with increased catabolic activity, infection, loss of appetite, and decreased intake,
- 25 which further increase the risk of developing opportunistic infections, such as tuberculosis.
- Similarly, this study found that patients with Hgb level of <10 and 10-12.5 at base-line were 2.00
- 27 and 2.54 times at higher risk of developing TB than those with Hgb level >12.5 at base-line.
- 28 Hematologic complications were risk factors for the incidence of TB among PLHIV. This
- 29 finding is in line with those of studies conducted in Ethiopia, Uganda, Tanzania, and South

- 1 Africa [44-47]. The Possible explanation might be malnutrition, side effects of medications,
- 2 opportunistic infections, and advanced stage of the disease. Undiagnosed TB could explain low
- 3 Hgb level at early enrollment. Variables like CD4 cell count and WHO clinical stage were not
- 4 independently associated in this study.

## Limitation of the study

- 6 Though the study did its best to indicate the incidence and predictors of tuberculosis among
- 7 PLHIV using a five-year retrospective data, it is not free from limitations. The retrospective
- 8 nature of the study limited the inclusion of all possible factors that could affect the incidence of
- 9 tuberculosis. Variables such as housing condition and household income were some of the
- 10 plausible factors that were not measured in this study.

#### Conclusion

- The overall incidence of TB among PLHIV was found to be comparable with similar studies in
- Ethiopia. However, it was higher in the first year of follow-up. HIV infected individuals with
- history of TB, not using IPT, base-line BMI<18.5kg/m<sup>2</sup>, ambulatory and bedridden functional

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright

- status, and having baseline Hgb<12.5g/dl were the determinants of the incidence of TB among
- 16 PLHIV. Therefore, attention to PLHIV and prompt diagnosis and treatment of TB is
- 17 recommended. Furthermore, prospective studies need to include all factors that influence the risk
- of TB among PLHIV.

#### List of abbreviations

- 20 AHR, Adjusted hazard ratio; AIDS, Acquired immune deficiency syndrome; ART, Anti-
- 21 Retroviral Therapy; BMI, Body mass index; CD4, cluster differentiation; CI, Confidence
- 22 interval; CPT, Cotrimoxazole prophylaxis therapy; EDHS, Ethiopian Demographic health
- survey; HIV, Human immune deficiency; HAART, Highly active anti retro viral therapy; Hgb,
- 24 Hemoglobin; INH, Isoniazid; IQR, Inter quartile range; IPT, Isoniazid prophylaxis therapy; IRIS,
- 25 Immune reconstitution inflammatory syndrome; PLHIV/AIDS, People living with HIV/AIDS;
- 26 PY, person-year observation; TB, tuberculosis; WHO, World health organization

## 27 Competing interests

The authors declare that they have no conflict of interest.

# 1 Funding

2 No specific fund was obtained for this study

# 3 Data sharing statement

4 All data supporting our findings will be shared up on the request.

#### 5 Authors' contributions

- 6 AA, DM and MKY involved in the conception, design, data collection, analysis and report
- 7 writing. DM, AMS, FB, and MKY assisted with the design, approved the proposal with some
- 8 revisions, participated in data analysis and manuscript preparation. All authors read and
- 9 approved the final manuscript.

# 11 Acknowledgement

- We would like to extend our thanks to Afar Regional Health Beauro for permission to conduct
- the study and providing the necessary preliminary information during the study. We are indebted
- to data collectors and supervisors without whom this project wouldn't have gone so far.
- 15 .

#### References

- 18 1. WHO: Global tuberculosis report 2016. 2016.
- 19 2. HIV/AIDS JUNPo: **World AIDS Day 2014 Report-Fact sheet**. *Geneva, Switzerland* 2014.
- 21 3. WHO: **Global tuberculosis report 2013**: World Health Organization; 2013.
- 4. WHO: **Global tuberculosis control 2009**: World Health Organization; 2009.
- WHO: Global tuberculosis control 2009: epidemiology, strategy, financing. Geneva, Switzerland: World Health Organization, 2009. In.; 2011.
- Zumla A, George A, Sharma V, Herbert RHN, of Ilton BM, Oxley A, Oliver M: The
   WHO 2014 global tuberculosis report—further to go. The Lancet Global Health 2015,
   3(1):e10-e12.
- 7. Organization WH: **Global tuberculosis report 2013. Geneva: WHO; 2013.** See

  http://apps who int/iris/bitstream/10665/91355/1/9789241564656\_eng pdf) and also

  (http://www who int/tb/publications/global\_report/gtbr13\_annex\_4\_key\_indicators pdf

  2014.
- 32 8. Demographic E: **Health Survey (2011) Addis Ababa**. Ethiopia and Calverton, Maryland, USA: Central Statistical Agency and ICF International 2012.
- Pawlowski A, Jansson M, Sköld M, Rottenberg ME, Källenius G: Tuberculosis and HIV co-infection. *PLoS Pathog* 2012, 8(2):e1002464.
- Health EMo: Ethiopian Federal Ministry of Health/Ethiopian Health & Nutrition Research Institute National. TB/HIV surveillance report. 2012.

- 11. Batista JdAL, Maruza M, de Alencar Ximenes RA, Santos ML, Montarroyos UR, de Barros Miranda-Filho D, Lacerda HR, Rodrigues LC: Incidence and risk factors for tuberculosis in people living with HIV: cohort from HIV referral health centers in **Recife, Brazil**. *PloS one* 2013, **8**(5):e63916.
  - 12. Jagodziński J, Zielonka TM, Błachnio M: Socio-economic status and duration of TB symptoms in males treated at the Mazovian Treatment Centre of Tuberculosis and Lung Diseases in Otwock. Pneumonol Alergol Pol 2012, 80(6):533-540.
  - 13. Wilkinson D: Drugs for preventing tuberculosis in HIV infected persons. The Cochrane Library 2000.
- 14. Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, Sterling TR, Chaisson RE, Williams BG, Harries AD: Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012, (7):e1001270.
- 15. Alvi A, Rizwan M, Sunosi RA, Jerah ABA: Does khat chewing increases the risk of Mycobacterium tuberculosis infection by macrophage immune modulation? Medical hypotheses 2014, 82(6):667-669.
- 16. Kibret KT, Yalew AW, Belaineh BG, Asres MM: Determinant factors associated with occurrence of tuberculosis among adult people living with HIV after antiretroviral treatment initiation in Addis Ababa, Ethiopia: a case control study. *PloS one* 2013, (5):e64488.
- Amoakwa K, Martinson NA, Moulton LH, Barnes GL, Msandiwa R, Chaisson RE: Risk 17. Factors for Developing Active Tuberculosis After the Treatment of Latent Tuberculosis in Adults Infected With Human Immunodeficiency Virus. In: Open forum infectious diseases: 2015: Oxford University Press; 2015: ofu120.
  - 18. Bendayan D, Littman K, Polansky V: Active tuberculosis and human immunodeficiency virus co-infection in Israel: a retrospective study. The Israel Medical Association journal: IMAJ 2010, 12(2):100-103.
  - 19. Hwang J-H, Choe PG, Kim NH, Bang JH, Song K-H, Park WB, Kim ES, Park SW, Kim H-B, Kim NJ: Incidence and risk factors of tuberculosis in patients with human immunodeficiency virus infection. Journal of Korean medical science 2013, 28(3):374-377.
- 20. Méda ZC. Sombié I. Sanon OW. Maré D. Morisky DE. Chen Y-MA: Risk factors of tuberculosis infection among HIV/AIDS patients in Burkina Faso. AIDS research and human retroviruses 2013, **29**(7):1045-1055.
- 21. Metcalfe JZ, Porco TC, Westenhouse J, Damesyn M, Facer M, Hill J, Xia Q, Watt JP, Hopewell PC, Flood J: Tuberculosis and HIV co-infection, California, USA, 1993-. Emerg Infect Dis 2013, **19**(3):400-406.
- 22. Ibrahim J: Tuberculosis: an eight year (2000-2007) retrospective study at the University of Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia. Southeast *Asian Journal of Tropical Medicine and Public Healt* 2010, **41**(2).
- 23. Maro I, Lahey T, MacKenzie T, Mtei L, Bakari M, Matee M, Pallangyo K, von Reyn C: Low BMI and falling BMI predict HIV-associated tuberculosis: a prospective study in Tanzania. The International Journal of Tuberculosis and Lung Disease 2010, (11):1447-1453.

- Nantha YS: Influence of diabetes mellitus and risk factors in activating latent tuberculosis infection: A case for targeted screening in Malaysia. Med J Malaysia 2012, 67(5):467-472.
- Assebe LF, Reda HL, Wubeneh AD, Lerebo WT, Lambert SM: The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study. BMC public health 2015, 15(1):1.
- Okwera A, Mafigiri DK, Guwatudde D, Whalen C, Joloba M: Level of understanding of co-trimoxazole use among HIV infected, recurrent pulmonary tuberculosis suspects at a national referral tuberculosis clinic in Kampala, Uganda: a qualitative analysis. African health sciences 2015, 15(1):49-57.
- 12 27. ECSA: Report of Centeral statistical agency., 2014.
- 13 28. Gudina EK, Gudissa FG: Prevalence of tuberculosis in HIV in Ethiopia in early HAART era: Retrospective analysis. The Pan African medical journal 2013, 14.
- 15 29. WHO: WHO Global TB report 2014.

- Getahun H, Gunneberg C, Granich R, Nunn P: **HIV infection-associated tuberculosis:** the epidemiology and the response. Clin Infect Dis 2010, **50 Suppl 3**:S201-207.
- 18 31. FMOH: Guideline for clinical and programatic management of TB ,TB/HIV and Leprosy in Ethiopia manual. In.; 2013.
- 20 32. Addis Alene K, Nega A, Wasie Taye B: Incidence and predictors of tuberculosis 21 among adult people living with human immunodeficiency virus at the University of 22 Gondar Referral Hospital, Northwest Ethiopia. BMC Infect Dis 2013, 13:292.
- Abebe A, et al.: Assessing the Effect of Highly Active Anti-Retroviral Treatment and Associated Factors on Incidence of Tuberculosis among Adult HIV Positive Individuals in Assela, Ethiopia. Health Medical and informatics 2014, 5(3):p. 5.
- 26 34. Liu E, Makubi A, Drain P, Spiegelman D, Sando D, Li N, Chalamilla G, Sudfeld CR,
   27 Hertzmark E, Fawzi WW: Tuberculosis incidence rate and risk factors among HIV 28 infected adults with access to antiretroviral therapy. Aids 2015.
- Haraka F, Glass TR, Sikalengo G, Gamell A, Ntamatungiro A, Hatz C, Tanner M, Furrer H, Battegay M, Letang E: A Bundle of Services Increased Ascertainment of Tuberculosis among HIV-Infected Individuals Enrolled in a HIV Cohort in Rural Sub-Saharan Africa. PLoS One 2015, 10(4):e0123275.
- 36. Hwang JH, Choe PG, Kim NH, Bang JH, Song KH, Park WB, Kim ES, Park SW, Kim HB, Kim NJ *et al*: **Incidence and risk factors of tuberculosis in patients with human immunodeficiency virus infection**. *J Korean Med Sci* 2013, **28**(3):374-377.
- 37. Syed Suleiman SA, Ishaq Aweis DM, Mohamed AJ, Razakmuttalif A, Moussa MA: Role of diabetes in the prognosis and therapeutic outcome of tuberculosis. *Int J Endocrinol* 2012, **2012**:645362.
- 39 38. Mor Z, Lidji M, Cedar N, Grotto I, Chemtob D: **Tuberculosis Incidence in HIV/AIDS**40 **Patients in Israel, 1983–2010**. *PLoS One* 2013, **8**(11).
- Namale PE, Abdullahi LH, Fine S, Kamkuemah M, Wilkinson RJ, Meintjes G:

  Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis.

  Future Microbiol 2015, 10:1077-1099.
- 40. Amuha MG, Kutyabami P, Kitutu FE, Odoi-Adome R, Kalyango JN: **Non-adherence to**45 **anti-TB drugs among TB/HIV co-infected patients in Mbarara Hospital Uganda:**46 **prevalence and associated factors**. *Afr Health Sci* 2009, **9 Suppl** 1:S8-15.

- 41. Assebe LF, Reda HL, Wubeneh AD, Lerebo WT, Lambert SM: The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study. BMC Public Health 2015, 15:346.

  5 42. Dowdy DW, Golub JE, Saraceni V, Moulton LH, Cayalcante SC, Cohn S, Pacheco AG.
  - 42. Dowdy DW, Golub JE, Saraceni V, Moulton LH, Cavalcante SC, Cohn S, Pacheco AG, Chaisson RE, Durovni B: Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model. *J Acquir Immune Defic Syndr* 2014, 66(5):552-558.
- Wood R, Bekker LG: Isoniazid preventive therapy for tuberculosis in South Africa:
   an assessment of the local evidence base. S Afr Med J 2014, 104(3):174-177.
- Maro I, Lahey T, MacKenzie T, Mtei L, Bakari M, Matee M, Pallangyo K, von Reyn CF:
   Low BMI and falling BMI predict HIV-associated tuberculosis: a prospective study in Tanzania. *Int J Tuberc Lung Dis* 2010, 14(11):1447-1453.
- Melkamu H, Seyoum B, Dessie Y: Determinants of Tuberculosis Infection among
   Adult HIV Positives Attending Clinical Care in Western Ethiopia: A Case-Control
   Study. AIDS Res Treat 2013, 2013:279876.
- Kerkhoff AD, Wood R, Cobelens FG, Gupta-Wright A, Bekker LG, Lawn SD:
   Resolution of anaemia in a cohort of HIV-infected patients with a high prevalence
   and incidence of tuberculosis receiving antiretroviral therapy in South Africa. BMC
   Infect Dis 2014, 14:3860.
  - 47. Kerkhoff AD, Wood R, Cobelens FG, Gupta-Wright A, Bekker LG, Lawn SD: The predictive value of current haemoglobin levels for incident tuberculosis and/or mortality during long-term antiretroviral therapy in South Africa: a cohort study. BMC Med 2015, 13:70.

BMJ Open

Page 2

The RECORD statement – checklist of items, extended from the STROBE statement that should be reported in observational studies using routinely collected health data.

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items  6 Februs	Location in manuscript where items are reported
Title and abstrac	et			Vie	
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	The study design in the title is indicated in page-1 and the abstract is found on page-2	RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included.  RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract.  RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	
Introduction	_			9	
Background rationale	2	Explain the scientific background and rationale for the investigation being reported	The introduction section is found on page 4	April 9, 20	
Objectives	3	State specific objectives, including any prespecified hypotheses	The objective of the study is stated on page 5 line 13-14	on April 9, 2024 by guest	
Methods				U	
Study Design	4	Present key elements of study design early in the paper	Study design in the method section is found on page 5 line no 17.	rotected by copyright	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, For peer review only - htt	Study setting is located on page 5 line 16.	·	

ge 27 of 31			BMJ Open	mjopen-
		follow-up, and data collection		201:
Participants	6	(a) Cohort study - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study - Give the eligibility criteria, and the sources and methods of selection of participants  (b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed Case-control study - For matched studies, give matching criteria and the number of controls per case	Study population and eligibility criteria is found on page 6	RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail of this is not possible, an explanation should be provided.  RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.  RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data lankage process, including the number of andividuals with linked data at each stage.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.	Study variables and measurement is located on page 6 line 11.	RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported an explanation should be provided.
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement).  Describe comparability of assessment methods if there is more than one group	Data collection tool and procedure is located on page7 line 18	should be provided. of ected by copyright.

			BMJ Open	njopen:	Page 28 of
Bias	9	Describe any efforts to address potential sources of bias		2017-01	
Study size	10	Explain how the study size was arrived at	Sample size calculation and procedure is located on page 7 line 7	6961 on 6 Fe	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why		oruary 2018. Dow	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) Cohort study - If applicable, explain how loss to follow-up was addressed  Case-control study - If applicable, explain how matching of cases and controls was addressed  Cross-sectional study - If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses	Data processing and analysis is found on page 7 line 27	nloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protecte	
Data access and cleaning methods			Data processing and analysis is found on page 7 line 27	RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to creat the study population.	

	_		1	<u>,                                    </u>
				RECORD 12.2: Authors should provide
				information on the data deaning
				methods used in the stuck.
Linkage				RECORD 12.3: State whether the study
				included person-level, institutional-
				level, or other data linkage across two
				or more databases. The methods of
				linkage and methods of kinkage quality
				evaluation should be provided.
Results				
Participants	13	(a) Report the numbers of	Report on the	RECORD 13.1: Describe in detail the
		individuals at each stage of the	number of	selection of the persons included in the
		study (e.g., numbers potentially	participants is	study ( <i>i.e.</i> , study population selection)
		eligible, examined for eligibility,	located on page 8	including filtering based on data
		confirmed eligible, included in	line 19	quality, data availability and linkage.
		the study, completing follow-up,		The selection of included persons can
		and analysed)		be described in the text and/or by means
		(b) Give reasons for non-		of the study flow diagram.
		participation at each stage.		
		(c) Consider use of a flow		j. b
		diagram		<u>a</u> .
Descriptive data	14	(a) Give characteristics of study	Descriptive data is	
Descriptive data	1.	participants (e.g., demographic,	located from page 8	or or
		clinical, social) and information	to 10	Þ.
		on exposures and potential	10 10	orii (
		confounders		, N
		(b) Indicate the number of		024
		participants with missing data for		by
		each variable of interest		Oc.
		(c) <i>Cohort study</i> - summarise		om/ on April 9, 2024 by guest. Protecte
		follow-up time (e.g., average and		Pro
		total amount)		)tec
Outcome data	15	Cohort study - Report numbers of	The outcome of the	ä
Outcome data	13	outcome events or summary	study is located on	by copyright
		measures over time	page 11	CO P
		Case-control study - Report	page 11	yrig
		numbers in each exposure		ੜ.
		_		
		category, or summary measures		

				en	
		of exposure  Cross-sectional study - Report numbers of outcome events or summary measures		2017-016961	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounderadjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	The main results including 95% confidence limit is reported from page 17 to 18	on 6 February 2018. Downloaded from http://bmjc	
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	10/10	qpen.bmj.con	
Discussion		unaryses		on I	
Key results	18	Summarise key results with reference to study objectives	The discussion section is found on page 19	April 9, 20	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	The limitation of the study is located on page 21 line 5	RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question (s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of	The conclusion section is found on page 21 line 11	opyright.	

**BMJ Open** 

Page 30 of 31

		analyses, results from similar studies, and other relevant evidence		2017-0169			
Generalisability	21	Discuss the generalisability (external validity) of the study results	Regarding the generalizability, since the study was conducted in the setting where more than 75 of HIV/AIDS peoples are enrolled we can generalize the finding to northeast Ethiopia	61 on 6 February 2018. Downloaded fr			
Other Information	Other Information						
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Funding information is located on page 22	http://bmjopen.bn			
Accessibility of protocol, raw data, and programming code			Regarding data sharing statement, it is located on page 22. And it will be shared up on the request.	RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data or programming code.			

<sup>\*</sup>Reference: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Längan SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.

<sup>\*</sup>Checklist is protected under Creative Commons Attribution (CC BY) license.

# **BMJ Open**

# Incidence and determinants of TB infection among adult HIV-infected patients attending HIV care in Northeast Ethiopia: a retrospective cohort study

Journal:	BMJ Open
Manuscript ID	bmjopen-2017-016961.R1
Article Type:	Research
Date Submitted by the Author:	22-Jun-2017
Complete List of Authors:	Ahmed, Ausman; Jigjiga University, Department of Public health Mekonnen, Desalew; Addis Ababa University, Internal Medicine Shiferaw, Atsede; University of Gondar, Department of Health Informatics Belayneh, Fanuel; Hawassa University Yenit, Melaku; Melaku Kindie Department of Epidemiology and Biostatistics College of Medicine and Health Sciences Institute of Public Health, University of Gondar,
<b>Primary Subject Heading</b> :	Infectious diseases
Secondary Subject Heading:	HIV/AIDS, Public health
Keywords:	Incidence, TB, HIV/AIDS people, Northeast Ethiopia

SCHOLARONE™ Manuscripts

1	Incidence and determinants of TB infection among adult HIV-infected patients attending
2	HIV care in Northeast Ethiopia: a retrospective cohort study
3	Ausman Ahmed <sup>1</sup> , Desalew Mekonnen <sup>2</sup> , Atsede Mazengia Shiferaw <sup>3</sup> , Fanuel Belayneh <sup>4</sup> , Melaku
4	Kindie Yenit <sup>5*</sup>
5	<sup>1</sup> Department of Public health, JigJiga University, JigJiga, Ethiopia
6	<sup>2</sup> Department of Internal Medicine, Addis Ababa University, Ethiopia
7	<sup>3</sup> Department of Health Informatics, University of Gondar, Gondar, Ethiopia
8	<sup>4</sup> School of Public and Environmental Health, Hawassa University, Hawassa, Ethiopia
9	<sup>5*</sup> Department of Epidemiology and Biostatistics, University of Gondar, Gondar, Ethiopia
10	
11	
12	Email addresses:
13	AA: soyra3362@yahoo.com
14	DM: desalewm@yahoo.com
15	MKY: melaku98@gmail.com
16	FB: fanuelbelayneh@gmail.com
17	AMS: atsede.mazengia@yahoo.com
18	
19 20	*Corresponding author Melaku Kindie Yenit
21	Email: melaku98@gmail.com
22	Tell: +251-913002871
23	Tell: +251-913002871  P.o.box: 196
24	University of Gondar
25 26 27 28 29 30 31 32	

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright

1 Abstract

- **Objective:** This study assessed the incidence of tuberculosis and its predictors among adults
- 3 living with HIV/AIDS in government health facilities of northeast Ethiopia.
- **Setting:** A five year retrospective cohort study was conducted from May to June 2015 on 451
- 5 adult HIV/AIDS infected individuals who enrolled in the chronic HIV Care Clinic of
- 6 government health facilities of northeast Ethiopia.
- 7 Participants: A total of 451 HIV infected adults who newly enrolled in the chronic adult HIV
- 8 Care Clinic from July 1, 2010 with complete information were followed until May 2015.
- **Primary outcome measure:** The primary outcome was the proportion of patients diagnosed
- with TB or TB incidence rate.
- 11 Secondary outcome measure: The incidence of TB was investigated in relation to years of
- 12 follow-up
- **Results:** A total of 451 charts with complete information were followed for 1377.41 Person-
- Years (PY) of observation. The overall incidence density of tuberculosis was 8.6 per 100 person-
- year observation. Previous TB disease (AHR 3.65, 95% CI 1.97-6.73), being bedridden (AHR
- 16 5.45, 95% CI 1.16-25.49), being underweight (BMI<18.5kg/m<sup>2</sup>) (AHR 2.53, 95 % CI 1.27-
- 5.05), taking isoniazid preventive therapy (IPT) (AHR 0.14, 95% CI 0.05-0.39), hemoglobin
- below 11 g/dL (AHR 2.31, 95% CI 1.35- 3.93), being in WHO clinical stage III and IV (AHR
- 19 2.84, 95% CI 1.11, 7.27), and (AHR 3.07, 95% CI 1.08, 8.75), respectively, were significant for
- 20 the incidence of tuberculosis.
- 21 Conclusion: The incidence of TB among adults living with HIV/AIDS in the first three years of
- 22 follow-up was higher compared with that of subsequent years. Previous TB disease, not
- 23 receiving IPT, low BMI, low hemoglobin level, being in advanced WHO clinical stage, and
- 24 bedridden condition were determinants of the incidence of tuberculosis. Therefore, addressing
- 25 the significant predictors and improving TB/HIV collaborative activities should be strengthened
- in the study setting.

### Strengths and limitations of this study

- The study which involved a five-year follow up covered longer time than other similar studies and is expected to show the long term impact of HIV on TB.
- The study attempted to show the incidence of TB and its predictors among people living with HIV (PLHIV) using a five-year retrospective data.
- The retrospective nature of the method prevented the inclusion of all possible factors that affect the incidence of tuberculosis.
- Some participants whose data were incomplete were excluded from the study because if such patients had TB they would undermine the findings of the study.
- Variables such as housing condition and household income were some of the plausible factors that were not measured in this study.
- Culture confirmation was not performed during the study period.
  - Inability to address TB contacts (other family member/co-inhabitant with TB) is the limitation of the study. The authors didn't address this variable because it was not easy to find it in the study.
  - Since the study was conducted in a single region of Ethiopia, it might not indicate the actual incidence of TB in other regions of the country.

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright.

#### Introduction

TB is an infectious disease caused by bacillus Mycobacterium tuberculosis. It typically affects 

the lungs (pulmonary TB), but it can also affect other sites (extra pulmonary TB) and has

- remained a major global health problem. In 2015, Tuberculosis (TB) was one of the top 10
- causes of death worldwide and the leading cause of death among HIV positive people, ranking
- above HIV/AIDS as one of the leading causes of death from infectious diseases (1). Out of the
- 1.4 million TB-caused deaths reported in 2015, 0.4 million occurred to HIV positive TB patients.
- Globally, it was estimated that there were 10.4 million TB cases, including 1.2 million among
- HIV positive people (1).
- Globally, nearly 78 million people have contracted HIV infection since the beginning of the
- pandemic, and close to 39 million died of AIDS related causes; TB was responsible for twenty-
- five percent of these deaths (2). According to the World Health Organization (WHO) 2014
- report, there were an estimated 1.1 million cases of TB co-infected with HIV (3), where the
- majority (90%) of the TB-HIV co-infected people were living in resource limited settings like
- Ethiopia (4-6). In the African region that has the highest TB/HIV burden; three-out of four TB
- patients knew their HIV status. In fact, 70% of the TB patients known to be living with HIV in
- 2013 were started on antiretroviral therapy (ART). Sub-Saharan Africa is among the regions
- highly hit by the HIV epidemic, covering more than three-quarters (79%) of the burden of TB-
- HIV co-infections (7).
- In Ethiopia, TB remains one of the leading causes of mortality and the third major cause of
- hospital admissions. In the last ten years, the number of new cases has increased from 55,000 to
- 100,000, and the rise in the number of tuberculosis cases has been due to the rapid spread of HIV
- infection. According to the 2011 Ethiopian Demographic and Health Survey (EDHS) report, the
- average prevalence of HIV in Ethiopia was 1.5%, while it was 1.8% in where the study was
- conducted. Similarly, it was reported that the prevalence of TB was 211 per 100,000 of the
- population (8), and the global TB report indicated that Ethiopia ranked 10<sup>th</sup> among 22 TB high
- burden countries. Moreover, Ethiopia is one of the high TB/HIV burden countries, and the
- prevalence of TB/HIV co-infection was 15% in 2012 (6, 7). TB/HIV co-infection which
- constitutes an immense burden in the health system in the country is associated with diagnostic
- and therapeutic challenges. The dual epidemics have drained resources and overburdened the

limited health work-force (9). Hence, the Ministry of Health designed a strategy to increase the percentage of TB patients tested for HIV and vice versa. As a result, the percentage of TB patients tested for HIV increased from 16 percent in 2007 to 92 percent in 2012, and the proportion of HIV patients screened for TB from 25 percent in 2007 to 92 percent in 2012 (10). Though HIV increases the risk of developing TB, it is not the only determinant for developing it. Various reports indicated that socio-demographic (11, 12), clinical (13, 14), life style (14, 15) and environmental (16) factors were some of the determinants of the incidence of TB infection among HIV positive individuals. Among the clinical factors, low cluster of differentiation 4 (CD4 count) (17-21), low hemoglobin level, diabetes and other opportunistic infections, and functional status showed significant associations with the incidence of TB (20, 22-24). However, Isoniazid Preventive Therapy (IPT), Antiretroviral Therapy (ART), and Co-trimoxazole Preventive Therapy (CPT) treatments reduce the risk of TB infection among HIV positive individuals (23, 25, 26). In resource limited countries such as Ethiopia, where there is poor access to health care, very few studies are conducted on the determinants of the incidence of TB among HIV infected people. As a matter of fact, it is important to know the variables which are the risk factors to better understand the etiology of HIV/TB co-infection in the region. This can contribute to the development of interventions to reduce risks. Therefore, this study assessed the incidence of TB and its determinants among HIV positive people in northeast Ethiopia. As a

#### Methods

#### Study design and setting

A five year retrospective cohort study was conducted on HIV positive patients attending the chronic HIV care clinics in selected government health facilities of the Afar Regional State, northwest Ethiopia from July 2010 to June 2011. The region is located in the north-eastern part of Ethiopia and has a total population of 1,678,000 of whom only 289,000 live in urban and semi-urban areas (27). In the region, there are four hospitals, 40 health centers, and 15 private clinics providing health services. When HIV care service was first introduced to the region in 2006, 15 public health institutions provided chronic HIV care and support to around more than 4,000 people living with HIV (PLHIV). Two health centers (Awash, and Samara) and three hospitals (Asayta, Abala, and Dubti General) were selected based on the availability of TB/HIV

second outcome, the study considered the incidence of TB in relation to years of follow-up.

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright

1 clients. These health institutions were providing chronic HIV care and follow up to TB to about

85% of the patients living with HIV in the region.

#### Study population and eligibility criteria

- 5 All HIV/AIDS patients aged 15 years and above and newly enrolled into HIV care in selected
- 6 government health facilities of Afar Region from July 2010 to June 2011 were the population
- 7 under study. These individuals, who enrolled into HIV care from July 2010 to June, 2011 were
- 8 followed for five years, until May 2015. A total of 503 people living with HIV were registered
- 9 during the period July 2010 to June 2011. Individuals with incomplete information, like missing
- the date of enrollment, outcome of interest, and follow-up data were excluded from the study.
- However, individuals' chart deleted for analysis were compared to the study groups and showed
- 12 no significant baseline demographic characteristics. In addition, those who died or were lost to
- follow-up were considered as censored.

#### Measurements and study variables

The outcome variable in this study was the incidence rate of TB co-infection among HIV positive patients. An event of an incidence of TB in this study was considered as any form of TB that was not only diagnosed clinically or radio-graphically but also confirmed by laboratory examinations or by patients who have empirically started anti-TB treatment after enrollment. Patients taking anti-tuberculosis treatment at the time of enrollment were excluded from the study. TB was diagnosed using microscopic examinations of three sputum samples, chest x-ray, and fine needle aspiration of lymphadenopathy. Culture confirmation was not available in the study areas during the study period. When an individual became diagnosed with active TB, treatment was given based on the National TB Program, which was 8 months of treatment (currently 6 months). HIV positive individuals who were lost to follow-up, transferred, died, and not diagnosed for TB until the end of the follow-up period were considered as censored. Study variables, including socio-demographic and economic characteristics, such as age, sex, educational status, employment status, residence, religion, family size, marital status; and clinical characteristics, such as WHO clinical stage, baseline CD4 count, functional status, and history of TB along with body mass index (BMI) and hemoglobin level were reviewed. Functional status was measured at baseline, and a person was categorized as working, if "he/she was able to perform usual work in or out of the house" and bedridden if "he/she was not able to perform

activities of daily living". CPT prophylaxis in this study was defined as a patient who took co-

- trimaxazole for longer than one month for a prophylaxis purpose. Isoniazid preventive therapy
- 2 (IPT) use in this study was defined as a patient who took IPT for at least 3 months. Substance use
- 3 in this study was referred to as use of at least one of the substances (alcohol, khat, cigarettes, and
- 4 illicit drugs) in an individual's life time to alter the mood or behavior. Illicit drugs were defined
- 5 as the use of psychoactive substances, like hashish, cannabis, and heroin, for which the
- 6 production, sale, or use is prohibited.

#### Sample size and sampling procedure

- 8 All HIV/AIDS patients aged 15 years and above and enrolled newly into HIV care from July
- 9 2010 to June 2011 were the population under study. Sample size was calculated using the single
- proportion formula, considering the following assumptions: 17% prevalence of TB among HIV
- positive people in Jimma, Ethiopia (28), 95% level of confidence, 3.5 margin of error, and 3.3%
- expected incomplete record(29). Finally, the minimum sample size of 458 was obtained. Thus,
- there were 503 PLHIV registered in the selected health facilities of chronic HIV care clinics, all
- of the 503 records were included in the study.
- In Afar Region, where the study was conducted, there were four hospitals, 40 health centers, and
- 16 15 private clinics providing health services to the community. Out of these health facilities, two
- health centers (Awash and Samara), and three hospitals (Asayta, Abala and Dubti General) were
- selected based on client flow and availability of TB and HIV follow-up services. In these
- selected health facilities, 503 HIV positive people were newly registered from July 2010 to June
- 20 2011. However, people living with HIV and registered in health facilities from July 2010 to June
- 21 2011 and had complete information were followed until May 2015.

#### Data collection tool and procedure

- Data were collected through chart reviewing, using patient chart data extraction format by nurses
- 24 who took training on ART. All records of HIV/AIDS patients between July 2010 and May 2015
- 25 were considered. Charts were retrieved by using patient medical record numbers and ART
- 26 registration numbers found on the database of the selected health facilities. Forms used for
- 27 laboratory request, TB records, ART intake, and patient cards were reviewed. Data quality was
- 28 assured by using a pretested questionnaire and trained data collectors. Data completeness and
- 29 consistency was checked by supervisors. The data clerk and case managers assisted the data
- 30 collectors by identifying charts.

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright

#### Data Processing and Analysis

Extracted data were checked for completeness, coded, entered, and cleaned into EPI-INFO version 7 and exported to SPSS version 20.0 software for further analysis. Statistical summary measures and incidence density were calculated. Descriptive statistics were used to characterize the socio-demographic and clinical variables. The event of interest was TB incidence. The incidence of TB (measured by incidence rate and incidence density rate) was stratified by sociodemographic and clinical variables. The Kaplan-Meier estimates were used to describe time to event distributions. Log-rank tests were used to compare time-to-event across the different categories. Time-to-event data that the study considered and survival analysis were carried out, the cox proportional hazards model was fitted, and a life table was used to estimate cumulative probabilities. Bi-variable and multivariate cox regression model was used to identify the predictors of the incidence of TB. Variables with p-value less than 0.2 in the bi-variable analysis were considered for the multivariate cox proportional hazard model. A 95% confidence interval of hazard ratio (HR) was computed and variables with less than 0.05 p-values in the multivariate cox proportional hazards model were taken as significant predictors for the outcome variable. Moreover, basic assumptions of cox proportional hazard model were checked using the Schoenfield residuals test.

#### Ethical consideration

- Ethical clearance was obtained from the Institutional Review Board (IRB) of the Institute of Public Health, the University of Gondar. A letter of permission was obtained from the Afar Regional Health Bueuro (ARHO), and a written permission letter was sent to each selected health facilities. In addition, confidentiality was maintained by using only unique identification
- codes rather than patient names and identifications.

#### Results

#### Socio-demographic and clinical characteristics of PLHIV

A total of 451 records of PLHIV enrolled at health facilities from July 1, 2010 to June 30, 2011 were reviewed and followed until May 2015. The charts of 451 HIV/AIDS patients with complete information were analyzed in the study, while 52 charts were excluded from the analysis because they did not contain complete information (**Figure-1**). Out of the 451 patients

- that remained in the analysis, more than half, 267(59.2%), were females and more than half, 242
- 2 (53.7%) were aged 26-34 years. The mean age ( $\pm$ SD) of the patients was 32.6( $\pm$ 7.5) years. Most
- of the respondents, 410 (90.9%), were urban residents, and 275 (61.0%) were Muslims (**Table**
- 4 1).
- 5 Almost half, 234 (51.9%), of the participants were self-employed. Only 76 (16.9%) of the
- 6 patients had more than 5 family members. Almost half, 212 (47%), of the subjects never went to
- 7 formal school. More than two-thirds (68.1%) of the patients were currently or formerly married
- 8 Of the 130 (28.8%) patients recorded as substance users, 14 (5.0%) were tobacco users, 26
- 9 (20.0%) alcohol consumers, and 90 (75.0%) were using both of these (**Table 1**).

- Out of the total 451 study participants with complete information for analysis, more than half
- 12 (45.4%) had a baseline WHO clinical stage I and II. The majority, 440 (97.6%), of the
- participants were enrolled with working functional status. Almost half, 218 (51.7%), of the
- participants were underweight (BMI less than 18.5 kg/m<sup>2</sup>), whereas more than three-quarters,
- 15 344 (76.3%), of the study subjects were anemic (Hgb<11g/dL). During the five year
- retrospective follow up, most, 413 (91.6%), of the participants were provided with co-
- trimoxazole preventive therapy (CPT), while only 94 (20.8%) received isoniazid preventive
- therapy (IPT). Similarly, nearly half 215 (47.7%) of the respondents were initiated into ART
- therapy either on WHO clinical stage or CD4 cell count. More than one-third 170 (37.7%) of the
- 20 HIV/AIDS positive people took a combination of TDF, 3TC and EFV; likewise, one-fifth, 110
- 21 (24.4%), of the patients took AZT, 3TC, and EFV. Another one-fifth, 96 (21.3%), of the patients
- changed their initial regimen, 92 due to substitution, and 4 due to switching to second line
- treatment for HIV. Out of the 96 HIV/AIDS patients who changed their initial regimen, side
- effect and development of TB were the major reasons for 50 (52.1%) and 29 (30.2%),
- 25 respectively (**Table 1**).

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright.

Table 1: Socio-demographic and clinical characteristics of PLHIV who were enrolled for chronic HIV care at selected government health facilities in Afar Regional State, northeast

**3 Ethiopia from 2010-2011** 

Characteristics	Frequency	Percent (%)
Age in years (mean=32.6, SD=7.5)	-	
15-25	55	12.2
26-34	242	53.7
35-44	119	26.3
<b>≥</b> 45	35	7.8
Sex		
Male	184	40.8
Female	267	59.2
Marital status		
Single	144	31.9
Married	200	44.3
Divorced	77	17.1
Widowed	30	6.7
Residence	30	0.7
Urban	410	90.9
Rural	41	9.1
Religion	71	<b>7.1</b>
Muslim	275	61.0
Orthodox	165	36.6
Others	11	2.4
		<b>2.4</b>
Educational status	212	47.0
Illiterate	212	47.0
Primary school	177	39.2
Above secondary	62	13.8
Family size	216	47.0
1-3	216	47.9
4-5	159	35.3
<u>≥</u> 5	76	16.8
Occupation		
Self-employed	234	51.9
Governmental employed	45	10.0
Non-employed	172	38.1
Substance use		
Yes	130	28.8
No	321	71.2
Type of substance used		
Tobacco	14	5.0
Alcohol	26	20.0
Both tobacco and alcohol	90	75.0
On ART		
Yes	215	47.7
No	236	52.3
WHO clinical stage	230	32.3
&	200	45.4
III	172 69	39.0
IV	60	15.6

11 44 124 125 158	97.6 2.4 9.8 27.5 27.7 35.0
11 44 124 125 158	9.8 27.5 27.7 35.0 51.7
44 124 125 158	9.8 27.5 27.7 35.0
124 125 158 218	27.5 27.7 35.0 51.7
124 125 158 218	27.5 27.7 35.0 51.7
124 125 158 218	27.5 27.7 35.0 51.7
125 158 218	27.7 35.0 51.7
218	35.0 51.7
218	51.7
203	/(U ')
	48.3
	<b>-</b> 6.0
	76.3
107	23.7
	91.6
38	8.4
	20.8
357	79.2
65	14.4
89	19.7
	24.4
	37.7
17	3.8
74	16.4
377	83.6
34	7.5
17	92.5
35	7.8
16	92.2
92	20.4
4	0.9
55	78.7
29	30.2
	52.1
4	4.2
13	13.5
	344 007 313 38 94 357 65 89 10 70 17 74 77 34 17 35 16 92 44 555 99 60 4

AZT, Zidovudine; BMI, Body mass index; CD4, Cluster of differentiation; CPT, Cotrimoxazole Preventive Therapy; D4T, Stavudine; EFV, Efaverenze; Hgb, Hemoglobin; IPT, "isoniazid preventive therapy; NVP, Neverapine; OI, Opportunistic Infection; TB, Tuberculosis; TDF, Tenofevir; 3TC, Lamavudine; WHO, World Health Organization

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright

## The incidence of TB stratified with socio-demographic and clinical characteristics

Out of the total 451 HIV/AIDS patients, 119 (26.4%) developed active TB infection during the follow-up period, while 332 were censored (40 patients were transferred out, 13 died, 21 lost to follow-up, and 258 remained TB-negative till the end of follow-up period) (Figure-1). Therefore, the overall TB incidence rate in the five year retrospective data was 8.64 cases per 100 Person-years (PY) of observation. The incidence of patients diagnosed with TB at the end of one year was 4.9 per 100 person-year observation. The sum of the whole follow-up period for all 451 HIV/AIDS infected individuals was 1377.41 Person-years of observation. The minimum and maximum follow-up observation was 0.03 and 58.8 months, respectively. The median (IQR) follow-up period was 46.74 months of observation [IOR=15.95-52.42 months]. Females constituted more than half, 67 (56.3%) of the total TB disease. Three-quarters, 91 (76.47%), of the cases were pulmonary TB. The majority, 114 (96%) of the TB incidents occurred in the first one year of follow-up; 46 (38.6%) of the TB incidents within the first month of follow up, and 68 (57.14%) within the first year of follow up. The incidence of TB was 105 cases and 14 cases among urban and rural dwellers, respectively. The test of equality for survival distribution for different levels of different categories was performed with Kaplan Meier, using the long rank test. The cumulative probability of TB patient's survival at the end of one year, two, three, and four years was 0.77, 0.68, 0.34 and 0.10, respectively. The median survival time was 54 months (Figure-2). An association of differences was observed among the explanatory variables, like BMI and IPT. BMI, IPT use, WHO stage, Hgb level and bed-ridden functional status had a significant difference for tuberculosis free survival. To mention some, BMI <18.5 kg/m<sup>2</sup> had low TB free survival compared to those with BMI >18.5 kg/m<sup>2</sup> with the overall comparison result long rank of p-value p<0.002 and for the IPT was p<0.0001 which shows a significant difference of TB free survival among patients provided with IPT (Figure 3-7). Out of the participants who developed TB, 41 (34.5%) had previous TB disease, and 8 (6.7%) were bedridden at the time of enrollment. One hundred fifteen (96.6%) of TB cases were not given INH prophylactic therapy. Fifty (42.0%) participants with incident cases of TB were enrolled with Hgb level below11g/dL (Table-2).

Table 2: The incidence of tuberculosis stratified by socio-demographic and clinical characteristics of PLHIV on HIV chronic care at selected government health facilities of Afon Pagional State. July 2010 to May 2015

Afar Regional State, July 2010 to May 2015							
Characteristics	Total	TB incidence	Person-Years observation				
_	N (%)	N (%)	(PY)				
Years of follow-up ( medi	. —						
One year	88(19.5)	68(57.1)	35.07				
Two years	41(9.0)	28(23.5)	54.73				
Three years	32(7.0)	11(9.3)	76.66				
Forth	89(19.8)	9(7.6)	322.67				
Fifth	201(44.6)	3(2.5)	888.28				
Age (years)							
15-25	55(12.2)	14(11.7)	158.81				
26-34	242(53.7)	63(52.9)	739.05				
35-44	119(26.3)	30(25.3)	384.1				
≥45	35(7.8)	12(10.1)	95.45				
Sex							
Male	184(40.8)	52(43.7)	536.9				
Female	267(59.2)	67(56.3)	840.51				
Residence							
Urban	410(90.9)	105(88.2)	1260.67				
Rural	41(9.1)	14(11.8)	116.74				
Marital status							
Single	144(31.9)	30(25.2)	435.14				
Married	200(44.3)	52(43.7)	616.07				
Divorced	77(17.1)	30(25.2)	184.5				
Widowed	30(6.7)	7(7.9)	91.61				
<b>Educational status</b>							
Illiterate	212(47.0)	55(46.2)	683.8				
Primary School	177(39.3)	49 (41.2)	510.54				
Secondary and above	62(13.7)	15(12.6)	183.07				
Occupation							
Self-employed	234(51.8)	59(49.6)	741.68				
Government-employed	45(10.1)	9(7.6)	121.45				
Non- employment	172(38.1)	51(42.8)	514.28				
Religion							
Muslim	275(61.0)	70(58.8)	826.69				
Orthodox	165(36.6)	47(39.5)	520.89				
Others	11(2.4)	2(1.7)	29.83				
Family size							
1-3	216(47.9)	51(42.9)	668.68				
4-5	159(35.3)	43(36.1)	484.74				
>5	76(16.8)	25(21.0)	223.99				
Substance use		•					
Yes	130(28.8)	42(35.3)	379.7				
No	321(71.2)	77(64.7)	997.71				
Previous TB disease							

Yes	74(16.4)	41(34.5)	164.74
No	377(83.6)	78(65.5)	1212.67
<b>Opportunistic infection (Ol</b>	(I)		
Yes	34(7.5)	19(16)	85.28
No	417(92.5)	100(84)	1292.13
Chronic illness			
Yes	35(7.8)	11(9.2)	106.28
No	416(92.2)	108(90.8)	1271.13
Bedridden			
Yes	11 (2.4)	8(6.7)	33
No	440(97.6)	111(93.3)	1356.76
BMI (kg/m2)			
<18.5	218(48.3)	75(64)	626.46
>18.5	203(45.0)	42(36)	750.95
Hgb level (g/dL)			
<11	107(23.7)	50(42.0)	233.8
>11	344(76.3)	69(58.0)	1143.6
CD4 cell count (cells/uL)		, ,	
<100	44(9.7)	22(18.5)	84.77
100-200	124(27.5)	40(33.6)	343.72
201-349	125(27.7)	29(24.4)	384.29
>350	158(35.0)	28(23.5)	564.63
On ART			
Yes	215 (47.7)	36 (30.3)	941.7
No	236(52.3)	83(69.7)	435.71
WHO clinical stage	, ,		
I & II	210(46.6%)	36(30.3)	785.3
III	172(38.1)	59(49.6)	464.98
IV	69(15.3)	24(20.1)	187.13
Initial regimen	• •		
d4t-3TC-NVP	65(14.4)	14(11.7)	223.56
AZT-3TC-EFV	89(19.7)	20(16.8)	296.28
AZT-3TC-NVP	110(24.4)	28(23.5)	349.17
TDF-3TC-EFV	170(37.7)	52(43.7)	461.71
Others	17(3.8)	5(4.3)	46.69
IPT use	• •	• •	
Yes	94(20.8)	4(3.4)	363.60
No	357(79.1)	115(96.6)	1013.81
CPT use	<b>.</b> ,	·/	2.12
Yes	413(91.6)	108(90.8)	1259.65
No	38(8.4)	11(9.2)	117.76

<sup>1</sup> AZT, Zidovudine; BMI, Body mass index; CD4, Cluster of differentiation; CPT, Cotrimoxazole

<sup>2</sup> Preventive Therapy; D4T, Stavudine; EFV, Efaverenze; Hgb, Hemoglobin; IPT, isoniazid

<sup>3</sup> preventive therapy; NVP, Neverapine; OI, Opportunistic Infection; TB, Tuberculosis; TDF,

<sup>4</sup> Tenofevir; 3TC, Lamavudine; WHO, World Health Organization

#### **Determinants of TB incidence**

- 2 In the bivariable cox regression analysis, marital status, family size, substance use, history of TB,
- 3 baseline CD4 count, WHO clinical stage, opportunistic infection, body mass index (BMI),
- 4 hemoglobin level, isoniazid preventive therapy (IPT), and functional status were found to be the
- 5 predictors for the incidence of tuberculosis at a p-value of less than 0.2. Consequently, these
- 6 variables were subjected to multivariate cox regression analysis; finally, previous TB disease,
- 5 bed-ridden functional status, hemoglobin, BMI, IPT and advanced WHO clinical stage were
- 8 found statistically significant determinants of TB free survival at a p-value of less than 0.05.
- 9 Accordingly, the multivariate cox regression analysis indicated that people living with HIV
- 10 (PLHIV) and had history of TB disease were 3.65 times at higher risk of developing TB at any
- time compared to PLHIV who had no history of TB (AHR 3.65, 95% CI 1.97-6.73). PLHIV who
- were in bed-ridden functional status at base-line were 5.45 times at more risk of developing TB
- compared with PLHIV not in bedridden functional status (AHR 5.45, 95% CI 1.16-25.49).
- Similarly, PLHIV with baseline BMI less than 18.5kg/m<sup>2</sup> were 2.53 times at higher risk of
- developing TB at any time compared with those with BMI greater than 18.5kg/m<sup>2</sup> (AHR 2.53, 95
- % CI 1.27-5.05). Individuals who took Isoniazid preventive therapy (IPT) were 86% less likely
- to develop TB at any time compared to those who didn't take IPT (AHR 0.14, 95% CI 0.05-
- 18 0.39). PLHIV in WHO clinical stage III and IV had a greater risk of developing TB compared
- 19 with WHO stage I and II (AHR 2.84, 95% CI 1.11, 7.27), and (AHR3.07, 95% CI 1.08, 8.75),
- 20 respectively. The study also revealed that the incidence of TB in the first three years of follow-
- up was higher when compared with the other subsequent years. In addition, PLHIV who were
- 22 underweight (Hgb <11g/dL) were 2.31 times at higher risk of developing TB compared with
- 23 those with Hgb level greater than 11 g/dL (AHR 2.31, 95% CI 1.35- 3.93) (**Table-3**).

Table 3: Cox regression analysis of the determinants of the incidence of tuberculosis among adult PLHIV on chronic HIV care at selected government health facilities of Afar Regional State from July 2010 to May, 2015

Variables	Survival stat		Total	CHR(95% CI)	m July 2010 to May, 2018 AHR(95% CI)**
variables	Event (TB)	Censored	10001	CIIK(50 70 CI)	11111(50 % CI)
Marital status		censorea			
Single	30	114	144	1.00	1.00
Married	52	148	200	1.34 (0.80-2.23)	1.26 (0.65-2.43)
Divorce	30	47	77	2.43 (1.32-4.46)	1.75 (0.83-3.68)
Widowed	7	23	30	1.16 (0.45-2.95)	2.42 (0.79-7.38)
	/	23	30	1.10 (0.43-2.93)	2.42 (0.79-7.36)
Family size 1-3	51	165	216	1.00	1.00
4-5	43	116	159	1.19 (0.75-1.92)	0.49 (0.25-1.34)
>5	25	51	76	1.58 (0.89-2.81)	0.71 (0.35-1.76)
Substance use		0.0	400	4.54 (0.06.0.05)	4 45 (0.04.0.50)
Yes	42	88	130	1.51 (0.96-2.37)	1.47 (0.84-2.56)
No	77	244	321	1.00	1.00
Previous TB di					
Yes	41	33	74	4.76 (2.83-8.03)	3.65 (1.97-6.73)**
No	78	299	377	1.00	1.00
Opportunistic	infection (OI)				
Yes	19	15	34	4.02 (1.97,8.19)	2.31 (0.98-5.45)
No	100	317	417	1.00	1.00
Bedridden					
Yes	8	3	11	7.90	5.45 (1.16, 25.49)**
				(2.06,30.31)	
No	111	329	440	1.00	1.00
BMI (kg/m <sup>2</sup> )					
<18.5	75	143	218	2.01(1.29-3.12)	2.53(1.27-5.05)**
≥18.5	42	161	203	1.00	1.00
<u>-</u> 10.3 Length of follo		101	203	1.00	1.00
≤ 1 year	68	20	88	78.76 (36.7,	83.76 (33.94, 206.7)**
≤ 1 year	00	20	00	168.9)	03.70 (33.74, 200.7)
2 2 220000	39	34	73	· · · · · · · · · · · · · · · · · · ·	33.81(14.12, 80.96)**
2-3 years	39	34	13		33.81(14.12, 80.90)***
4 5	10	270	200	55.6)	1.00
4-5 years	12	278	290	1.00	1.00
WHO clinical	0	17.4	200	1.00	1.00
I &II	36	174	200	1.00	1.00
III	59	113	172	2.52 (1.57-4.07)	2.84(1.11-7.27)**
IV	24	45	69	2.58 (1.40-4.75)	3.07(1.08-8.75)**
Hgb level (g/dl					
<11	50	57	107	3.49 (2.20-5.55)	2.31(1.35-3.93)**
<u>&gt;</u> 11	69	275	344	1.00	1.00
CD4 count (cel	lls/uL)				
<100	22	22	44	4.64 (2.26-9.52)	1.14(0.46-2.82)
100-200	40	84	124	2.21 (1.27-3.85)	1.29(0.66-2.57)
201-349	29	96	125	1.40 (0.78-2.51)	0.99(0.49-1.99)
≥350	28	130	158	1.00	1.00
IPT					
Yes	4	90	94	0.09 (0.03-0.26)	0.14 (0.05, 0.39)**
No	115	242	357	1.00	1.00
	gnificant at p-val			1.00	1.00

<sup>\*\*</sup> Variable significant at p-value less than 0.05

#### Discussion

TB and HIV remain the major public health problems in many parts of the world. Ethiopia is among the TB high burden countries with an estimated annual incidence of 211cases per 100,000 people and a prevalence of 224 cases per 100,000 (30).

In this study, the overall incidence of TB among PLHIV was 8.64 cases per 100 person-year (PY) observation. This finding is similar to those reported from Gondar and Assela, Ethiopia, which are 7 and 7.9 cases per 100 person-year (PY) observations (31, 32). Similarly, the finding is consistent with that of a study in Tanzania and other Sub-Saharan countries ranging from 7.6-8.2 per 100 person-year observation (PY) (33, 34). However, the incidence density of TB in this study is higher compared with those of studies conducted in Korea, Israel, and Malaysia (35-37). The lower incidence of TB in the latter studies compared with this one might be due to the availability of better preventive, diagnostic, and treatment setups and strategies for controlling TB in such countries when compared with our study setting. In addition, low health care coverage, a high burden of HIV, and the fact that the study setting is so unprivileged might explain the difference. Furthermore, late enrollment at health facilities due to late presentation of HIV infected people at health facilities increases the progression of latent infection to active TB after HIV chronic care. It was noted that individuals with late presentation might get new infections or IRIS after initiation into highly active antiretroviral therapy (HAART), and Immune Reconstitution Inflammatory Syndrome (IRIS) related TB is commonly seen within the first six months of initiation into HAART (38). Similarly, it was revealed that the incidence of TB is significantly associated with the length of follow-up year. It was reported that the incidence of TB decreased as the years of follow-up increased, and a higher incidence of TB was reported in the first three of follow-up years compared with the other subsequent years.

Out of the determinants of the incidence of TB infection in the multivariate cox regression analysis, the study revealed that previous TB disease, using IPT, bedridden functional status, low hemoglobin level, advanced WHO staging (III and IV), years of follow-up, and low BMI were found to be significantly associated with the incidence of TB. Individuals who had history of TB disease had greater risk of developing TB compared with those who had no history of TB treatment. Poor compliance for anti-TB treatment at the first episode, reactivation or re-infection

- 1 of individuals with the existing diminished immunity might be the reasons for higher incidence
- 2 of TB among individuals with history of TB infection. This finding is consistent with those of
- 3 studies conducted in Uganda, Malaysia, and Israel (36, 37, 39).
- 5 PLHIV who took Isoniazid preventive therapy (IPT) were found to be protective for the
- 6 incidence of TB. Individuals who took Isoniazid preventive therapy (IPT) were 86% less likely
- 7 to develop TB at any time compared to those who didn't take IPT (AHR=0.14, 95% CI: 0.05-
- 8 0.39). This might be due to the role of IPT in reducing the incidence of TB among people living
- 9 with HIV. The finding is consistent with those of studies in Ethiopia, South Africa, and Brazil
- 10 (40-42). In spite of this fact, poor uptake, ambiguity, and fear of drug resistance might contribute
- 11 to no-IPT use.
- Similarly, in this study, patients' functional status at baseline was found to be the predictor for
- TB incidence. Patients' bedridden functional status at baseline was 5.45 times at higher risk of
- developing TB compared with individuals with working functional status at baseline. This might
- be due to the fact that debilitated patients will be prone to malnutrition, and lack of physical
- activity exposes them to many diseases, including TB. This finding is in line with those of other
- studies conducted in Ethiopia (16, 31, 43).
- Out of the anthropometric variables, HIV patients who were underweight (BMI <18.5 kg/m<sup>2</sup>)
- were 2.53 times at higher risk of developing TB compared to individuals with BMI≥18.5 kg/m².
- This finding was consistent with that of a study done in Tanzania (44), Ethiopia, and South
- 21 Africa (33, 45). The possible explanations might be that a low BMI category is a proxy indicator
- for malnutrition, and malnutrition in HIV patients is associated with increased catabolic activity,
- 23 infection, loss of appetite, and decreased intake, which further increase the risk of developing
- opportunistic infections such as tuberculosis.
- 25 Similarly, this study found that patients with Hgb level of <11 g/dL at base-line were 2.31 times
- at higher risk of developing TB than those with Hgb level >11 at base-line. Hematologic
- 27 complications were risk factors for the incidence of TB among PLHIV. This finding is similar
- with those of studies conducted in Ethiopia, Uganda, Tanzania, and South Africa (44-47). The
- 29 possible explanation might be malnutrition, side effects of medications, opportunistic infections,

- and advanced stage of the disease. Undiagnosed TB could explain low Hgb level at early
- 2 enrollment.
- 3 The other important result which was found to have a significant association with the incidence
- 4 of TB was advanced clinical staging (III & IV). PLHIV with advanced WHO staging (III and IV,
- 5 respectively) had 2.84 and 3.07 times higher risk of developing TB compared with people with
- 6 stages(I &II). The finding corresponded to that studies conducted in Nigeria (48), South Africa
- 7 (49), and Gambia (50). This might be due to the fact that once patients get into late stages; the
- 8 immunity protective capacity will be minimal, making them predisposed to tuberculosis
- 9 infection. Something worth to mentioning as well is that TB is one of AIDS' defining factor to
- 10 categorize patients into late WHO clinical staging which used HIV/AIDS clinics in Ethiopia as
- 11 criteria.

#### Limitations of the study

- 13 Though the study did its best to indicate the incidence and predictors of tuberculosis among
- 14 PLHIV using a five-year retrospective data, it is not free from limitations. The retrospective
- 15 nature of the study limited the inclusion of all possible factors that could affect the incidence of
- tuberculosis. Variables such as housing condition and household income were some of the
- plausible factors that were not measured in this study. Unable to conduct *culture confirmation*
- 18 (the gold standard method) is another limitation of the study. Inability to address TB contacts
- 19 (other family member/co-inhabitant) is also the limitation of the study. The authors didn't
- 20 address this variable because it was not easy to get it in the study type. Since the study was
- 21 conducted in the single region of Ethiopia, it might not indicate the actual incidence of TB in
- 22 other regions of the country.

#### Conclusion

- The overall incidence of TB among PLHIV was found to be comparable with those of similar
- 25 studies in Ethiopia. However, it was higher in the first year of follow-up. HIV infected
- individuals with history of TB disease, not using IPT, in underweight status (BMI<18.5kg/m<sup>2</sup>),
- bedridden functional status, being anemic (Hgb<11g/dL), advanced WHO stage (III &IV), and
- 28 shorter duration of follow-up were determinants of the incidence of TB among PLHIV.
- 29 Therefore, our study suggested early screening and diagnosis among high risk PLHIV such as

- those in bed-ridden functional status, underweight (BMI <18.5kg/m²), and anemic (Hgb
- 2 <11g/dL). In addition, providing IPT to PLHIV without active TB and intensified TB case
- 3 screening for those with advanced WHO stage is highly recommended. In addition, emphasis
- 4 should be given to those with shorter follow-up period. Therefore, attention to PLHIV and
- 5 prompt diagnosis and treatment of TB are recommended. Furthermore, prospective studies need
- 6 to include all factors that influence the risk of TB among PLHIV. Since our study was conducted
- 7 in a single region of Ethiopia, collaborative projects that can include several regions of the
- 8 country is recommended to give a more balanced view of the incidence of TB and potential risk
- 9 factors in HIV-infected patients.

#### List of abbreviations

- 11 AHR, Adjusted hazard ratio; AIDS, Acquired immune deficiency syndrome; ART, Anti-
- Retroviral Therapy; BMI, Body mass index; CD4, cluster differentiation 4; CI, Confidence
- interval; CPT, Cotrimoxazole prophylaxis therapy; EDHS, Ethiopian Demographic health
- survey; HIV, Human immune deficiency; HAART, Highly active anti retro viral therapy; Hgb,
- Hemoglobin; INH, Isoniazid; IQR, Inter quartile range; IPT, Isoniazid preventive therapy; IRIS,
- 16 Immune reconstitution inflammatory syndrome; PLHIV/AIDS, People living with HIV/AIDS;
- 17 PY, person-year observation; TB, tuberculosis; WHO, World health organization

# 18 Competing interests

- 19 The authors declare that they have no conflict of interest.
- 20 Funding
- 21 No specific fund was obtained for this study
- 22 Data sharing statement
- 23 All data supporting our findings will be shared upon the request.
- 24 Authors' contributions
- AA, DM and MKY involved in the conception, design, data collection, analysis and report
- writing. DM, AMS, FB, and MKY assisted with the design, approved the proposal with some
- 27 revisions, participated in data analysis and manuscript preparation. All authors read and
- approved the final manuscript.

#### Acknowledgement

- We would like to extend our thanks to Afar Regional Health Beauro for permission to conduct
- the study and providing the necessary preliminary information during the study. We are indebted
- to data collectors and supervisors without whom this project wouldn't have gone so far.

#### References

- World Health Organization. Global tuberculosis report 2016. World Health Organization: Geneva, 1. 2016.
- World Health Organization/HIV/AIDS JUNPo. World AIDS Day 2014 Report-Fact sheet. 2. Geneva, Switzerland, 2014.
- World Health Organization. Global tuberculosis report 2013. World Health Organization; 2013. 3.
- World Health Organization. Global tuberculosis control 2009: World Health Organization; 2009. 4.
- World Health Organization. Global tuberculosis control 2009: epidemiology, strategy, financing. 5.
- Geneva, Switzerland: World Health Organization, 2009. 2011.
- Zumla A, George A, Sharma V, Herbert RHN, of Ilton BM, Oxley A, et al. The WHO 2014 global tuberculosis report—further to go. The Lancet Global Health. 2015;3(1):e10-e2.
- World Health Organization. Global Tuberculosis Report 2013. World Health Organization:
- Geneva, 2013. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656\_eng.pdf.
- Demographic E. Health Survey (2011) Addis Ababa. Ethiopia and Calverton, Maryland, USA:
- Central Statistical Agency and ICF International. 2012.
- Pawlowski A, Jansson M, Sköld M, et al.. Tuberculosis and HIV co-infection. PLoS Pathog. 9.
- 2012;8(2):e1002464.
- Health EMo. Ethiopian Federal Ministry of Health/Ethiopian Health & Nutrition Research
- Institute National. TB/HIV surveillance report. 2012.
- Batista JdAL, Maruza M, de Alencar Ximenes RA, et al. Incidence and risk factors for
- tuberculosis in people living with HIV: cohort from HIV referral health centers in Recife, Brazil. PloS one. 2013;8(5):e63916.
- Jagodziński J, Zielonka TM, Błachnio M. Socio-economic status and duration of TB symptoms in 12.
- males treated at the Mazovian Treatment Centre of Tuberculosis and Lung Diseases in Otwock.
- Pneumonol Alergol Pol. 2012;80(6):533-40.
- 13. Wilkinson D. Drugs for preventing tuberculosis in HIV infected persons. The Cochrane Library. 2000.
- 14. Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in
- adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001270.
- Alvi A, Rizwan M, Sunosi RA, et al. Does khat chewing increases the risk of Mycobacterium
- tuberculosis infection by macrophage immune modulation? Medical hypotheses. 2014;82(6):667-9.
- Kibret KT, Yalew AW, Belaineh BG, et al. Determinant factors associated with occurrence of
- tuberculosis among adult people living with HIV after antiretroviral treatment initiation in Addis Ababa,
- Ethiopia: a case control study. PloS one. 2013;8(5):e64488.
- Amoakwa K, Martinson NA, Moulton LH, et al. Risk Factors for Developing Active
- Tuberculosis After the Treatment of Latent Tuberculosis in Adults Infected With Human
- Immunodeficiency Virus. Open forum infectious diseases; 2015: Oxford University Press.
  - 18. Bendayan D, Littman K, Polansky V. Active tuberculosis and human immunodeficiency virus co-
- infection in Israel: a retrospective study. The Israel Medical Association journal: IMAJ. 2010;12(2):100-
- 3.
- 19. Hwang J-H, Choe PG, Kim NH, et al. Incidence and risk factors of tuberculosis in patients with
- human immunodeficiency virus infection. Journal of Korean medical science. 2013;28(3):374-7.

6

7

8

9

10

11

12

13

14

15

16

17

18 19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36 37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

59

- 1 20. Méda ZC, Sombié I, Sanon OW, et al. Risk factors of tuberculosis infection among HIV/AIDS patients in Burkina Faso. AIDS research and human retroviruses. 2013;29(7):1045-55.
- 3 21. Metcalfe JZ, Porco TC, Westenhouse J, et al. Tuberculosis and HIV co-infection, California, USA, 1993–2008. Emerg Infect Dis. 2013;19(3):400-6.
- 5 22. Ibrahim J. Tuberculosis: an eight year (2000-2007) retrospective study at the University of
- 6 Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia. Southeast Asian Journal of Tropical Medicine and Public Healt. 2010;41(2).
- 8 23. Maro I, Lahey T, MacKenzie T, et al. Low BMI and falling BMI predict HIV-associated
- 9 tuberculosis: a prospective study in Tanzania. The International Journal of Tuberculosis and Lung Disease. 2010;14(11):1447-53.
- 11 24. Nantha YS. Influence of diabetes mellitus and risk factors in activating latent tuberculosis infection: A case for targeted screening in Malaysia. Med J Malaysia. 2012;67(5):467-72.
- 13 25. Assebe LF, Reda HL, Wubeneh AD, et al. The effect of isoniazid preventive therapy on incidence
- of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study. BMC public health. 2015;15(1):1.
- 16 26. Okwera A, Mafigiri DK, Guwatudde D, et al. Level of understanding of co-trimoxazole use
- among HIV infected, recurrent pulmonary tuberculosis suspects at a national referral tuberculosis clinic in
- 18 Kampala, Uganda: a qualitative analysis. African health sciences. 2015;15(1):49-57.
- 19 27. Ethiopia Central Statistical Agency. Report of Centeral statistical agency., 2014.
- 20 28. Gudina EK, Gudissa FG. Prevalence of tuberculosis in HIV in Ethiopia in early HAART era:
- 21 Retrospective analysis. The Pan African medical journal. 2013;14.
- 22 29. Melkamu H, Seyoum B, Dessie Y. Determinants of tuberculosis infection among adult HIV
- positives attending clinical care in western Ethiopia: a case-control study. AIDS research and treatment. 2013;2013.
- 25 30. World Health Organization. WHO Global TB report 2014.
- 26 31. Addis Alene K, Nega A, Wasie Taye B. Incidence and predictors of tuberculosis among adult
- people living with human immunodeficiency virus at the University of Gondar Referral Hospital,
- Northwest Ethiopia. BMC Infect Dis. 2013;13:292.
- 29 32. Abebe A, Etana B, Tsadik M, et al. Assessing the Effect of Highly Active Anti-Retroviral
- 30 Treatment and Associated Factors on Incidence of Tuberculosis among Adult HIV Positive Individuals in
- 31 Assela, Ethiopia. J Health Med Informat. 2014;5(156):2.
- 32 33. Liu E, Makubi A, Drain P, et al. Tuberculosis incidence rate and risk factors among HIV-infected
- adults with access to antiretroviral therapy. Aids. 2015.
- 34. Haraka F, Glass TR, Sikalengo G, et al. A Bundle of Services Increased Ascertainment of
- Tuberculosis among HIV-Infected Individuals Enrolled in a HIV Cohort in Rural Sub-Saharan Africa.
- 36 PLoS One. 2015;10(4):e0123275.
- 37 35. Hwang JH, Choe PG, Kim NH, et al. Incidence and risk factors of tuberculosis in patients with
- human immunodeficiency virus infection. J Korean Med Sci. 2013;28(3):374-7.
- 39 36. Syed Suleiman SA, Ishaq Aweis DM, Mohamed AJ, et al. Role of diabetes in the prognosis and
- 40 therapeutic outcome of tuberculosis. Int J Endocrinol. 2012;2012:645362.
- 41 37. Mor Z, Lidji M, Cedar N, et al. Tuberculosis Incidence in HIV/AIDS Patients in Israel, 1983–
- 42 2010. PLoS One. 2013;8(11).
- 43 38. Namale PE, Abdullahi LH, Fine S, et al. Paradoxical TB-IRIS in HIV-infected adults: a
- systematic review and meta-analysis. Future Microbiol. 2015;10:1077-99.
- 45 39. Amuha MG, Kutyabami P, Kitutu FE, et al. Non-adherence to anti-TB drugs among TB/HIV co-
- 46 infected patients in Mbarara Hospital Uganda: prevalence and associated factors. Afr Health Sci. 2009;9
- 47 Suppl 1:S8-15.
- 48 40. Assebe LF, Reda HL, Wubeneh AD, et al. The effect of isoniazid preventive therapy on incidence
- of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort
- 50 study. BMC Public Health. 2015;15:346.

41. 

- Dowdy DW, Golub JE, Saraceni V, et al. Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model. J Acquir Immune Defic Syndr. 2014;66(5):552-8.
- Wood R, Bekker LG. Isoniazid preventive therapy for tuberculosis in South Africa: an assessment of the local evidence base. S Afr Med J. 2014:104(3):174-7.
- Fekadu S, Teshome W, Alemu G. Prevalence and determinants of Tuberculosis among HIV infected patients in south Ethiopia. The Journal of Infection in Developing Countries. 2015;9(08):898-

904.

- 44. Maro I, Lahey T, MacKenzie T, et al. Low BMI and falling BMI predict HIV-associated tuberculosis: a prospective study in Tanzania. Int J Tuberc Lung Dis. 2010;14(11):1447-53.
- Melkamu H, Seyoum B, Dessie Y. Determinants of Tuberculosis Infection among Adult HIV
- Positives Attending Clinical Care in Western Ethiopia: A Case-Control Study. AIDS Res Treat.
- 2013;2013:279876.
- Kerkhoff AD, Wood R, Cobelens FG, et al. Resolution of anaemia in a cohort of HIV-infected
- patients with a high prevalence and incidence of tuberculosis receiving antiretroviral therapy in South
- Africa. BMC Infect Dis. 2014;14:3860.
- Kerkhoff AD, Wood R, Cobelens FG, et al. The predictive value of current haemoglobin levels 47.
- for incident tuberculosis and/or mortality during long-term antiretroviral therapy in South Africa: a cohort
- study. BMC Med. 2015;13:70.
- Akanbi MO, Achenbach CJ, Feinglass J, et al. Tuberculosis after one year of combination
- antiretroviral therapy in Nigeria: a retrospective cohort study. AIDS research and human retroviruses.
- 2013:29(6):931-7.
- 49. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long
- term incidence and risk factors in a South African cohort. Aids. 2005;19(18):2109-16.
- Hill PC, Jackson-Sillah D, Donkor SA, et al. Risk factors for pulmonary tuberculosis: a clinic-
- based case control study in The Gambia. BMC Public Health. 2006;6(1):156.

# Figure legends

- Figure 1: Flow chart showing selection of HIV/AIDS people at selected Governmental health
- facilities in Northeast Ethiopia, July 2010 to May, 2015
- Figure 2: Kaplan Meier curve of TB survival proportion of HIV/AIDS people at selected
- Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015
- Figure 3: Kaplan Meier survival curve of TB patients based on the BMI category among PLHIV
- at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015
- Figure 4: Kaplan Meier survival curve of TB patients based on the WHO stage among PLHIV at
- selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015
- Figure 5: Kaplan Meier survival curve of TB patients based on hemoglobin level among PLHIV
- at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015
- Figure 6: Kaplan Meier survival curve of TB patients based on the bed-ridden functional among
- PLHIV at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015
- Figure 7: Kaplan Meier survival curve of TB patients based on IPT use among PLHIV at
- selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015




Figure 1: Flow chart showing selection of HIV/AIDS people at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015




Figure 2: Kaplan Meier curve of TB survival proportion of HIV/AIDS people at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015

325x420mm (300 x 300 DPI)




Figure 3: Kaplan Meier survival curve of TB patients based on the BMI category among PLHIV at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015

325x420mm (300 x 300 DPI)




Figure 4: Kaplan Meier survival curve of TB patients based on the WHO stage among PLHIV at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015

325x420mm (300 x 300 DPI)




Figure 5: Kaplan Meier survival curve of TB patients based on hemoglobin level among PLHIV at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015




Figure 6: Kaplan Meier survival curve of TB patients based on the bed-ridden functional among PLHIV at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright.




Figure 7: Kaplan Meier survival curve of TB patients based on IPT use among PLHIV at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015

routinely collected health data.

v	RECORD items 5				
Title and abstrac	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
		(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	<ul> <li>Study design is indicated in the title and abstract sections (page 1 line-2 OR on page-2 line-4)</li> <li>Abstract section is informative and is indicated in page-2</li> </ul>	RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included.  RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract.  RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	The type of data which was retrospective cohort is given in the title and the abstract section (pages 1&2)  The geographical region (northeast Ethiopia) is mentioned in the title and abstract sections (pages 1 & 2)
Introduction				<u>9</u>	
Background rationale	2	Explain the scientific background and rationale for the investigation being reported	<ul> <li>Background/Introd uction section is presented on page-4</li> <li>Rationale of the study is mentioned on page-5 lines 13-</li> </ul>	rotected by copyright.	

				en	
			18	2017-0	
Objectives	3	State specific objectives, including any prespecified hypotheses	Objectives of the study are indicated on page-5 lines 17-20. In addition, it is also clearly mentioned in the abstract section on page-2 lines 13-16.	16961 on 6 February 2018. Downloaded	
Methods				<u>0</u> 0.	
Study Design	4	Present key elements of study design early in the paper	• Study design is found on page 5 lines 23-24.	from http://bi	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Study setting is stated on page-5 line 21 to page-6 line 2.	njopen.bmj.com/ c	
Participants	6	(a) Cohort study - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study - Give the eligibility criteria, and the sources and methods of selection of participants	Study population and eligibility criteria are found on page-6 lines 4- 13	RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in details. If this is not possible, an explanation should be provided.  RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.	<ul> <li>The methods of data collection are on page 7</li> <li>The flow diagram indicating how the study subjects are selected is presented in figure 1.</li> </ul>

BMJ Open

 Page 32 of 37

		(b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed Case-control study - For matched studies, give matching criteria and the number of controls per case		flow diagram or other graphical display to demonstrate the data kinkage process, including the number of individuals with linked data at each stage.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.	<ul> <li>Measurement and study variables are presented on page-6, lines 14 to page -7 line-6</li> </ul>	RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported an explanation should be provided.
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement).  Describe comparability of assessment methods if there is more than one group	Data collection     tool and     procedure is     located on page-7     lines 22-30	m http://bmjopen.bmj.co
Bias	9	Describe any efforts to address potential sources of bias		m/ on
Study size	10	Explain how the study size was arrived at	Sample size     calculation and     procedure is     described on page-     7 lines 7-14	April 9, 2024 by guest.
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why		Protected by copyright
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to	Data processing     and analysis is     found on page-8,  p://bmjopen.bmj.com/site.	

			<b>→</b>	
Data access and cleaning methods  Linkage	examine subgroups and interactions (c) Explain how missing data were addressed (d) Cohort study - If applicable, explain how loss to follow-up was addressed Case-control study - If applicable, explain how matching of cases and controls was addressed Cross-sectional study - If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses	Data access and cleaning is found on page-7 lines 22-27	RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.  RECORD 12.2: Authors should provide information on the data geaning methods used in the study.  RECORD 12.3: State whether the study	<ul> <li>How the authors accessed data is stated in the data collection procedure (page-7)</li> <li>Information on data coding, entering and cleaning is given in the data processing and analysis sub-sections (page-8, lines 1-17)</li> <li>The study</li> </ul>
Linkage	••		The one 12.3. State whether the study	- The study
			included person-level, institutional-	

BMJ Open

 Page 34 of 37

					level, or other data linkage across two or more databases. The nethods of linkage and methods of hage quality evaluation should be provided.		setting is on page 5 lines 21 to page 6 lines 1-2
Results					<u>б</u>		
Participants	13	(a) Report the numbers of individuals at each stage of the study (e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram	•	Number of participants included in this study is indicated on page-8 lines 27-28 Flow diagram representing how study participants are presented on figure-1.	RECORD 13.1: Describe in detail the selection of the persons included in the study ( <i>i.e.</i> , study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagrams.	•	A flow diagram indicating the eligibility of study participants for the study is presented in a graph 1.
Descriptive data	14	(a) Give characteristics of study participants ( <i>e.g.</i> , demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time ( <i>e.g.</i> , average and total amount)	•	Descriptive data, including the socio-demographic and clinical factors are located from pages 8-11	bmj.com/ on April 9, 2024 by guest. Pr		
Outcome data	15	Cohort study - Report numbers of outcome events or summary measures over time  Case-control study - Report numbers in each exposure category, or summary measures of exposure  Cross-sectional study - Report		The outcome data (incidence of TB) is on pages 12-14	rotected by copyright.		

				en-:
		numbers of outcome events or summary measures		2017-01
Main results	16	(a) Give unadjusted estimates and, if applicable, confounderadjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	The adjusted estimates with 95% confidence interval are reported on page 16	16961 on 6 February 2018. Downloaded from http
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	None	://bmjopen.bi
Discussion				ا <u>ئے</u> : ۰۰
Key results	18	Summarise key results with reference to study objectives	The discussion section is presented on pages 17-19	om/ on April 9, 20;
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	The limitation of the study is pointed out on page 19 lines 12-22	RECORD 19.1: Discuss the implications of using data that were not created or collected to a swer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of	The conclusion section is on page 19 line 23 to page tp://bmiopen.bmi.com/site	byright.

BMJ Open

 Page 36 of 37

		analyses, results from similar studies, and other relevant evidence	20 lines 1-9	2017-0169	
Generalisability	21	Discuss the generalisability (external validity) of the study results	Since the study was conducted in a setting where more than 85% of HIV/AIDS patients are enrolled, we can generalize the finding to northeast Ethiopia	61 on 6 February 2018. Downlo	
Other Informatio	n			ad de	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Funding information is on page 20 lines 20- 21	d from http://bmjop	
Accessibility of protocol, raw data, and programming code			Data sharing statements are on page 20 lines 22- 23	RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data or programming code.	Data collection procedure is on page-7 and data sharing statement is on page 24.

\*Reference: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Længan SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECOR) Statement. *PLoS Medicine* 2015; in press.

<sup>\*</sup>Checklist is protected under Creative Commons Attribution (<u>CC BY</u>) license.

# **BMJ Open**

# Incidence and determinants of TB infection among adult HIV patients attending HIV care in Northeast Ethiopia: a retrospective cohort study

Journal:	BMJ Open
Manuscript ID	bmjopen-2017-016961.R2
Article Type:	Research
Date Submitted by the Author:	28-Sep-2017
Complete List of Authors:	Ahmed, Ausman; Jigjiga University, Department of Public health Mekonnen, Desalew; Addis Ababa University, Internal Medicine Shiferaw, Atsede; University of Gondar, Department of Health Informatics Belayneh, Fanuel; Hawassa University Yenit, Melaku; Melaku Kindie Department of Epidemiology and Biostatistics College of Medicine and Health Sciences Institute of Public Health, University of Gondar,
<b>Primary Subject Heading</b> :	Infectious diseases
Secondary Subject Heading:	HIV/AIDS, Public health
Keywords:	Incidence, TB, HIV/AIDS people, Northeast Ethiopia

SCHOLARONE™ Manuscripts

1	
2	
3	
4	
5	
0 7	
8	
9	
10	
11	
12	
13	
15	
16	
17	
18	
19	
20	
22	
23	
24	
25	
26 27	
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 31 31 31 31 31 31 31 31 31 31 31 31	
29	
30	
31	
32	
34	
35	
36	
3/	
38 39	
40	
41	
42	
43	
44 45	
45	
47	
48	
49	
50 51	
51	
53	
54	

17

- 1 Incidence and determinants of TB infection among adult HIV patients attending HIV care
- 2 in northeast Ethiopia: A retrospective cohort study
- 3 Ausman Ahmed<sup>1</sup>, Desalew Mekonnen<sup>2</sup>, Atsede Mazengia Shiferaw<sup>3</sup>, Fanuel Belayneh<sup>4</sup>, Melaku
- 4 Kindie Yenit<sup>5\*</sup>
- <sup>1</sup>Department of Public Health, JigJiga University, JigJiga, Ethiopia
- <sup>2</sup>Department of Internal Medicine, Addis Ababa University, Ethiopia
- <sup>3</sup>Department of Health Informatics, University of Gondar, Gondar, Ethiopia
- <sup>4</sup>School of Public and Environmental Health, Hawassa University, Hawassa, Ethiopia
- 9 5\*Department of Epidemiology and Biostatistics, University of Gondar, Gondar, Ethiopia
- 11 Email addresses:
- 12 AA: soyra3362@yahoo.com
- 13 DM: <u>desalewm@yahoo.com</u>
- 14 AMS: <u>atsede.mazengia@yahoo.com</u>
- FB: <u>fanuelbelayneh@gmail.com</u>
- 16 MKY: melaku98@gmail.com
- 18 \*Corresponding author
- 19 Melaku Kindie Yenit
- 20 Email: <u>melaku98@gmail.com</u>
- 21 Cell Phone: +251-913002871
- 22 P.o.box: 196
- 23 University of Gondar

- 26
- 27
- 28
- 29 30
- 31
- 32
- 33
- 34 35

56 57 58

59

#### 1 Abstract

- 2 Objective: This study assessed the incidence of tuberculosis and its predictors among adults
- 3 living with HIV/AIDS in government health facilities of northeast Ethiopia.
- 4 Setting: A five year retrospective cohort study was conducted from May to June 2015 on 451
- 5 adult HIV/AIDS infected individuals who enrolled in the HIV Care Clinics of government health
- 6 facilities of northeast Ethiopia.
- 7 Participants: A total of 451 HIV infected adults who newly enrolled in the adult HIV Care
- 8 Clinic from July 1, 2010 with complete information were followed until May 2015.
- **Primary outcome measure:** The primary outcome was the proportion of patients diagnosed
- with TB or TB incidence rate.
- 11 Secondary outcome measure: The incidence of TB was investigated in relation to years of
- 12 follow-up
- 13 Results: A total of 451 charts with complete information were followed for 1377.41 Person-
- Years (PY) of observation. The overall incidence density of tuberculosis was 8.6 per 100 person-
- year observation. Previous TB disease [Adjusted Hazard Ratio (AHR) 3.65, 95% CI 1.97-6.73],
- being bedridden [AHR 5.45, 95% CI 1.16-25.49], being underweight [Body Mass Index (BMI)
- 17 <18.5kg/m<sup>2</sup>) (AHR 2.53, 95 % CI 1.27-5.05)], taking isoniazid preventive therapy (IPT) (AHR
- 18 0.14, 95% CI 0.05-0.39), hemoglobin below 11 g/dL (AHR 2.31, 95% CI 1.35- 3.93), being in
- 19 WHO clinical stage III and IV (AHR 2.84, 95% CI 1.11, 7.27), and (AHR 3.07, 95% CI 1.08,
- 20 8.75), respectively, were significant for the incidence of tuberculosis.
- 21 Conclusion: The incidence of TB among adults living with HIV/AIDS in the first three years of
- follow-up was higher compared with that of subsequent years. Previous TB disease, no IPT, low
- 23 BMI and hemoglobin level, advanced WHO clinical stage and bedridden condition were the
- 24 determinants of the incidence of tuberculosis. Therefore, addressing the significant predictors
- and improving TB/HIV collaborative activities should be strengthened in the study setting.

# Strengths and limitations of this study

- The study which involved a five-year follow up covered longer time than other similar studies and is expected to show the long term impact of HIV on TB.
- The study attempted to show the incidence of TB and its predictors among people living with HIV (PLHIV) using a five-year retrospective data.
- The retrospective nature of the method prevented the inclusion of all possible factors that affect the incidence of tuberculosis.
- Some participants whose data were incomplete were excluded from the study because if such patients had TB they would undermine the findings of the study.
- The sample size used, due to the overall low incidence rate of TB, had limited power to provide clinically relevant conclusions for some risk factors, such as CD4 counts.
- As there was no culture confirmation of TB infections during the study, the cases in the study might be potential ones.
- Inability to address TB contacts (other family members/co-inhabitants) due to the type of study and the introduction of selection bias due to the exclusion of patients who did not use the hospitals chosen are also the limitation of the study.
- Since the study was conducted in a single region of Ethiopia, it might not indicate the actual incidence of TB in other regions of the country.

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright

### Introduction

TB is an infectious disease caused by bacillus *Mycobacterium tuberculosis* which affects the lungs (pulmonary TB), but it can also affect other sites (extra pulmonary TB) and has remained a major global health problem. In 2015, Tuberculosis (TB) was one of the top 10 causes of death worldwide and the leading killer among HIV positive people, exceeding HIV/AIDS as a killer with infectious diseases (1). Out of the 1.4 million TB-caused deaths reported in 2015, 0.4 million occurred to HIV positive TB patients. Globally, it was estimated that there were 10.4 million TB cases, including 1.2 million among the HIV positive people (1).

Worldwide, nearly 78 million people have contracted HIV infection since the beginning of the pandemic, and close to 39 million died of AIDS-related causes for 25% of which TB was responsible (2). According to the World Health Organization (WHO) 2014 report, there were an estimated 1.1 million cases of TB co-infected with HIV (3), where the majority (90%) of the TB-HIV co-infected people were living in resource limited settings, like Ethiopia (4-6). In the African region, that has the highest TB/HIV burden; three out of four TB patients knew their HIV status. In fact, 70% of the TB patients known to be living with HIV in 2013 were started on antiretroviral therapy (ART). Sub-Saharan Africa is among the regions highly hit by the HIV epidemic, covering more than three-quarters (79%) of the burden of TB-HIV co-infections (7).

In Ethiopia, TB remains one of the leading causes of mortality and the third major cause of hospital admissions. In the last ten years, the number of new cases has increased from 55,000 to 100,000, and the rise in the number of tuberculosis cases has been due to the rapid spread of HIV infection. According to the 2011 Ethiopian Demographic and Health Survey (EDHS) report, the average prevalence of HIV in Ethiopia was 1.5%, while it was 1.8% where the study was conducted. Similarly, it was reported that the prevalence of TB was 211 per 100,000 of the population (8), and the global TB report indicated that Ethiopia ranked 10<sup>th</sup> among the 22 TB high burden countries with a TB/HIV co-infection prevalence of 15% in 2012 (6, 7). TB/HIV co-infection which constitutes an immense burden in the health system in the country is associated with diagnostic and therapeutic challenges. The dual epidemic has been draining resources and overburdening the limited health work-force (9). Hence, the Ministry of Health designed a strategy to increase the percentage of TB patients tested for HIV and vice versa. As a result, the

- 1 percentage of TB patients tested for HIV increased from 16 percent in 2007 to 92 percent in
- 2 2012, and HIV patients screened for TB from 25 percent in 2007 to 92 percent in 2012 (10).
- 3 Though HIV increases the risk of developing TB, it is not the only determinant for it. Various
- 4 reports indicated that socio-demographic (11, 12), clinical (13, 14), life style (14, 15) and
- 5 environmental (16) factors were some of the determinants of the incidence of TB infection
- 6 among HIV positive individuals. Among the clinical factors, low cluster of differentiation (CD4
- 7 count) (17-21), low hemoglobin level, diabetes and other opportunistic infections, and functional
- 8 status showed significant associations with the incidence of TB (20, 22-24). However, Isoniazid
- 9 Preventive Therapy (IPT), Antiretroviral Therapy (ART), and Co-trimoxazole Preventive
- 10 Therapy (CPT) treatments reduce the risk of TB infection among HIV positive individuals (23,
- 25, 26). In resource limited countries such as Ethiopia, where there is poor access to health care,
- very few studies are conducted on the determinants of the incidence of TB among HIV infected
- people. As a matter of fact, it is important to know the variables which are risk factors for better
- understanding the etiology of HIV/TB co-infection in the region. This can contribute to the
- development of interventions to reduce risks. Therefore, this study assessed the incidence of TB
- and its determinants among HIV positive people in northeast Ethiopia. As a second outcome, the
- study considered the incidence of TB in relation to years of follow-up.

## Methods

# Study design and setting

- 20 A five-year retrospective cohort study was conducted on HIV positive patients attending the
- 21 chronic HIV care clinics in selected government health facilities of the Afar Regional State,
- northeast Ethiopia, from July 2010 to June 2011. The region is located in the north-eastern part
- of Ethiopia and has a total population of 1,678,000 of whom only 289,000 live in urban and
- semi-urban areas (27). In the region, there are four hospitals, 40 health centers, and 15 private
- clinics actively providing services. When HIV care service was first introduced to the region in
- 26 2006, 15 public health institutions provided chronic HIV care and support to around more than
- 27 4,000 people living with HIV (PLHIV). For this study, two health centers (Awash, and Samara)
- and three hospitals (Asayta, Abala, and Dubti General) were selected based on the availability of
- 29 TB/HIV clients. These health institutions were providing chronic HIV care and follow up to
- about 85% of the patients living with HIV in the region.

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright.

# Study population and eligibility criteria

All HIV/AIDS patients aged 15 years and above and newly enrolled for HIV care in selected government health facilities of Afar Region from July 2010 to June 2011 participated in the study. These individuals, who enrolled for HIV care from July 2010 to June 2011, were followed for five years, until May 2015. Out of the total 503 people living with HIV and registered during July 2010 to June 2011 in the selected hospitals, 451 records with complete information were included in the analysis. Fifty-two records with incomplete information, like missing the date of enrollment, outcome of interest, and follow-up data were excluded. However, individual charts deleted for analysis were compared to the study groups and showed no significant baseline demographic characteristics. In addition, those who died or were lost to follow-up were considered as censored. 

## Measurements and study variables

The outcome variable in this study was the incidence rate of TB co-infection among HIV positive patients, and it was calculated using the total duration of follow-up for the whole cohort in person-year observation (PY). For individuals who did not develop TB, the duration of followup from the time of enrolment for HIV care until the end was considered as TB-free. For those who developed TB, TB-free survival time was measured from the time of enrolment in the HIV Care Program until the development of TB. An event of an incidence of TB in this study was considered as any form of TB that was not only diagnosed clinically or radio-graphically but also confirmed by laboratory examinations or by patients who have empirically started anti-TB treatment after enrollment. However, since there was no culture confirmation of TB infections during the study period, the cases in the study might be potential ones. When an individual became diagnosed with active TB, treatment was given based on the National TB Program, which was 8 months of treatment (currently 6 months). Patients taking anti-tuberculosis treatment at the time of enrollment were excluded from the study. HIV positive individuals who were lost to follow-up, transferred, died, and not diagnosed for TB until the end of the follow-up period were considered as censored. Study variables, such as age, sex, educational status, employment status, residence, religion, family size, marital status, plus clinical characteristics, like WHO clinical stage, baseline cluster of differentiation (CD4 count), bedridden functional status, history of TB along with body mass index (BMI), hemoglobin level including sociodemographic and economic characteristics were reviewed. Bedridden functional status was

- 1 measured by asking the patient whether he or she was able to perform activities of daily living or
- 2 not. If he/she said "yes", it was taken as bedridden functional status and coded '1'; otherwise,
- 3 he/she was deemed to be not bedridden functional status. In this study, CPT prophylaxis was
- 4 defined as a patient who took co-trimoxazole for longer than one month for a prophylaxis
- 5 purpose. Isoniazid preventive therapy (IPT) use was defined as a patient who took IPT for at
- 6 least 3 months. Substance use was referred to as use of at least one of the substances (alcohol,
- 7 khat, cigarettes, and illicit drugs) in an individual's life time to alter mood or behavior. Illicit
- 8 drugs were defined as psychoactive substances, like hashish, cannabis, and heroin, the
- 9 production, sale, or use of which is prohibited.

# 10 Sample size and sampling procedure

- All HIV/AIDS patients aged 15 years and above and enrolled newly into HIV care from July
- 12 2010 to June 2011 were participated in the study. Sample size was calculated using the single
- proportion formula, considering the following assumptions: 17% prevalence of TB among HIV
- positive people in Jimma, Ethiopia (28), 95% level of confidence, 3.5 margin of error, and 3.3%
- expected incomplete record (29). Finally, the minimum sample size of 458 was obtained.
- Though, 503 PLHIV were registered in the selected health facilities for chronic HIV care, a total
- of 451 patients with complete information were included in the analysis, while 52 records were
- 18 excluded because of incomplete information.
- In Afar Region, where the study was conducted, there were four hospitals, 40 health centers, and
- 20 15 private clinics providing services to the community. Out of these, two health centers (Awash
- and Samara), and three hospitals (Asayta, Abala and Dubti General) were selected based on
- 22 client flow and the availability of TB and HIV follow-up services. In these selected health
- facilities, 503 HIV positive people were newly registered from July 2010 to June 2011.
- However, people living with HIV and registered in the facilities from July 2010 to June 2011 and
- 25 had complete information were followed until May 2015.

# Data collection tool and procedure

- Nurses trained on ART collected the data by reviewing charts and using the patient chart data
- extraction format. All records of HIV/AIDS patients between July 2010 and May 2015 were
- 29 considered. Charts were retrieved by using patient medical record and ART registration numbers
- found on the database of the selected health facilities. Forms used for laboratory request, TB

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright

- 1 records, ART intake, and patient cards were reviewed. Data quality was assured by using a
- 2 pretested questionnaire and trained data collectors. Data completeness and consistency was
- 3 checked by supervisors. The data clerk and case managers assisted the data collectors by
- 4 identifying charts.

# **Data Processing and Analysis**

- 6 Extracted data were checked for completeness, coded, entered, and cleaned into EPI-INFO
- 7 version 7 and exported to SPSS version 20.0 software for further analysis. Statistical summary
- 8 measures and incidence density were calculated. Descriptive statistics were used to characterize
- 9 the socio-demographic and clinical variables. The event of interest was TB incidence. The
- incidence of TB (measured by incidence and incidence density rates) was stratified by socio-
- demographic and clinical variables. Kaplan-Meier estimates were used to describe time to event
- distributions. Log-rank tests were used to compare time-to-event across the different categories.
- Time-to-event data that the study considered and survival analysis were carried out; the cox
- 14 proportional hazards model was fitted, and a life table was used to estimate cumulative
- probabilities. The bi-variable and multivariate cox regression model was used to identify the
- predictors of the incidence of TB. Variables with p-values of less than 0.2 in the bi-variable
- analysis were considered for the multivariate cox proportional hazard model. A 95% confidence
- interval of the hazard ratio (HR) was computed, and variables with less than 0.05 p-values in the
- multivariate cox proportional hazards model were taken as significant predictors for the outcome
- variable. Moreover, basic assumptions of the cox proportional hazard model were checked using
- 21 the Schoenfield residuals test.

#### Ethical considerations

- 23 Ethical clearance was obtained from the Institutional Review Board (IRB) of the Institute of
- 24 Public Health, the University of Gondar. A letter of permission was secured from the Afar
- 25 Regional Health Bueuro (ARHO), and a written permission letter was sent to each selected
- health facilities. In addition, confidentiality was maintained by using only unique identification
- 27 codes rather than patient names and identifications.

### Results

# 2 Socio-demographic and clinical characteristics of PLHIV

- 3 Out of the total 503 PLHIV registered at the selected hospitals from July 2010 to June 2011, 451
- 4 records with complete information were followed until May 2015. The charts of 451 HIV/AIDS
- 5 patients with complete information were analyzed, while 52 records were excluded because they
- 6 did not contain complete information (**Figure-1**). Out of the 451 patients that remained in the
- analysis, more than half (267/59.2%) were female, and over half of the total (242/53.7%) were
- 8 26-34 years of age. The mean age ( $\pm$ SD) of the patients was 32.6 ( $\pm$ 7.5) years. Most of the
- 9 respondents, 410 (90.9%), were urban dwellers and 275 (61.0%) Muslims (**Table 1**).
- Almost half, 234 (51.9%), of the participants were self-employed. Only 76 (16.9%) had more
- than 5 family members. Almost half, 212 (47%), of the subjects never went to formal school.
- More than two-thirds (68.1%) of the patients were currently or formerly married. Of the 130
- 14 (28.8%) patients recorded as substance users, 14 (5.0%) were tobacco users, 26 (20.0%) alcohol
- 15 consumers, and 90 (75.0%) used both (**Table 1**).
- Out of the total 451 study participants with complete information for analysis, more than half
- 18 (45.4%) had a baseline WHO clinical stage I and II. The majority, 440 (97.6%), of the
- 19 participants were enrolled with working functional status. Almost half, 218 (51.7%), of the
- 20 participants were underweight (BMI less than 18.5 kg/m²), whereas more than three-quarters,
- 21 344 (76.3%), were anemic (Hgb<11g/dL). During the five year retrospective follow up, most,
- 413 (91.6%), of the participants were provided with co-trimoxazole preventive therapy (CPT),
- while only 94 (20.8%) received isoniazid preventive therapy (IPT). Similarly, nearly half, 215
- 24 (47.7%), of the respondents were initiated into ART therapy either on WHO clinical stage or
- 25 CD4 cell count. More than one-third, 170 (37.7%), of the HIV/AIDS positive people took a
- combination of Tenofovir (TDF), Lamivudine (3TC), and Efavirenz (EFV); likewise, one-fifth,
- 27 110 (24.4%), of the patients took Zidovudine (AZT), Lamivudine (3TC), and Efavirenz (EFV).
- Another one-fifth, 96 (21.3%), of the patients changed their initial regimen, 92 due to
- substitution and 4 due to switching to second line treatment for HIV. Out of the 96 HIV/AIDS
- 30 patients who changed their initial regimen, side effect and development of TB were the major
- 31 reasons for 50 (52.1%) and 29 (30.2%), respectively (**Table 1**).

Characteristics	Frequency	Percent (%)
Age in years (mean=32.6, SD=7.5)		
15-25	55	12.2
26-34	242	53.7
35-44	119	26.3
≥45	35	7.8
Sex		
Male	184	40.8
Female	267	59.2
Marital status	_0,	<u> </u>
Single	144	31.9
Married	200	44.3
Divorced	77	17.1
Widowed	30	6.7
	30	0.7
Residence	410	00.0
Urban	410	90.9
Rural	41	9.1
Religion	<b>V</b>	
Muslim	275	61.0
Orthodox	165	36.6
Others	11	2.4
<b>Educational status</b>		
Illiterate	212	47.0
Primary school	177	39.2
Above secondary	62	13.8
Family size		
1-3	216	47.9
4-5	159	35.3
≥5	76	16.8
Occupation	, 0	10.0
Self-employed	234	51.9
Governmental employed	45	10.0
	172	38.1
Non-employed	1/2	36.1
Substance use	120	20.0
Yes	130	28.8
No	321	71.2
Type of substance used		
Tobacco	14	5.0
Alcohol	26	20.0
Both tobacco and alcohol	90	75.0
On ART		
Yes	215	47.7
No	236	52.3
WHO clinical stage		
I & II	200	45.4
III	172	39.0
III IV	172 69	39.0 15.6

Bedridden   No	D 1 111		
Yes         11         2.4           CD4 cell count (cells/uL)         44         9.8           100-200         124         27.5           201-349         125         27.7           3350         158         35.0           BMI (kg/m²)         35.0         8.5           218.5         218         51.7           >18.5         203         48.3           Hgb level (g/dL)         43         48.3           11         107         23.7           CPT use         413         91.6           No         38         8.4           IPT use         413         91.6           Yes         94         20.8           No         357         79.2           Initial regimen         44         42.2           44-3TC-NVP         65         14.4           AZT-3TC-EFV         89         19.7           AZT-3TC-FFV         110         24.4           TDF-3TC-EFV         170         37.7           Others         17         3.8           Previous TB disease         74         16.4           Yes         74         16.4           No <td></td> <td>4.40</td> <td>07.6</td>		4.40	07.6
CD4 cell count (cells/uL)   <			
100		11	2.4
100-200		4.4	0.0
201-349   125   27.7   35.0   158   35.0   BMI (kg/m²)			
350   350   350   350   360			
BMI (kg/m²)			
Section   Sect	_	158	35.0
>18.5     203     48.3       Hgb level (g/dL)     344     76.3       ≥11     107     23.7       CPT use     91.6       Yes     413     91.6       No     38     8.4       IPT use     94     20.8       Yes     94     20.8       No     357     79.2       Initial regimen     44-3TC-NVP     65     14.4       AZT-3TC-EFV     89     19.7       AZT-3TC-EFV     170     37.7       Others     17     3.8       Previous TB disease     74     16.4       Yes     74     16.4       No     377     83.6       Opportunistic infection (OI)     92.5       Yes     34     7.5       No     417     92.5       Chronic illness     92.5     20.4       Yes     35     7.8       No     416     92.2       Regimen change     92     20.4       To Second line     4     0.9       Not changed     355     78.7       Reason for change     92     30.2       Due to TB development     29     30.2       Due to side effect     50     52.1       Fai	\ <b>U</b> /		
High level (g/dL)			
<11		203	48.3
≥11       107       23.7         CPT use       7         Yes       413       91.6         No       38       8.4         IPT use       94       20.8         Yes       94       20.8         No       357       79.2         Initial regimen       7       70.2         d4t-3TC-NVP       65       14.4         AZT-3TC-NVP       110       24.4         TDF-3TC-EFV       170       37.7         Others       17       3.8         Previous TB disease       74       16.4         Yes       74       16.4         No       377       83.6         Opportunistic infection (OI)       377       83.6         Opportunistic infection (OI)       417       92.5         Chronic illness       35       7.8         Yes       35       7.8         No       417       92.5         Chronic illness       2       20.4         Yes       35       7.8         No       416       92.2         Regimen change       2       20.4         To First line       9       2       20.			
CPT use       413       91.6         Yes       413       91.6         No       38       8.4         IPT use         Yes       94       20.8         No       357       79.2         Initial regimen       44       79.2         Initial regimen       44       79.2         Initial regimen       44       79.2         Initial regimen       44       79.2         Initial regimen       65       14.4       14.4         AZT-3TC-FFV       89       19.7			
Yes     413     91.6       No     38     8.4       IPT use     94     20.8       Yes     94     20.8       No     357     79.2       Initial regimen     d4t-3TC-NVP       d4t-3TC-NVP     65     14.4       AZT-3TC-EFV     89     19.7       AZT-3TC-NVP     110     24.4       TDF-3TC-EFV     170     37.7       Others     17     3.8       Previous TB disease       Yes     74     16.4       No     377     83.6       Opportunistic infection (OI)       Yes     34     7.5       No     417     92.5       Chronic illness     7.8       Yes     35     7.8       No     416     92.2       Regimen change     92     20.4       To Second line     4     0.9       Not changed     355     78.7       Reason for change     9     30.2       Due to ide effect     50     52.1       Failure of treatment     4     4.2       Others     13     13.5       Form of TB     Pulmonary     91     76.4       extra pulmonary     28 </td <td>≥11</td> <td>107</td> <td>23.7</td>	≥11	107	23.7
No	CPT use		
PT use   94   20.8   No   357   79.2	Yes	413	91.6
Yes     94     20.8       No     357     79.2       Initial regimen     79.2       Initial regimen     14.4       AZT-3TC-NVP     65     14.4       AZT-3TC-EFV     89     19.7       AZT-3TC-NVP     110     24.4       TDF-3TC-EFV     170     37.7       Others     17     3.8       Previous TB disease       Yes     74     16.4       No     377     83.6       Opportunistic infection (OI)     377     83.6       Opportunistic infection (OI)     417     92.5       Chronic illness     7.8     7.8       Yes     35     7.8       No     416     92.2       Regimen change     70     20.4       To Second line     4     0.9       Not changed     355     78.7       Reason for change     78.7     78.7       Pues to TB development     29     30.2       Due to side effect     50     52.1       Failure of treatment     4     4.2       Others     13     13.5       Form of TB     Pulmonary     91     76.4       extra pulmonary     28     23.6	No	38	8.4
No	IPT use		
Initial regimen   d4t-3TC-NVP   65	Yes	94	20.8
d4t-3TC-NVP     65     14.4       AZT-3TC-EFV     89     19.7       AZT-3TC-NVP     110     24.4       TDF-3TC-EFV     170     37.7       Others     17     3.8       Previous TB disease       Yes     74     16.4       No     377     83.6       Opportunistic infection (OI)       Yes     34     7.5       No     417     92.5       Chronic illness       Yes     35     7.8       No     416     92.2       Regimen change     2     20.4       To First line     92     20.4       To Second line     4     0.9       Not changed     355     78.7       Reason for change     29     30.2       Due to TB development     29     30.2       Due to side effect     50     52.1       Failure of treatment     4     4.2       Others     13     13.5       Form of TB     Pulmonary     91     76.4       extra pulmonary     28     23.6	No	357	79.2
d4t-3TC-NVP     65     14.4       AZT-3TC-EFV     89     19.7       AZT-3TC-NVP     110     24.4       TDF-3TC-EFV     170     37.7       Others     17     3.8       Previous TB disease       Yes     74     16.4       No     377     83.6       Opportunistic infection (OI)       Yes     34     7.5       No     417     92.5       Chronic illness       Yes     35     7.8       No     416     92.2       Regimen change     2     20.4       To First line     92     20.4       To Second line     4     0.9       Not changed     355     78.7       Reason for change     29     30.2       Due to TB development     29     30.2       Due to side effect     50     52.1       Failure of treatment     4     4.2       Others     13     13.5       Form of TB     Pulmonary     91     76.4       extra pulmonary     28     23.6	Initial regimen		
AZT-3TC-NVP TDF-3TC-EFV TDF-3TC-EFV TOthers T17 TOTO TOTO TOTO TOTO TOTO TOTO TOTO		65	14.4
AZT-3TC-NVP TDF-3TC-EFV TDF-3TC-EFV TOthers T17 TOTO TOTO TOTO TOTO TOTO TOTO TOTO	AZT-3TC-EFV	89	19.7
TDF-3TC-EFV       170       37.7         Others       17       3.8         Previous TB disease         Yes       74       16.4         No       377       83.6         Opportunistic infection (OI)         Yes       34       7.5         No       417       92.5         Chronic illness         Yes       35       7.8         No       416       92.2         Regimen change       92       20.4         To First line       92       20.4         To Second line       4       0.9         Not changed       355       78.7         Reason for change       30.2       30.2         Due to TB development       29       30.2         Due to side effect       50       52.1         Failure of treatment       4       4.2         Others       13       13.5         Form of TB       Pulmonary       91       76.4         extra pulmonary       28       23.6			24.4
Others     17     3.8       Previous TB disease     377     16.4       No     377     83.6       Opportunistic infection (OI)     377     83.6       Yes     34     7.5       No     417     92.5       Chronic illness     7.8       Yes     35     7.8       No     416     92.2       Regimen change     92     20.4       To First line     92     20.4       To Second line     4     0.9       Not changed     355     78.7       Reason for change       Due to TB development     29     30.2       Due to side effect     50     52.1       Failure of treatment     4     4.2       Others     13     13.5       Form of TB     91     76.4       extra pulmonary     91     76.4       extra pulmonary     28     23.6	TDF-3TC-EFV		37.7
Previous TB disease         Yes       74       16.4         No       377       83.6         Opportunistic infection (OI)         Yes       34       7.5         No       417       92.5         Chronic illness         Yes       35       7.8         No       416       92.2         Regimen change       92       20.4         To First line       92       20.4         To Second line       4       0.9         Not changed       355       78.7         Reason for change       78.7       78.7         Due to TB development       29       30.2         Due to side effect       50       52.1         Failure of treatment       4       4.2         Others       13       13.5         Form of TB       Pulmonary       91       76.4         extra pulmonary       28       23.6			
Yes       74       16.4         No       377       83.6         Opportunistic infection (OI)         Yes       34       7.5         No       417       92.5         Chronic illness         Yes       35       7.8         No       416       92.2         Regimen change         To First line       92       20.4         To Second line       4       0.9         Not changed       355       78.7         Reason for change       9       30.2         Due to TB development       29       30.2         Due to side effect       50       52.1         Failure of treatment       4       4.2         Others       13       13.5         Form of TB       Pulmonary       91       76.4         extra pulmonary       28       23.6			
No       377       83.6         Opportunistic infection (OI)         Yes       34       7.5         No       417       92.5         Chronic illness         Yes       35       7.8         No       416       92.2         Regimen change         To First line       92       20.4         To Second line       4       0.9         Not changed       355       78.7         Reason for change       78.7       78.7         Reason for change       30.2       30.2         Due to TB development       29       30.2         Due to side effect       50       52.1         Failure of treatment       4       4.2         Others       13       13.5         Form of TB       76.4       4         Pulmonary       91       76.4         extra pulmonary       28       23.6		74	16.4
Opportunistic infection (OI)         Yes       34       7.5         No       417       92.5         Chronic illness         Yes       35       7.8         No       416       92.2         Regimen change       92       20.4         To First line       92       20.4         To Second line       4       0.9         Not changed       355       78.7         Reason for change       78.7       78.7         Due to TB development       29       30.2         Due to side effect       50       52.1         Failure of treatment       4       4.2         Others       13       13.5         Form of TB       Pulmonary       91       76.4         extra pulmonary       28       23.6			
Yes       34       7.5         No       417       92.5         Chronic illness			
No       417       92.5         Chronic illness       7.8         Yes       35       7.8         No       416       92.2         Regimen change       20.4       92         To First line       92       20.4         To Second line       4       0.9         Not changed       355       78.7         Reason for change       30.2       30.2         Due to TB development       29       30.2         Due to side effect       50       52.1         Failure of treatment       4       4.2         Others       13       13.5         Form of TB       91       76.4         extra pulmonary       28       23.6		34	7.5
Chronic illness         Yes       35       7.8         No       416       92.2         Regimen change         To First line       92       20.4         To Second line       4       0.9         Not changed       355       78.7         Reason for change       78.7       78.7         Due to TB development       29       30.2         Due to side effect       50       52.1         Failure of treatment       4       4.2         Others       13       13.5         Form of TB       76.4         Pulmonary       91       76.4         extra pulmonary       28       23.6			
Yes       35       7.8         No       416       92.2         Regimen change         To First line       92       20.4         To Second line       4       0.9         Not changed       355       78.7         Reason for change       Due to TB development       29       30.2         Due to side effect       50       52.1         Failure of treatment       4       4.2         Others       13       13.5         Form of TB       76.4         Pulmonary       91       76.4         extra pulmonary       28       23.6			7_1
No       416       92.2         Regimen change       30.4       20.4         To First line       92       20.4         To Second line       4       0.9         Not changed       355       78.7         Reason for change       30.2       30.2         Due to TB development       29       30.2         Due to side effect       50       52.1         Failure of treatment       4       4.2         Others       13       13.5         Form of TB       91       76.4         extra pulmonary       28       23.6		35	7.8
Regimen change         To First line       92       20.4         To Second line       4       0.9         Not changed       355       78.7         Reason for change       50       52.1         Due to TB development       29       30.2         Due to side effect       50       52.1         Failure of treatment       4       4.2         Others       13       13.5         Form of TB       91       76.4         extra pulmonary       28       23.6			
To First line       92       20.4         To Second line       4       0.9         Not changed       355       78.7         Reason for change       30.2         Due to TB development       29       30.2         Due to side effect       50       52.1         Failure of treatment       4       4.2         Others       13       13.5         Form of TB       91       76.4         extra pulmonary       28       23.6			7=12
To Second line       4       0.9         Not changed       355       78.7         Reason for change       Due to TB development       29       30.2         Due to side effect       50       52.1         Failure of treatment       4       4.2         Others       13       13.5         Form of TB       91       76.4         extra pulmonary       28       23.6		92	20.4
Not changed       355       78.7         Reason for change       30.2       30.2         Due to TB development       29       30.2         Due to side effect       50       52.1         Failure of treatment       4       4.2         Others       13       13.5         Form of TB       91       76.4         extra pulmonary       28       23.6			
Reason for change         Due to TB development       29       30.2         Due to side effect       50       52.1         Failure of treatment       4       4.2         Others       13       13.5         Form of TB         Pulmonary       91       76.4         extra pulmonary       28       23.6			
Due to TB development       29       30.2         Due to side effect       50       52.1         Failure of treatment       4       4.2         Others       13       13.5         Form of TB       91       76.4         extra pulmonary       28       23.6		333	76.7
Due to side effect       50       52.1         Failure of treatment       4       4.2         Others       13       13.5         Form of TB       91       76.4         extra pulmonary       28       23.6		29	30.2
Failure of treatment       4       4.2         Others       13       13.5         Form of TB       Pulmonary       91       76.4         extra pulmonary       28       23.6	*		
Others       13       13.5         Form of TB       5       13         Pulmonary       91       76.4         extra pulmonary       28       23.6			
Form of TB Pulmonary 91 76.4 extra pulmonary 28 23.6			
Pulmonary 91 76.4 extra pulmonary 28 23.6		13	13.3
extra pulmonary 28 23.6		01	76 1
	·		

AZT, Zidovudine; BMI, Body mass index; CD4, Cluster of differentiation 4; CPT, Co-trimoxazole Preventive Therapy; D4T, Stavudine; EFV, Efavirenz; Hgb, Hemoglobin; IPT, isoniazid preventive therapy; NVP, Nevirapine; OI, Opportunistic Infection; TB, Tuberculosis; TDF, Tenofovir; 3TC, Lamivudine; WHO, World Health Organization

# The incidence of TB stratified with socio-demographic and clinical characteristics

Out of the total 451 HIV/AIDS patients, 119 (26.4%) developed active TB infection during the follow-up period, while 332 were censored (40 transferred out, 13 died, 21 lost to follow-up, and 258 remained TB-negative till the end of follow-up period) (Figure-1). Therefore, the overall TB incidence rate in the five year retrospective data was 8.64 cases per 100 Person-years (PY) of observation. The incidence of patients diagnosed with TB at the end of one year was 4.9 per 100 person-year observation. The sum of the whole follow-up period for all 451 HIV/AIDS infected individuals was 1377.41 Person-years of observation. The minimum and maximum follow-up observation was 0.03 and 58.8 months, respectively. The median (IQR) follow-up period was 46.74 months of observation [IOR=15.95-52.42 months]. Females constituted more than half, 67 (56.3%), of the total TB patients. Three-quarters, 91 (76.47%), of the cases were pulmonary TB. About 68 (57.14%) of the TB incidents occurred within the first year of follow up. The incidence of TB was 105 cases and 14 cases among urban and rural dwellers, respectively. The test of equality for survival distribution for different levels of different categories was performed with Kaplan Meier, using the long rank test. The cumulative probability of TB patient survival at the end of one year, two, three, and four years was 0.77, 0.68, 0.34 and 0.10, respectively. The median survival time was 54 months (Figure-2). In terms of survival curves, there were significant variations among underweight and normal weight (p<0.002) (Figure-3); different WHO clinical stage categories (P<0.001) (**Figure-4**); anemic and non-anemic (p<0.001) (Figure-5); bedridden and otherwise (p<0.002) (Figure-6); and IPT receivers and non-receivers (P<0.0001) (Figure-7). Out of the participants who developed TB, 41 (34.5%) had previous TB disease, and 8 (6.7%) were bedridden at the time of enrollment. One hundred fifteen (96.6%) of the TB cases were not given INH prophylactic therapy. Fifty (42.0%) with incident cases of TB were enrolled with Hgb level below11g/dL (Table-2).

Table 2: The incidence of tuberculosis stratified by socio-demographic and clinical characteristics of PLHIV on HIV chronic care at selected government health facilities of Afar Regional State, July 2010 to May 2015

Characteristics         Total N(%)         TB incidence N(%)         Person-Vears observation (PY)           Vears of follow-up (median=46.74, IQR=15.95-52.42, months)         Onc year         88(19.5)         68(57.1)         35.07           Two years         41(9.0)         28(23.5)         54.73           Three years         32(7.0)         11(9.3)         76.66           Forth         89(19.8)         9(7.6)         322.67           Fifth         201(44.6)         3(2.5)         888.28           Age (years)         15-25         55(12.2)         14(11.7)         158.81           26-34         242(53.7)         63(52.9)         739.05           35-44         119(26.3)         30(25.3)         384.1           ≥45         35(7.8)         12(10.1)         95.45           Sex         8         840.51           Male         184(40.8)         52(43.7)         536.9           Female         267(59.2)         67(56.3)         840.51           Residence         1         14(11.8)         116.74           Warial status         44(40.9)         105(88.2)         1260.67           Bural         44(31.9)         30(25.2)         435.14           Marrial sta	Regional State, July 2010 to May 2015						
Vears of follow-up ( median=46.74, IQR=15.95-52.42, months)           One year         88(9.5)         68(57.1)         35.07           Two years         41(9.0)         28(23.5)         54.73           Three years         32(7.0)         11(9.3)         76.66           Forth         89(19.8)         9(7.6)         322.67           Fifth         201(44.6)         3(2.5)         888.28           Age (vears)         88.22         32.3         32.5           15-25         55(12.2)         14(11.7)         158.81           26-34         242(63.7)         63(52.9)         739.05           35-44         119(26.3)         30(25.3)         384.1           ≥45         35(7.8)         12(10.1)         95.45           Sex         840.51         840.51           Male         184(40.8)         52(43.7)         536.9           Female         267(59.2)         67(56.3)         840.51           Residence         Urban         410(90.9)         105(88.2)         1260.67           Rural         41(9.1)         14(11.8)         116.74           Marrial status         Single         144(31.9)         30(25.2)         435.14	Characteristics						
One year         88(19.5)         68(57.1)         35.07           Two years         41(9.0)         28(23.5)         54.73           Three years         32(7.0)         11(9.3)         76.66           Forth         89(19.8)         9(7.6)         322.67           Fifth         201(44.6)         3(2.5)         888.28           Age (years)         15-25         55(12.2)         14(11.7)         158.81           26-34         242(53.7)         63(52.9)         739.05           35-44         119(26.3)         30(25.3)         384.1           245         35(7.8)         12(10.1)         95.45           Sex         Male         184(40.8)         52(43.7)         536.9           Female         267(59.2)         67(56.3)         840.51           Residence         Urban         410(90.9)         105(88.2)         1260.67           Rural         41(9.1)         14(11.8)         116.74           Marrital status         Single         144(31.9)         30(25.2)         435.14           Married         200(44.3)         52(43.7)         616.07           Divorced         77(17.1)         30(25.2)         435.14           Married				(PY)			
Two years							
Three years 32(7.0) 11(9.3) 76.66 Forth 89(19.8) 9(7.6) 322.67 Fifth 201(44.6) 3(2.5) 888.28 Age (years)  15-25 55(12.2) 14(11.7) 158.81 26-34 242(53.7) 63(52.9) 739.05 35-44 119(26.3) 30(25.3) 384.1 ≥45 35(7.8) 12(10.1) 95.45 Sex  Male 184(40.8) 52(43.7) 536.9 Female 267(59.2) 67(56.3) 840.51 Residence  Urban 410(90.9) 105(88.2) 1260.67 Rural 41(9.1) 14(11.8) 116.74  Marital status Single 144(31.9) 30(25.2) 435.14 Married 200(44.3) 52(43.7) 616.07 Divorced 77(17.1) 30(25.2) 184.5 Widowed 30(6.7) 7(7.9) 91.61 Educational status  Illiterate 212(47.0) 55(46.2) 683.8 Primary School 177(39.3) 49 (41.2) 510.54 Secondary and above 62(13.7) 51(2.6) 183.07 Occupation  Self-employed 234(51.8) 59(49.6) 741.68 Government-employed 45(10.1) 9(7.6) 121.45 Non- employment 172(38.1) 51(42.8) 514.28 Religion  Muslim 275(61.0) 70(58.8) 826.69 Orthodox 165(36.6) 47(39.5) 520.89 Others 11(2.4) 2(1.7) 29.83 Family size  1-3 216(47.9) 51(42.9) 668.68 4-5 159(35.3) 43(36.1) 484.74 ≥ 5 159(35.3) 43(36.1)	2		` /				
Forth 89(19.8) 9(7.6) 322.67 Fifth 201(44.6) 3(2.5) 888.28  Age (years)  15-25 55(12.2) 14(11.7) 158.81 26-34 242(53.7) 63(52.9) 739.05 35.44 119(26.3) 30(25.3) 384.1 245 35(7.8) 12(10.1) 95.45  Sex  Male 184(40.8) 52(43.7) 536.9 Female 267(59.2) 67(56.3) 840.51  Residence  Urban 410(90.9) 105(88.2) 1260.67 Rural 41(9.1) 14(11.8) 116.74  Marrial status  Single 144(31.9) 30(25.2) 435.14  Married 200(44.3) 52(43.7) 616.07  Divorced 77(17.1) 30(25.2) 184.5  Widowed 30(6.7) 7(7.9) 91.61  Educational status  Illiterate 212(47.0) 55(46.2) 683.8  Primary School 177(39.3) 49 (41.2) 510.54 Secondary and above 62(13.7) 15(12.6) 183.07  Occupation  Self-employed 234(51.8) 59(49.6) 741.68 Government-employed 45(10.1) 9(7.6) 121.45 Non- employment 172(38.1) 51(42.8) 514.28  Religion  Muslim 275(61.0) 70(58.8) 826.69 Orthodox 165(36.6) 47(39.5) 520.89 Others 11(2.4) 2(1.7) 29.83  Family size  1-3 216(47.9) 51(42.9) 668.68 4-5 159(35.3) 43(36.1) 484.74 >>5 5 76(16.8) 25(21.0) 223.99  Substance use  Yes 130(28.8) 42(35.3) 379.7	•	` ′	` /				
Fifth 201(4.6) 3(2.5) 888.28  Age (years)  15-25 55(12.2) 14(11.7) 158.81 26-34 242(53.7) 63(52.9) 739.05 35-44 119(26.3) 30(25.3) 384.1 ≥45 35(7.8) 12(10.1) 95.45  Sex  Male 184(40.8) 52(43.7) 536.9 Female 267(59.2) 67(56.3) 840.51  Residence  Urban 410(90.9) 105(88.2) 1260.67 Rural 41(9.1) 14(11.8) 116.74  Marital status  Single 144(31.9) 30(25.2) 435.14 Married 200(44.3) 52(43.7) 616.07 Divorced 77(17.1) 30(25.2) 184.5 Widowed 30(6.7) 7(7.9) 91.61  Educational status  Illiterate 212(47.0) 55(46.2) 683.8 Primary School 177(39.3) 49 (41.2) 510.54 Secondary and above 62(13.7) 15(12.6) 183.07  Occupation  Self-employed 234(51.8) 59(49.6) 741.68 Government-employed 45(10.1) 9(7.6) 121.45 Non- employment 172(38.1) 51(42.8) 510.54  Religion  Muslim 275(61.0) 70(58.8) 826.69 Orthodox 165(36.6) 47(39.5) 520.89 Orthodox 165(36.6) 47(39.5) 520.89 Orthors 11(2.4) 2(1.7) 29.83  Family size  1-3 216(47.9) 51(42.9) 668.68 4-5 159(35.3) 43(36.1) 484.74 ≥5 159(35.3) 43(36	•	, ,	` /				
Age (years)         15-25       55(12.2)       14(11.7)       158.81         26-34       242(53.7)       63(52.9)       739.05         35-44       119(26.3)       30(25.3)       384.1         ≥45       35(7.8)       12(10.1)       95.45         Sex         Male       184(40.8)       52(43.7)       536.9         Female       267(59.2)       67(56.3)       840.51         Residence         Urban       410(90.9)       105(88.2)       1260.67         Rural       41(9.1)       14(11.8)       116.74         Married       20(44.3)       52(43.7)       616.07         Divorced       77(17.1)       30(25.2)       435.14         Married       200(44.3)       52(43.7)       616.07         Divorced       77(17.1)       30(25.2)       184.5         Widowed       30(6.7)       7(7.9)       91.61         Educational status         Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07		` ′	9(7.6)				
15-25         55(12.2)         14(11.7)         158.81           26-34         242(53.7)         63(52.9)         739.05           35-44         119(26.3)         30(25.3)         384.1           245         35(7.8)         12(10.1)         95.45           Sex           Male         184(40.8)         52(43.7)         536.9           Female         267(59.2)         67(56.3)         840.51           Residence           Urban         410(90.9)         105(88.2)         1260.67           Rural         41(9.1)         14(11.8)         116.74           Married         414(31.9)         30(25.2)         435.14           Married         200(44.3)         52(43.7)         616.07           Divorced         77(17.1)         30(25.2)         435.14           Married         200(44.3)         52(43.7)         616.07           Divorced         77(17.1)         30(25.2)         184.5           Widowed         30(6.7)         7(7.9)         91.61           Educational status           Illiterate         212(47.0)         55(46.2)         683.8 </td <td></td> <td>201(44.6)</td> <td>3(2.5)</td> <td>888.28</td>		201(44.6)	3(2.5)	888.28			
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$							
35-44 119(26.3) 30(25.3) 384.1 ≥45 35(7.8) 12(10.1) 95.45  Sex  Male 184(40.8) 52(43.7) 536.9 Female 267(59.2) 67(56.3) 840.51  Residence Urban 410(90.9) 105(88.2) 1260.67 Rural 41(9.1) 14(11.8) 116.74  Marital status Single 144(31.9) 30(25.2) 435.14 Married 200(44.3) 52(43.7) 616.07 Divorced 77(17.1) 30(25.2) 184.5 Widowed 30(6.7) 7(7.9) 91.61  Educational status Illiterate 212(47.0) 55(46.2) 683.8 Primary School 177(39.3) 49 (41.2) 510.54 Secondary and above 62(13.7) 15(12.6) 183.07  Occupation  Occupation  Self-employed 234(51.8) 59(49.6) 741.68 Government-employed 45(10.1) 9(7.6) 121.45 Non- employment 172(38.1) 51(42.8) 514.28  Religion  Muslim 275(61.0) 70(58.8) 826.69 Orthodox 165(36.6) 47(39.5) 520.89 Others 11(2.4) 2(1.7) 29.83  Family size  1-3 216(47.9) 51(42.9) 668.68 4-5 159(35.3) 43(36.1) 484.74 2-5 76(16.8) 25(21.0) 223.99  Substance use  Yes 130(28.8) 42(35.3) 379.7			14(11.7)	158.81			
≥45	26-34	242(53.7)	63(52.9)	739.05			
Sex         Male         184(40.8)         52(43.7)         536.9           Female         267(59.2)         67(56.3)         840.51           Residence         Urban         410(90.9)         105(88.2)         1260.67           Rural         41(9.1)         14(11.8)         116.74           Marital status         Single         144(31.9)         30(25.2)         435.14           Married         200(44.3)         52(43.7)         616.07           Divorced         77(17.1)         30(25.2)         184.5           Widowed         30(6.7)         7(7.9)         91.61           Educational status         Illiterate         212(47.0)         55(46.2)         683.8           Primary School         177(39.3)         49 (41.2)         510.54           Secondary and above         62(13.7)         15(12.6)         183.07           Occupation         Self-employed         234(51.8)         59(49.6)         741.68           Government-employed         45(10.1)         9(7.6)         121.45           Non- employment         172(38.1)         51(42.8)         514.28           Religion         Muslim         275(61.0)         70(58.8)         826.69	35-44	119(26.3)	30(25.3)	384.1			
Male       184(40.8)       52(43.7)       536.9         Female       267(59.2)       67(56.3)       840.51         Residence       Urban       410(90.9)       105(88.2)       1260.67         Rural       41(9.1)       14(11.8)       116.74         Marital status       Single       144(31.9)       30(25.2)       435.14         Married       200(44.3)       52(43.7)       616.07         Divorced       77(17.1)       30(25.2)       184.5         Widowed       30(6.7)       7(7.9)       91.61         Educational status         Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation       Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion         Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5	≥45	35(7.8)	12(10.1)	95.45			
Female         267(59.2)         67(56.3)         840.51           Residence         Urban         410(90.9)         105(88.2)         1260.67           Rural         41(9.1)         14(11.8)         116.74           Marital status         Single         144(31.9)         30(25.2)         435.14           Married         200(44.3)         52(43.7)         616.07           Divorced         77(17.1)         30(25.2)         184.5           Widowed         30(6.7)         7(7.9)         91.61           Educational status         Illiterate         212(47.0)         55(46.2)         683.8           Primary School         177(39.3)         49 (41.2)         510.54           Secondary and above         62(13.7)         15(12.6)         183.07           Occupation         Self-employed         234(51.8)         59(49.6)         741.68           Government-employed         45(10.1)         9(7.6)         121.45           Non- employment         172(38.1)         51(42.8)         514.28           Religion         Muslim         275(61.0)         70(58.8)         826.69           Orthodox         165(36.6)         47(39.5)         520.89           Oth	Sex						
Residence         Urban       410(90.9)       105(88.2)       1260.67         Rural       41(9.1)       14(11.8)       116.74         Marital status         Single       144(31.9)       30(25.2)       435.14         Married       200(44.3)       52(43.7)       616.07         Divorced       77(17.1)       30(25.2)       184.5         Widowed       30(6.7)       7(7.9)       91.61         Educational status         Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion         Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83 <td< td=""><td>Male</td><td>184(40.8)</td><td>52(43.7)</td><td>536.9</td></td<>	Male	184(40.8)	52(43.7)	536.9			
Urban       410(90.9)       105(88.2)       1260.67         Rural       41(9.1)       14(11.8)       116.74         Marital status       Single       144(31.9)       30(25.2)       435.14         Married       200(44.3)       52(43.7)       616.07         Divorced       77(17.1)       30(25.2)       184.5         Widowed       30(6.7)       7(7.9)       91.61         Educational status       Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation       Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion       Wuslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(3	Female	267(59.2)	67(56.3)	840.51			
Rural       41(9.1)       14(11.8)       116.74         Marital status       Single       144(31.9)       30(25.2)       435.14         Married       200(44.3)       52(43.7)       616.07         Divorced       77(17.1)       30(25.2)       184.5         Widowed       30(6.7)       7(7.9)       91.61         Educational status       Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation       Value       Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion       Wuslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size       1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74       25       76(16.8)	Residence						
Marital status         Single       144(31.9)       30(25.2)       435.14         Married       200(44.3)       52(43.7)       616.07         Divorced       77(17.1)       30(25.2)       184.5         Widowed       30(6.7)       7(7.9)       91.61         Educational status         Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Octupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion       Religion       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99	Urban	410(90.9)	105(88.2)	1260.67			
Single       144(31.9)       30(25.2)       435.14         Married       200(44.3)       52(43.7)       616.07         Divorced       77(17.1)       30(25.2)       184.5         Widowed       30(6.7)       7(7.9)       91.61         Educational status         Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion         Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)	Rural	41(9.1)	14(11.8)	116.74			
Married       200(44.3)       52(43.7)       616.07         Divorced       77(17.1)       30(25.2)       184.5         Widowed       30(6.7)       7(7.9)       91.61         Educational status         Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion       Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.	Marital status						
Divorced       77(17.1)       30(25.2)       184.5         Widowed       30(6.7)       7(7.9)       91.61         Educational status       Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion       Wuslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Single	144(31.9)	30(25.2)	435.14			
Widowed       30(6.7)       7(7.9)       91.61         Educational status       Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion         Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Married	200(44.3)	52(43.7)	616.07			
Educational status         Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion         Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Divorced	77(17.1)	30(25.2)	184.5			
Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion         Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Widowed	30(6.7)	7(7.9)	91.61			
Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion       Secondary and above       82(6.9)       668.69         Orthodox       165(36.6)       70(58.8)       82(6.9)         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	<b>Educational status</b>						
Secondary and above       62(13.7)       15(12.6)       183.07         Occupation       Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion       Wuslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Illiterate	212(47.0)	55(46.2)	683.8			
Occupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion         Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Primary School	177(39.3)	49 (41.2)	510.54			
Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion         Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Secondary and above	62(13.7)	15(12.6)	183.07			
Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion       Wuslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Occupation						
Non- employment       172(38.1)       51(42.8)       514.28         Religion       Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Self-employed	234(51.8)	59(49.6)	741.68			
Religion         Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Government-employed	45(10.1)	9(7.6)	121.45			
ReligionMuslim275(61.0)70(58.8)826.69Orthodox165(36.6)47(39.5)520.89Others11(2.4)2(1.7)29.83Family size1-3216(47.9)51(42.9)668.684-5159(35.3)43(36.1)484.74>576(16.8)25(21.0)223.99Substance useYes130(28.8)42(35.3)379.7	Non- employment	172(38.1)	51(42.8)	514.28			
Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Religion						
Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Muslim	275(61.0)	70(58.8)	826.69			
Family size  1-3	Orthodox	165(36.6)	47(39.5)	520.89			
1-3 216(47.9) 51(42.9) 668.68 4-5 159(35.3) 43(36.1) 484.74 >5 76(16.8) 25(21.0) 223.99 Substance use Yes 130(28.8) 42(35.3) 379.7	Others	11(2.4)	2(1.7)	29.83			
4-5 159(35.3) 43(36.1) 484.74 >5 76(16.8) 25(21.0) 223.99 <b>Substance use</b> Yes 130(28.8) 42(35.3) 379.7	Family size		, ,				
4-5 159(35.3) 43(36.1) 484.74 >5 76(16.8) 25(21.0) 223.99 <b>Substance use</b> Yes 130(28.8) 42(35.3) 379.7	1-3	216(47.9)	51(42.9)	668.68			
>5 76(16.8) 25(21.0) 223.99 <b>Substance use</b> Yes 130(28.8) 42(35.3) 379.7	4-5	159(35.3)		484.74			
<b>Substance use</b> Yes 130(28.8) 42(35.3) 379.7	>5	76(16.8)	` /	223.99			
Yes 130(28.8) 42(35.3) 379.7	Substance use		` /				
		130(28.8)	42(35.3)	379.7			
()	No	321(71.2)	77(64.7)	997.71			

Previous TB disease			
Yes	74(16.4)	41(34.5)	164.74
No	377(83.6)	78(65.5)	1212.67
Opportunistic infection (O	( )	,	
Yes	34(7.5)	19(16)	85.28
No	417(92.5)	100(84)	1292.13
Chronic illness	,	,	
Yes	35(7.8)	11(9.2)	106.28
No	416(92.2)	108(90.8)	1271.13
Bedridden	,	,	
Yes	11 (2.4)	8(6.7)	33
No	440(97.6)	111(93.3)	1356.76
BMI (kg/m <sup>2</sup> )		` ,	
<18.5	218(48.3)	75(64)	626.46
>18.5	203(45.0)	42(36)	750.95
Hgb level (g/dL)		, ,	
<11	107(23.7)	50(42.0)	233.8
≥11	344(76.3)	69(58.0)	1143.6
CD4 cell count (cells/uL)		, ,	
<100	44(9.7)	22(18.5)	84.77
100-200	124(27.5)	40(33.6)	343.72
201-349	125(27.7)	29(24.4)	384.29
>350	158(35.0)	28(23.5)	564.63
On ART			
Yes	215 (47.7)	36 (30.3)	941.70
No	236(52.3)	83(69.7)	435.71
WHO clinical stage			
I & II	210(46.6%)	36(30.3)	785.3
III	172(38.1)	59(49.6)	464.98
IV	69(15.3)	24(20.1)	187.13
Initial regimen			
d4t-3TC-NVP	65(14.4)	14(11.7)	223.56
AZT-3TC-EFV	89(19.7)	20(16.8)	296.28
AZT-3TC-NVP	110(24.4)	28(23.5)	349.17
TDF-3TC-EFV	170(37.7)	52(43.7)	461.71
Others	17(3.8)	5(4.3)	46.69
IPT use			
Yes	94(20.8)	4(3.4)	363.60
No	357(79.1)	115(96.6)	1013.81
CPT use			
Yes	413(91.6)	108(90.8)	1259.65
No	38(8.4)	11(9.2)	117.76

<sup>1</sup> AZT, Zidovudine; BMI, Body mass index; CD4, Cluster of differentiation 4; CPT, Co-trimoxazole

<sup>2</sup> Preventive Therapy; D4T, Stavudine; EFV, Efavirenz; Hgb, Hemoglobin; IPT, isoniazid preventive

therapy; NVP, Nevirapine; OI, Opportunistic Infections; TB, Tuberculosis; TDF, Tenofovir; 3TC,

<sup>4</sup> Lamivudine; WHO, World Health Organization

### **Determinants of TB incidence**

In the bivariable cox regression analysis, marital status, family size, substance use, history of TB, baseline CD4 count, WHO clinical stage, opportunistic infection, body mass index (BMI), hemoglobin level, isoniazid preventive therapy (IPT), and functional status were found to be predictors of the incidence of tuberculosis at a p-value of less than 0.2. Consequently, these variables were subjected to multivariate cox regression analysis and previous TB disease, bed-ridden functional status, hemoglobin, BMI, IPT and advanced WHO clinical stage were found

8 statistically significant determinants of TB free survival at a p-value of less than 0.05.

Accordingly, the multivariate cox regression analysis indicated that people living with HIV (PLHIV) and had history of TB disease were 3.65 times at higher risk of developing TB at any time than to PLHIV who had no history of TB (AHR 3.65, 95% CI 1.97-6.73). PLHIV who were in bed-ridden functional status at base-line were 5.45 times at more risk of developing TB compared with PLHIV not in bedridden functional status (AHR 5.45, 95% CI 1.16-25.49). Similarly, PLHIV with baseline BMI less than 18.5kg/m² were 2.53 times at higher risk of developing TB at any time than those with BMI greater than 18.5kg/m² (AHR 2.53, 95 % CI 1.27-5.05). Individuals who took Isoniazid preventive therapy (IPT) were 86% less likely to develop TB at any time compared to those who didn't take IPT (AHR 0.14, 95% CI 0.05-0.39). PLHIV in WHO clinical stage III and IV had a greater risk of developing TB compared with WHO stage I and II (AHR 2.84, 95% CI 1.11, 7.27), and (AHR3.07, 95% CI 1.08, 8.75), respectively. The study also revealed that the incidence of TB in the first three years of follow-up was higher when compared with the other subsequent years. In addition, PLHIV who were anemic (Hgb <11g/dL) were 2.31 times at higher risk of developing TB than those with Hgb level greater than 11 g/dL (AHR 2.31, 95% CI 1.35-3.93) (Table-3).

Table 3: Cox regression analysis of the determinants of the incidence of tuberculosis among adult on chronic HIV care at selected government health facilities of Afar Regional State from July 2010 to May 2015

Event (TB) Censored           Marital status           Single         30         114         144         1.00         1.00           Married         52         148         200         1.34 (0.80-2.23)         1.26 (0.65-2.4           Divorce         30         47         77         2.43 (1.32-4.46)         1.75 (0.83-3.6           Widowed         7         23         30         1.16 (0.45-2.95)         2.42 (0.79-7.3           Family size           1-3         51         165         216         1.00         1.00           4-5         43         116         159         1.19 (0.75-1.92)         0.49 (0.25-1.3           >5         25         51         76         1.58 (0.89-2.81)         0.71 (0.35-1.7           Substance use           Yes         42         88         130         1.51 (0.96-2.37)         1.47 (0.84-2.5           No         77         244         321         1.00         1.00           Previous TB disease           Yes         41         33         74         4.76 (2.83-8.03)         3.65 (1.97-6.73           No         78         299         377         1	to May, 2015						
Marital status   Single	riables			Total	CHR (95% CI)	AHR(95% CI)	
Single         30         114         144         1.00         1.00           Married         52         148         200         1.34 (0.80-2.23)         1.26 (0.65-2.4           Divorce         30         47         77         2.43 (1.32-4.46)         1.75 (0.83-3.6           Widowed         7         23         30         1.16 (0.45-2.95)         2.42 (0.79-7.3           Family size           1-3         51         165         216         1.00         1.00           4-5         43         116         159         1.19 (0.75-1.92)         0.49 (0.25-1.3           >5         25         51         76         1.58 (0.89-2.81)         0.71 (0.35-1.7           Substance use           Yes         42         88         130         1.51 (0.96-2.37)         1.47 (0.84-2.5           No         77         244         321         1.00         1.00           Previous TB disease           Yes         41         33         74         4.76 (2.83-8.03)         3.65 (1.97-6.73           No         78         299         377         1.00         1.00           Opportunistic infection (OI)		Event (TB)	Censored				
Married       52       148       200       1.34 (0.80-2.23)       1.26 (0.65-2.4 Divorce       30       47       77       2.43 (1.32-4.46)       1.75 (0.83-3.6 divided)       72 (0.83-3.6 divided)       1.75 (0.83-3.6 divided)       1.75 (0.83-3.6 divided)       1.75 (0.83-3.6 divided)       1.76 (0.83-3.6 divided)       1.76 (0.45-2.95)       2.42 (0.79-7.3 divided)       2.44 (0.75-1.92)       0.49 (0.25-1.3 divided)       2.55 (0.25-1.3 divided)       2.55 (0.25-1.3 divided)       2.55 (0.25-1.3 divided)       2.56 (0.25-1.3 divided)       2.56 (0.25-1.3 divided)       2.56 (0.25-1.3 divided)       2.57 (0.25-1.3 divided)       2.57 (0.25-1.3 divided)       2.51 (0.96-2.37) divided)       1.47 (0.84-2.5 divided)       2.55 (0.25-1.3 divided)       2.51 (0.96-2.37) divided)       1.47 (0.84-2.5 divided)       2.51 (0.96-2.37) divided)       1.47 (0.84-2.5 divided)       2.57 (0.96-2.37) divided)       1.47 (0.84-2.5 divided)       2.51 (0.96-2.37) d							
Divorce         30         47         77         2.43 (1.32-4.46)         1.75 (0.83-3.6)           Widowed         7         23         30         1.16 (0.45-2.95)         2.42 (0.79-7.3)           Family size           1-3         51         165         216         1.00         1.00           4-5         43         116         159         1.19 (0.75-1.92)         0.49 (0.25-1.3           >5         25         51         76         1.58 (0.89-2.81)         0.71 (0.35-1.7           Substance use           Yes         42         88         130         1.51 (0.96-2.37)         1.47 (0.84-2.5           No         77         244         321         1.00         1.00           Previous TB disease           Yes         41         33         74         4.76 (2.83-8.03)         3.65 (1.97-6.73           No         78         299         377         1.00         1.00           Opportunistic infection (OI)           Yes         19         15         34         4.02 (1.97-8.19)         2.31 (0.98-5.45)           No         100         317         417         1.00         1.00           <	ıgle		114	144		1.00	
Widowed       7       23       30       1.16 (0.45-2.95)       2.42 (0.79-7.3 femily size         1-3       51       165       216       1.00       1.00         4-5       43       116       159       1.19 (0.75-1.92)       0.49 (0.25-1.3 sept.)         >5       25       51       76       1.58 (0.89-2.81)       0.71 (0.35-1.7 sept.)         Substance use         Yes       42       88       130       1.51 (0.96-2.37)       1.47 (0.84-2.5 no.)         No       77       244       321       1.00       1.00         Previous TB disease         Yes       41       33       74       4.76 (2.83-8.03)       3.65 (1.97-6.73 no.)         No       78       299       377       1.00       1.00         Opportunistic infection (OI)         Yes       19       15       34       4.02 (1.97-8.19)       2.31 (0.98-5.45)         No       100       317       417       1.00       1.00         Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.0	arried	52	148	200	1.34 (0.80-2.23)	1.26 (0.65-2.43)	
Family size  1-3	vorce	30		77	2.43 (1.32-4.46)	1.75 (0.83-3.68)	
1-3	idowed	7	23	30	1.16 (0.45-2.95)	2.42 (0.79-7.38)	
4-5	mily size						
>5     25     51     76     1.58 (0.89-2.81)     0.71 (0.35-1.7)       Substance use       Yes     42     88     130     1.51 (0.96-2.37)     1.47 (0.84-2.5       No     77     244     321     1.00     1.00       Previous TB disease       Yes     41     33     74     4.76 (2.83-8.03)     3.65 (1.97-6.73)       No     78     299     377     1.00     1.00       Opportunistic infection (OI)       Yes     19     15     34     4.02 (1.97-8.19)     2.31 (0.98-5.45)       No     100     317     417     1.00     1.00       Bedridden       Yes     8     3     11     7.90 (2.06-30.31)     5.45 (1.16-25.49)*       No     111     329     440     1.00     1.00       BMI (kg/m²)       <18.5	3		165	216		1.00	
Substance use           Yes         42         88         130         1.51 (0.96-2.37)         1.47 (0.84-2.5 No         77         244         321         1.00 <td>5</td> <td>43</td> <td>116</td> <td>159</td> <td>1.19 (0.75-1.92)</td> <td>0.49 (0.25-1.34)</td>	5	43	116	159	1.19 (0.75-1.92)	0.49 (0.25-1.34)	
Yes       42       88       130       1.51 (0.96-2.37)       1.47 (0.84-2.5 No         No       77       244       321       1.00       1.00         Previous TB disease         Yes       41       33       74       4.76 (2.83-8.03)       3.65 (1.97-6.73 No         No       78       299       377       1.00       1.00         Opportunistic infection (OI)         Yes       19       15       34       4.02 (1.97-8.19)       2.31 (0.98-5.45)         No       100       317       417       1.00       1.00         Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5		25	51	76	1.58 (0.89-2.81)	0.71 (0.35-1.76)	
No       77       244       321       1.00       1.00         Previous TB disease         Yes       41       33       74       4.76 (2.83-8.03)       3.65 (1.97-6.73)         No       78       299       377       1.00       1.00         Opportunistic infection (OI)         Yes       19       15       34       4.02 (1.97-8.19)       2.31 (0.98-5.45)         No       100       317       417       1.00       1.00         Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5	bstance use						
No       77       244       321       1.00       1.00         Previous TB disease         Yes       41       33       74       4.76 (2.83-8.03)       3.65 (1.97-6.73)         No       78       299       377       1.00       1.00         Opportunistic infection (OI)         Yes       19       15       34       4.02 (1.97-8.19)       2.31 (0.98-5.45)         No       100       317       417       1.00       1.00         Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5	es	42	88	130	1.51 (0.96-2.37)	1.47 (0.84-2.56)	
Yes       41       33       74       4.76 (2.83-8.03)       3.65 (1.97-6.73)         No       78       299       377       1.00       1.00         Opportunistic infection (OI)         Yes       19       15       34       4.02 (1.97-8.19)       2.31 (0.98-5.45)         No       100       317       417       1.00       1.00         Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5	)	77	244	321	1.00		
No       78       299       377       1.00       1.00         Opportunistic infection (OI)         Yes       19       15       34       4.02 (1.97-8.19)       2.31 (0.98-5.45)         No       100       317       417       1.00       1.00         Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5	evious TB disea	se					
Opportunistic infection (OI)         Yes       19       15       34       4.02 (1.97-8.19)       2.31 (0.98-5.45)         No       100       317       417       1.00       1.00         Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5	żs	41	33	74	4.76 (2.83-8.03)	3.65 (1.97-6.73)**	
Yes       19       15       34       4.02 (1.97-8.19)       2.31 (0.98-5.45)         No       100       317       417       1.00       1.00         Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5       75       143       218       2.01(1.29-3.12)       2.53(1.27-5.05)***         ≥18.5       42       161       203       1.00       1.00         Length of follow-up       ≤ 1 year       68       20       88       78.76 (36.7-168.9)       83.76 (33.94-206.7         2-3 years       39       34       73       26.57 (12.7-55.6)       33.81(14.12-80.96)         4-5 years       12       278       290       1.00       1.00         WHO clinical stage       1       13       172       2.52 (1.57-4.07)       2.84(1.11-7.27)**         IV       24       45       69       2.58 (1.40-4.75)       3.07(1.08-8.75)**         Hgb level (g/dL)	)	78	299	377			
Yes       19       15       34       4.02 (1.97-8.19)       2.31 (0.98-5.45)         No       100       317       417       1.00       1.00         Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5       75       143       218       2.01(1.29-3.12)       2.53(1.27-5.05)***         ≥18.5       42       161       203       1.00       1.00         Length of follow-up       ≤ 1 year       68       20       88       78.76 (36.7-168.9)       83.76 (33.94-206.7         2-3 years       39       34       73       26.57 (12.7-55.6)       33.81(14.12-80.96)         4-5 years       12       278       290       1.00       1.00         WHO clinical stage         I &II       36       174       200       1.00       1.00         III       59       113       172       2.52 (1.57-4.07)       2.84(1.11-7.27)**         IV       24       45       69       2.58 (1.40-4.75)       3.07(1.08-8.75)** <th c<="" td=""><td>portunistic infe</td><td>ection (OI)</td><td></td><td></td><td></td><td></td></th>	<td>portunistic infe</td> <td>ection (OI)</td> <td></td> <td></td> <td></td> <td></td>	portunistic infe	ection (OI)				
Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)	S	19	15	34	4.02 (1.97-8.19)	2.31 (0.98-5.45)	
Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5	)	100	317	417	1.00	1.00	
No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5	dridden						
BMI (kg/m²) <18.5 75 143 218 2.01(1.29-3.12) 2.53(1.27-5.05)** ≥18.5 42 161 203 1.00 1.00  Length of follow-up ≤1 year 68 20 88 78.76 (36.7-168.9) 83.76 (33.94-206.7 2-3 years 39 34 73 26.57 (12.7-55.6) 33.81(14.12-80.96 4-5 years 12 278 290 1.00 1.00  WHO clinical stage I &II 36 174 200 1.00 1.00  III 59 113 172 2.52 (1.57-4.07) 2.84(1.11-7.27)** IV 24 45 69 2.58 (1.40-4.75) 3.07(1.08-8.75)**  Hgb level (g/dL)	es	8	3	11	7.90 (2.06-30.31)	5.45 (1.16-25.49)**	
<18.5	)	111	329	440	1.00	1.00	
≥18.5 42 161 203 1.00 1.00  Length of follow-up  ≤1 year 68 20 88 78.76 (36.7-168.9) 83.76 (33.94-206.7 2-3 years 39 34 73 26.57 (12.7-55.6) 33.81(14.12-80.96) 4-5 years 12 278 290 1.00 1.00  WHO clinical stage I &II 36 174 200 1.00 1.00  III 59 113 172 2.52 (1.57-4.07) 2.84(1.11-7.27)** IV 24 45 69 2.58 (1.40-4.75) 3.07(1.08-8.75)**  Hgb level (g/dL)	$MI (kg/m^2)$						
Length of follow-up         ≤1 year       68       20       88       78.76 (36.7-168.9)       83.76 (33.94-206.7)         2-3 years       39       34       73       26.57 (12.7-55.6)       33.81(14.12-80.96)         4-5 years       12       278       290       1.00       1.00         WHO clinical stage         I &II       36       174       200       1.00       1.00         III       59       113       172       2.52 (1.57-4.07)       2.84(1.11-7.27)**         IV       24       45       69       2.58 (1.40-4.75)       3.07(1.08-8.75)**         Hgb level (g/dL)	8.5	75	143	218	2.01(1.29-3.12)	2.53(1.27-5.05)**	
≤ 1 year 68 20 88 78.76 (36.7-168.9) 83.76 (33.94-206.7 2-3 years 39 34 73 26.57 (12.7-55.6) 33.81(14.12-80.96 4-5 years 12 278 290 1.00 1.00 WHO clinical stage I &II 36 174 200 1.00 1.00 III 59 113 172 2.52 (1.57-4.07) 2.84(1.11-7.27)** IV 24 45 69 2.58 (1.40-4.75) 3.07(1.08-8.75)** Hgb level (g/dL)	8.5	42	161	203	1.00	1.00	
2-3 years 39 34 73 26.57 (12.7-55.6) 33.81(14.12-80.96) 4-5 years 12 278 290 1.00 1.00  WHO clinical stage I &II 36 174 200 1.00 1.00 III 59 113 172 2.52 (1.57-4.07) 2.84(1.11-7.27)** IV 24 45 69 2.58 (1.40-4.75) 3.07(1.08-8.75)**  Hgb level (g/dL)	ngth of follow-u	ıp					
2-3 years 39 34 73 26.57 (12.7-55.6) 33.81(14.12-80.96) 4-5 years 12 278 290 1.00 1.00  WHO clinical stage I &II 36 174 200 1.00 1.00 III 59 113 172 2.52 (1.57-4.07) 2.84(1.11-7.27)** IV 24 45 69 2.58 (1.40-4.75) 3.07(1.08-8.75)**  Hgb level (g/dL)	l year	68	20	88	78.76 (36.7-168.9)	83.76 (33.94-206.7)**	
WHO clinical stage         I &II       36       174       200       1.00       1.00         III       59       113       172       2.52 (1.57-4.07)       2.84(1.11-7.27)**         IV       24       45       69       2.58 (1.40-4.75)       3.07(1.08-8.75)**         Hgb level (g/dL)       45       69       2.58 (1.40-4.75)       3.07(1.08-8.75)**		39	34	73	26.57 (12.7-55.6)	33.81(14.12-80.96)**	
I &II     36     174     200     1.00     1.00       III     59     113     172     2.52 (1.57-4.07)     2.84(1.11-7.27)**       IV     24     45     69     2.58 (1.40-4.75)     3.07(1.08-8.75)**       Hgb level (g/dL)	5 years	12	278	290	1.00	1.00	
III 59 113 172 2.52 (1.57-4.07) 2.84(1.11-7.27)** IV 24 45 69 2.58 (1.40-4.75) 3.07(1.08-8.75)** <b>Hgb level (g/dL)</b>	•	ge					
IV 24 45 69 2.58 (1.40-4.75) 3.07(1.08-8.75)** <b>Hgb level (g/dL)</b>	lΙΣ	36	174	200	1.00	1.00	
Hgb level (g/dL)		59	113	172	2.52 (1.57-4.07)	2.84(1.11-7.27)**	
		24	45	69	2.58 (1.40-4.75)	3.07(1.08-8.75)**	
	gb level (g/dL)					,	
		50	57	107	3.49 (2.20-5.55)	2.31(1.35-3.93)**	
$\geq 11$ 69 275 344 1.00 1.00	1	69	275	344	1.00	1.00	
CD4 count (cells/uL)		ıL)					
<100 22 24 44 4.64 (2.26-9.52) 1.14(0.46-2.82)	00	22	22	44	4.64 (2.26-9.52)	1.14(0.46-2.82)	
100-200 40 84 124 2.21 (1.27-3.85) 1.29(0.66-2.57)	0-200	40	84	124	,	1.29(0.66-2.57)	
201-349 29 96 125 1.40 (0.78-2.51) 0.99(0.49-1.99)		29	96				
≥350 28 130 158 1.00 1.00 1.00					,	,	
ĪPT							
		4	90	94	0.09 (0.03-0.26)	0.14 (0.05, 0.39)**	
No 115 242 357 1.00 1.00			242	357			

<sup>\*\*</sup> Variable significant at p-value less than 0.05

BMI, Body mass index; CD4, Cluster of differentiation 4; Cells/ul, cells per microliter (ul); Hgb, Hemoglobin; g/dl, grams (g) per decilitre (dL); OI, Opportunistic Infection; IPT, isoniazid preventive 

therapy; TB, Tuberculosis; WHO, World Health Organization

### **Discussion**

TB and HIV remain the major public health problems in many parts of the world. Ethiopia is among the TB high burden countries with an estimated annual incidence of 211 cases per 100,000 people and a prevalence of 224 cases per 100,000 (30).

In this study, the overall incidence of TB among PLHIV was 8.64 cases per 100 person-year (PY) observation. This finding is similar to those reported from Gondar and Assela, Ethiopia, which are 7 and 7.9 cases, respectively, per 100 person-year (PY) observations (31, 32). The finding is consistent with that of a study in Tanzania and other Sub-Saharan countries with incidence ranging from 7.6-8.2 per 100 person-year observation (PY) (33, 34). However, the incidence density of TB in this study is higher than those of studies conducted in Korea, Israel, and Malaysia (35-37). The lower incidence of TB in the latter studies compared with this one might be due to the availability of better preventive, diagnostic, and treatment setups and strategies for controlling TB in such countries when compared with our study setting. In addition, low health care coverage, high burden of HIV, and the fact that the study setting is so unprivileged might explain the difference. Furthermore, late enrollment at health facilities due to late presentation of HIV infected people at health facilities, increases the progression of latent infection to active TB after HIV chronic care. It was noted that individuals with late presentation might get new infections or IRIS after initiation into highly active antiretroviral therapy (HAART), and Immune Reconstitution Inflammatory Syndrome (IRIS) related TB is commonly seen within the first six months of initiation into HAART (38). Similarly, it was revealed that the incidence of TB is significantly associated with the length of follow-up year. It was reported that the incidence of TB decreased as the years of follow-up increased, and a higher incidence of TB was reported in the first three of follow-up years compared with the other subsequent years.

Out of the determinants of the incidence of TB infection in the multivariate cox regression analysis, the study revealed that previous TB disease, using IPT, bedridden functional status, low hemoglobin level, advanced WHO staging (III and IV), years of follow-up, and low BMI were

found to be significantly associated with the incidence of TB. Individuals who had history of TB

2 disease had greater risk of developing TB compared with those who had no history of TB

treatment. Poor compliance with anti-TB treatment at the first episode, reactivation or re-

infection of individuals with the existing diminished immunity might be the reasons for higher

incidence of TB among individuals with history of TB infection. This finding is consistent with

those of studies conducted in Uganda, Malaysia, and Israel (36, 37, 39).

8 PLHIV who took Isoniazid preventive therapy (IPT) were found to be protective of the incidence

9 of TB. Individuals who took Isoniazid preventive therapy (IPT) were 86% less likely to develop

TB at any time compared to those who didn't take IPT (AHR=0.14, 95% CI: 0.05-0.39). This

might be due to the role of IPT in reducing the incidence of TB among people living with HIV.

The finding is consistent with those of studies in Ethiopia, South Africa, and Brazil (40-42). In

spite of this fact, poor uptake, ambiguity, and fear of drug resistance might contribute to no-IPT

use.

Similarly, in this study, patients' functional status at baseline was found to be the predictor of TB

17 incidence. Patient bedridden functional status at baseline was 5.45 times at higher risk of

developing TB than individuals with working functional status at baseline. This might be due to

the fact that debilitated patients will be prone to malnutrition, and lack of physical activity

exposes them to many diseases, including TB. This finding is in line with those of other studies

21 conducted in Ethiopia (16, 31, 43).

Out of the anthropometric variables, HIV patients who were underweight (BMI <18.5 kg/m²)

were 2.53 times at higher risk of developing TB compared to individuals with BMI≥18.5 kg/m².

25 This finding was consistent with that of a study done in Tanzania (44), Ethiopia, and South

Africa (33, 45). The possible explanations might be that a low BMI category is a proxy indicator

of malnutrition, and malnutrition in HIV patients is associated with increased catabolic activity,

infection, loss of appetite, and decreased intake, which further increase the risk of developing

opportunistic infections such as tuberculosis.

Furthermore, this study found that patients with Hgb level of <11 g/dL at base-line were 2.31

times at higher risk of developing TB than those with Hgb level  $\ge 11$  at base-line. Hematologic

complications were risk factors for the incidence of TB among PLHIV. This finding is

concordant with those of studies conducted in Ethiopia, Uganda, Tanzania, and South Africa (44-

- 1 47). The possible explanation might be malnutrition, side effects of medications, opportunistic
- 2 infections, and advanced stage of the disease. Undiagnosed TB could explain low Hgb level at
- 3 early enrollment.
- 4 The other important result which was found to have a significant association with the incidence
- of TB was advanced clinical staging (III & IV). PLHIV with advanced WHO staging (III and
- 6 IV), respectively had 2.84 and 3.07 times higher risk of developing TB compared with people in
- 7 stages I & II. The finding corresponded to those of studies conducted in Nigeria (48), South
- 8 Africa (49), and Gambia (50). This might be due to the fact that once patients get into late stages;
- 9 the immunity protective capacity will be minimal, making them predisposed to tuberculosis
- infection. Something worth mentioning as well is that TB is one of the defining factors of AIDS
- that categorizes patients who use HIV/AIDS clinics in Ethiopia into late WHO clinical staging.

### Limitations of the study

- 13 Though the study did its best to indicate the incidence and predictors of tuberculosis among
- 14 PLHIV using a five-year retrospective data, it was not free from limitations. The retrospective
- 15 nature of the study limited the inclusion of all possible factors that could affect the incidence of
- tuberculosis. Variables such as housing condition and household income were some of the
- plausible factors that were not measured in this study. For some risk factors, such as CD4 count,
- 18 the sample size limited the power to provide clinically relevant conclusions because of the
- overall low incidence rate of TB. Inability to conduct culture confirmation (the gold standard
- 20 method) is another limitation of the study. Inability to address TB contacts (other family
- 21 member/co-inhabitant) and introduction of selection bias due to the exclusion of patients who did
- 22 not use the selected hospitals is the other drawback. Since the study was conducted in a single
- 23 region of Ethiopia, it might not indicate the actual incidence of TB in other regions of the
- 24 country.

#### Conclusion

- The overall incidence of TB among PLHIV was found to be comparable with those of similar
- 27 studies in Ethiopia. However, it was higher in the first year of follow-up than it was in the
- 28 subsequent years. HIV infected individuals with history of TB disease, not using IPT,
- underweight status (BMI<18.5kg/m<sup>2</sup>), bedridden functional status, being anemic (Hgb<11g/dL),
- advanced WHO stage (III &IV), and short duration of follow-up were determinants of the

- 1 incidence of TB among PLHIV. Therefore, our study suggested early screening and diagnosis
- 2 among high risk PLHIV such as those in bed-ridden functional status, underweight
- 3 (BMI<18.5kg/m<sup>2)</sup>, and anemic (Hgb <11g/dL). In addition, providing IPT to PLHIV without
- 4 active TB and intensified TB case screening for those with advanced WHO stage is highly
- 5 recommended. In addition, emphasis should be given to those with shorter follow-ups.
- 6 Therefore, attention to PLHIV and prompt diagnosis and treatment of TB are recommended.
- 7 Furthermore, prospective studies need to include all factors that influence the risk of TB among
- 8 PLHIV. Since our study was conducted in a single region of Ethiopia, collaborative projects that
- 9 can include several regions of the country are recommended to give a more balanced view of the
- incidence of TB and potential risk factors in HIV-infected patients.
- 11 List of abbreviations

- 12 AHR, Adjusted hazard ratio; AIDS, Acquired immune deficiency syndrome; ART, Anti-
- 13 Retroviral Therapy; BMI, Body mass index; CD4, cluster of differentiation 4; CI, Confidence
- 14 interval; CPT, Cotrimoxazole prophylaxis therapy; EDHS, Ethiopian Demographic health
- survey; HIV, Human immune deficiency; HAART, Highly active anti retro viral therapy; Hgb,
- Hemoglobin; INH, Isoniazid; IQR, Inter quartile range; IPT, Isoniazid preventive therapy; IRIS,
- 17 Immune reconstitution inflammatory syndrome; PLHIV/AIDS, People living with HIV/AIDS;
- 18 PY, person-year observation; TB, tuberculosis; WHO, World health organization
- 19 Competing interests
- The authors declare that they have no conflict of interest.
- 21 Funding
- No specific fund was obtained for this study.
- 23 Data sharing statement
- 24 All data supporting our findings will be shared upon request.
- 25 Authors' contributions
- AA, DM and MKY involved in the conception, design, data collection, analysis and report
- 27 writing. DM, AMS, FB, and MKY assisted with the design, approved the proposal with some
- 28 revisions, participated in data analysis and manuscript preparation. All authors read and
- approved the final manuscript.

## Acknowledgement

- We would like to extend our thanks to Afar Regional Health Beauro for permission to conduct
- the study and providing the necessary preliminary information during the study. We are indebted
- to data collectors and supervisors without whom this project wouldn't have gone so far.

### References

- World Health Organization. Global tuberculosis report 2016. World Health Organization: Geneva, 1. 2016.
- World Health Organization/HIV/AIDS JUNPo. World AIDS Day 2014 Report-Fact sheet. 2.
- Geneva, Switzerland. 2014.
- 3. World Health Organization. Global tuberculosis report 2013. World Health Organization; 2013.
- World Health Organization. Global tuberculosis control 2009: World Health Organization; 2009. 4.
- 5. World Health Organization. Global tuberculosis control 2009: epidemiology, strategy, financing.
- Geneva, Switzerland: World Health Organization, 2009. 2011.
- Zumla A, George A, Sharma V, Herbert RHN, of Ilton BM, Oxley A, et al. The WHO 2014 global tuberculosis report—further to go. The Lancet Global Health. 2015;3(1):e10-e2.
- World Health Organization. Global Tuberculosis Report 2013. World Health Organization:
- Geneva, 2013. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656\_eng.pdf.
- Demographic E. Health Survey (2011) Addis Ababa. Ethiopia and Calverton, Maryland, USA:
- Central Statistical Agency and ICF International. 2012.
- Pawlowski A, Jansson M, Sköld M, et al.. Tuberculosis and HIV co-infection. PLoS Pathog. 9. 2012;8(2):e1002464.
- Health EMo. Ethiopian Federal Ministry of Health/Ethiopian Health & Nutrition Research Institute National. TB/HIV surveillance report. 2012.
- Batista JdAL, Maruza M, de Alencar Ximenes RA, et al. Incidence and risk factors for tuberculosis in people living with HIV: cohort from HIV referral health centers in Recife, Brazil. PloS
- one. 2013;8(5):e63916.
- Jagodziński J, Zielonka TM, Błachnio M. Socio-economic status and duration of TB symptoms in 12.
- males treated at the Mazovian Treatment Centre of Tuberculosis and Lung Diseases in Otwock.
- Pneumonol Alergol Pol. 2012;80(6):533-40.
- Wilkinson D. Drugs for preventing tuberculosis in HIV infected persons. The Cochrane Library. 13.
- 2000.
- Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in 14. adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001270.
- Alvi A, Rizwan M, Sunosi RA, et al. Does khat chewing increases the risk of Mycobacterium
- tuberculosis infection by macrophage immune modulation? Medical hypotheses. 2014;82(6):667-9.
- Kibret KT, Yalew AW, Belaineh BG, et al. Determinant factors associated with occurrence of
- tuberculosis among adult people living with HIV after antiretroviral treatment initiation in Addis Ababa, Ethiopia: a case control study. PloS one. 2013;8(5):e64488.
- Amoakwa K, Martinson NA, Moulton LH, et al. Risk Factors for Developing Active Tuberculosis After the Treatment of Latent Tuberculosis in Adults Infected With Human
- Immunodeficiency Virus. Open forum infectious diseases; 2015: Oxford University Press.
- Bendayan D, Littman K, Polansky V. Active tuberculosis and human immunodeficiency virus co-
- infection in Israel: a retrospective study. The Israel Medical Association journal: IMAJ. 2010;12(2):100-3.
- 19. Hwang J-H, Choe PG, Kim NH, et al. Incidence and risk factors of tuberculosis in patients with human immunodeficiency virus infection. Journal of Korean medical science. 2013;28(3):374-7.

- 20. Méda ZC, Sombié I, Sanon OW, et al. Risk factors of tuberculosis infection among HIV/AIDS patients in Burkina Faso. AIDS research and human retroviruses. 2013;29(7):1045-55.
- Metcalfe JZ, Porco TC, Westenhouse J, et al. Tuberculosis and HIV co-infection, California, USA, 1993–2008. Emerg Infect Dis. 2013;19(3):400-6.
- Ibrahim J. Tuberculosis: an eight year (2000-2007) retrospective study at the University of
- Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia. Southeast Asian Journal of Tropical Medicine and Public Healt. 2010;41(2).
- Maro I, Lahey T, MacKenzie T, et al. Low BMI and falling BMI predict HIV-associated
- tuberculosis: a prospective study in Tanzania. The International Journal of Tuberculosis and Lung Disease. 2010;14(11):1447-53.

- Nantha YS. Influence of diabetes mellitus and risk factors in activating latent tuberculosis
- infection: A case for targeted screening in Malaysia. Med J Malaysia. 2012;67(5):467-72.
- Assebe LF, Reda HL, Wubeneh AD, et al. The effect of isoniazid preventive therapy on incidence
- of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study. BMC public health. 2015;15(1):1.
- Okwera A, Mafigiri DK, Guwatudde D, et al. Level of understanding of co-trimoxazole use
- among HIV infected, recurrent pulmonary tuberculosis suspects at a national referral tuberculosis clinic in
- Kampala, Uganda: a qualitative analysis. African health sciences. 2015;15(1):49-57.
- Ethiopia Central Statistical Agency. Report of Centeral statistical agency., 2014.
- Gudina EK, Gudissa FG. Prevalence of tuberculosis in HIV in Ethiopia in early HAART era: 28.
- Retrospective analysis. The Pan African medical journal. 2013;14.
- Melkamu H, Seyoum B, Dessie Y. Determinants of tuberculosis infection among adult HIV
- positives attending clinical care in western Ethiopia: a case-control study. AIDS research and treatment. 2013;2013.
- 30. World Health Organization. WHO Global TB report 2014.
- 31. Addis Alene K, Nega A, Wasie Taye B. Incidence and predictors of tuberculosis among adult
- people living with human immunodeficiency virus at the University of Gondar Referral Hospital,
- Northwest Ethiopia. BMC Infect Dis. 2013;13:292.
- Abebe A, Etana B, Tsadik M, et al. Assessing the Effect of Highly Active Anti-Retroviral
- Treatment and Associated Factors on Incidence of Tuberculosis among Adult HIV Positive Individuals in
- Assela, Ethiopia. J Health Med Informat. 2014;5(156):2.
- Liu E, Makubi A, Drain P, et al. Tuberculosis incidence rate and risk factors among HIV-infected 33.
- adults with access to antiretroviral therapy. Aids. 2015.
- Haraka F, Glass TR, Sikalengo G, et al. A Bundle of Services Increased Ascertainment of
- Tuberculosis among HIV-Infected Individuals Enrolled in a HIV Cohort in Rural Sub-Saharan Africa.
- PLoS One. 2015;10(4):e0123275.
- Hwang JH, Choe PG, Kim NH, et al. Incidence and risk factors of tuberculosis in patients with 35.
- human immunodeficiency virus infection. J Korean Med Sci. 2013;28(3):374-7.
- Syed Suleiman SA, Ishaq Aweis DM, Mohamed AJ, et al. Role of diabetes in the prognosis and
- therapeutic outcome of tuberculosis. Int J Endocrinol. 2012;2012:645362.
- Mor Z, Lidji M, Cedar N, et al. Tuberculosis Incidence in HIV/AIDS Patients in Israel, 1983-37.
- 2010. PLoS One. 2013;8(11).
- Namale PE, Abdullahi LH, Fine S, et al. Paradoxical TB-IRIS in HIV-infected adults: a
- systematic review and meta-analysis. Future Microbiol. 2015;10:1077-99.
- Amuha MG, Kutyabami P, Kitutu FE, et al. Non-adherence to anti-TB drugs among TB/HIV co-
- infected patients in Mbarara Hospital Uganda: prevalence and associated factors. Afr Health Sci. 2009;9
- Suppl 1:S8-15.
- Assebe LF, Reda HL, Wubeneh AD, et al. The effect of isoniazid preventive therapy on incidence
- of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort
- study. BMC Public Health. 2015;15:346.

- 41. Dowdy DW, Golub JE, Saraceni V, et al. Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model. J Acquir Immune Defic Syndr.
- 2014;66(5):552-8.
- Wood R, Bekker LG. Isoniazid preventive therapy for tuberculosis in South Africa: an assessment of the local evidence base. S Afr Med J. 2014;104(3):174-7.
  - Fekadu S, Teshome W, Alemu G. Prevalence and determinants of Tuberculosis among HIV
- infected patients in south Ethiopia. The Journal of Infection in Developing Countries. 2015;9(08):898-904.
- 44. Maro I, Lahey T, MacKenzie T, et al. Low BMI and falling BMI predict HIV-associated tuberculosis: a prospective study in Tanzania. Int J Tuberc Lung Dis. 2010;14(11):1447-53.
- Melkamu H, Seyoum B, Dessie Y. Determinants of Tuberculosis Infection among Adult HIV
- Positives Attending Clinical Care in Western Ethiopia: A Case-Control Study. AIDS Res Treat.
- 2013;2013:279876.
- Kerkhoff AD, Wood R, Cobelens FG, et al. Resolution of anaemia in a cohort of HIV-infected
- patients with a high prevalence and incidence of tuberculosis receiving antiretroviral therapy in South
  - Africa. BMC Infect Dis. 2014;14:3860.
- Kerkhoff AD, Wood R, Cobelens FG, et al. The predictive value of current haemoglobin levels 47.
- for incident tuberculosis and/or mortality during long-term antiretroviral therapy in South Africa: a cohort
- study. BMC Med. 2015;13:70.
- Akanbi MO, Achenbach CJ, Feinglass J, et al. Tuberculosis after one year of combination
- antiretroviral therapy in Nigeria: a retrospective cohort study. AIDS research and human retroviruses.
- 2013:29(6):931-7.
- Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long 49.
- term incidence and risk factors in a South African cohort. Aids. 2005;19(18):2109-16.
- Hill PC, Jackson-Sillah D, Donkor SA, et al. Risk factors for pulmonary tuberculosis: a clinic-
- based case control study in The Gambia. BMC Public Health. 2006;6(1):156.

# Figure legends

- Figure 1: Flow chart showing selection of HIV/AIDS people at selected Governmental health
- facilities in Northeast Ethiopia, July 2010 to May, 2015
- Figure 2: Kaplan Meier curve of TB survival proportion of HIV/AIDS people at selected
- Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015
- Figure 3: Kaplan Meier survival curve of TB patients based on the BMI category among PLHIV
- at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015
- Figure 4: Kaplan Meier survival curve of TB patients based on the WHO stage among PLHIV at
- selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015
- Figure 5: Kaplan Meier survival curve of TB patients based on hemoglobin level among PLHIV
- at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015
- Figure 6: Kaplan Meier survival curve of TB patients based on the bed-ridden functional among
- PLHIV at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015
- Figure 7: Kaplan Meier survival curve of TB patients based on IPT use among PLHIV at
- selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015




Figure 1: Flow chart showing selection of HIV/AIDS people at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015




Figure 2: Kaplan Meier curve of TB survival proportion of HIV/AIDS people at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015

325x420mm (300 x 300 DPI)




Figure 3: Kaplan Meier survival curve of TB patients based on the BMI category among PLHIV at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015

325x420mm (300 x 300 DPI)




Figure 4: Kaplan Meier survival curve of TB patients based on the WHO stage among PLHIV at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015

325x420mm (300 x 300 DPI)




Figure 5: Kaplan Meier survival curve of TB patients based on hemoglobin level among PLHIV at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015




Figure 6: Kaplan Meier survival curve of TB patients based on the bed-ridden functional among PLHIV at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright.




Figure 7: Kaplan Meier survival curve of TB patients based on IPT use among PLHIV at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015

routinely collected health data.

v			RECORD items 5		
Title and abstrac	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
		(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	<ul> <li>Study design is indicated in the title and abstract sections (page 1 line-2 OR on page-2 line-4)</li> <li>Abstract section is informative and is indicated in page-2</li> </ul>	RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included.  RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract.  RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	The type of data which was retrospective cohort is given in the title and the abstract section (pages 1&2)  The geographical region (northeast Ethiopia) is mentioned in the title and abstract sections (pages 1 & 2)
Introduction				<u>9</u>	
Background rationale	2	Explain the scientific background and rationale for the investigation being reported	<ul> <li>Background/Introd uction section is presented on page-4</li> <li>Rationale of the study is mentioned on page-5 lines 13-</li> </ul>	rotected by copyright.	

				en	
			18	2017-0	
Objectives	3	State specific objectives, including any prespecified hypotheses	Objectives of the study are indicated on page-5 lines 17-20. In addition, it is also clearly mentioned in the abstract section on page-2 lines 13-16.	16961 on 6 February 2018. Downloaded	
Methods				<u>0</u> 0.	
Study Design	4	Present key elements of study design early in the paper	• Study design is found on page 5 lines 23-24.	from http://bi	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Study setting is stated on page-5 line 21 to page-6 line 2.	njopen.bmj.com/ c	
Participants	6	(a) Cohort study - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study - Give the eligibility criteria, and the sources and methods of selection of participants	Study population and eligibility criteria are found on page-6 lines 4- 13	RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in details. If this is not possible, an explanation should be provided.  RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.  RECORD 6.3: If the study involved linkage of databases, consider use of a	<ul> <li>The methods of data collection are on page 7</li> <li>The flow diagram indicating how the study subjects are selected is presented in figure 1.</li> </ul>

BMJ Open

 Page 32 of 37

		(b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed Case-control study - For matched studies, give matching criteria and the number of controls per case		flow diagram or other graphical display to demonstrate the data kinkage process, including the number of individuals with linked data at each stage.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.	<ul> <li>Measurement and study variables are presented on page-6, lines 14 to page -7 line-6</li> </ul>	RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported an explanation should be provided.
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement).  Describe comparability of assessment methods if there is more than one group	Data collection     tool and     procedure is     located on page-7     lines 22-30	m http://bmjopen.bmj.co
Bias	9	Describe any efforts to address potential sources of bias		m/ on
Study size	10	Explain how the study size was arrived at	Sample size     calculation and     procedure is     described on page-     7 lines 7-14	April 9, 2024 by guest.
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why		Protected by copyright
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to	Data processing     and analysis is     found on page-8,  p://bmjopen.bmj.com/site.	

			<b>→</b>	
Data access and cleaning methods  Linkage	examine subgroups and interactions (c) Explain how missing data were addressed (d) Cohort study - If applicable, explain how loss to follow-up was addressed Case-control study - If applicable, explain how matching of cases and controls was addressed Cross-sectional study - If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses	Data access and cleaning is found on page-7 lines 22-27	RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.  RECORD 12.2: Authors should provide information on the data geaning methods used in the study.  RECORD 12.3: State whether the study	<ul> <li>How the authors accessed data is stated in the data collection procedure (page-7)</li> <li>Information on data coding, entering and cleaning is given in the data processing and analysis sub-sections (page-8, lines 1-17)</li> <li>The study</li> </ul>
Linkage	••		The one 12.3. State whether the study	- The study
			included person-level, institutional-	

BMJ Open

 Page 34 of 37

					level, or other data linkage across two or more databases. The nethods of linkage and methods of Bankage quality evaluation should be provided.		setting is on page 5 lines 21 to page 6 lines 1-2
Results					<u>б</u>		
Participants	13	(a) Report the numbers of individuals at each stage of the study (e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram	•	Number of participants included in this study is indicated on page-8 lines 27-28 Flow diagram representing how study participants are presented on figure-1.	RECORD 13.1: Describe in detail the selection of the persons included in the study ( <i>i.e.</i> , study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagrams.	•	A flow diagram indicating the eligibility of study participants for the study is presented in a graph 1.
Descriptive data	14	(a) Give characteristics of study participants ( <i>e.g.</i> , demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time ( <i>e.g.</i> , average and total amount)	•	Descriptive data, including the socio-demographic and clinical factors are located from pages 8-11	bmj.com/ on April 9, 2024 by guest. Pr		
Outcome data	15	Cohort study - Report numbers of outcome events or summary measures over time  Case-control study - Report numbers in each exposure category, or summary measures of exposure  Cross-sectional study - Report		The outcome data (incidence of TB) is on pages 12-14	rotected by copyright.		

				en -
		numbers of outcome events or summary measures		2017-0
Main results	16	(a) Give unadjusted estimates and, if applicable, confounderadjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	The adjusted estimates with 95% confidence interval are reported on page 16  The adjusted estimates with 95% confidence interval are reported on page 16	16961 on 6 February 2018. Downloaded from http:
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	None	://bmjopen.br
Discussion				٠ <u>٠</u> ; د
Key results	18	Summarise key results with reference to study objectives	The discussion section is presented on pages 17-19	om/ on April 9, 202
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.  Discuss both direction and magnitude of any potential bias	The limitation of the study is pointed out on page 19 lines 12-22	RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of	The conclusion section is on page 19 line 23 to page tp://bmiopen.bmi.com/site.	byright.

BMJ Open

 Page 36 of 37

		analyses, results from similar studies, and other relevant evidence	20 lines 1-9		2017-0169	
Generalisability	21	Discuss the generalisability (external validity) of the study results	Since the study was conducted in a setting where more than 85% of HIV/AIDS patients are enrolled, we can generalize the finding to northeast Ethiopia		81 on 6 Eebruary 2018 Downlo	
Other Information	n				<u>D</u>	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	<ul> <li>Funding information is on page 20 lines 20-</li> <li>21</li> </ul>		tomd//-atta most b	
Accessibility of protocol, raw data, and programming code			Data sharing statements are on page 20 lines 22- 23	-	cess any such as the	Data collection procedure is on page-7 and data sharing statement is on page 24.

\*Reference: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Lengan SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.

<sup>\*</sup>Checklist is protected under Creative Commons Attribution (<u>CC BY</u>) license.

# **BMJ Open**

# Incidence and determinants of tuberculosis infection among adult HIV patients attending HIV care in Northeast Ethiopia: a retrospective cohort study

Journal:	BMJ Open
Manuscript ID	bmjopen-2017-016961.R3
Article Type:	Research
Date Submitted by the Author:	13-Nov-2017
Complete List of Authors:	Ahmed, Ausman; Jigjiga University, Department of Public health Mekonnen, Desalew; Addis Ababa University, Internal Medicine Shiferaw, Atsede; University of Gondar, Department of Health Informatics Belayneh, Fanuel; Hawassa University Yenit, Melaku; Melaku Kindie Department of Epidemiology and Biostatistics College of Medicine and Health Sciences Institute of Public Health, University of Gondar,
<b>Primary Subject Heading</b> :	Infectious diseases
Secondary Subject Heading:	HIV/AIDS, Public health
Keywords:	Incidence, TB, HIV/AIDS people, Northeast Ethiopia

SCHOLARONE™ Manuscripts

- Incidence and determinants of tuberculosis infection among adult HIV patients attending
  HIV care in northeast Ethiopia: A retrospective cohort study

  Ausman Ahmed<sup>1</sup>, Desalew Mekonnen<sup>2</sup>, Atsede Mazengia Shiferaw<sup>3</sup>, Fanuel Belayneh<sup>4</sup>, Melaku

  Kindie Yenit<sup>5\*</sup>

  Department of Public Health, JigJiga University, JigJiga, Ethiopia
  - <sup>2</sup>Department of Internal Medicine, Addis Ababa University, Ethiopia
- <sup>3</sup>Department of Health Informatics, University of Gondar, Gondar, Ethiopia
- 8 <sup>4</sup>School of Public and Environmental Health, Hawassa University, Hawassa, Ethiopia
- 9 5\*Department of Epidemiology and Biostatistics, University of Gondar, Gondar, Ethiopia
- 11 Email addresses:
- 12 AA: soyra3362@yahoo.com
- 13 DM: <u>desalewm@yahoo.com</u>
- 14 AMS: <u>atsede.mazengia@yahoo.com</u>
- FB: <u>fanuelbelayneh@gmail.com</u>
- 16 MKY: melaku98@gmail.com
- 18 \*Corresponding author
- 19 Melaku Kindie Yenit
- 20 Email: melaku98@gmail.com
- 21 Cell Phone: +251-913002871
- 22 P.o.box: 196
- 23 University of Gondar

#### 1 Abstract

- 2 Objective: This study assessed the incidence of tuberculosis and its predictors among adults
- 3 living with HIV/AIDS in government health facilities of northeast Ethiopia.
- 4 Setting: A five year retrospective cohort study was conducted from May to June 2015 on 451
- 5 adult HIV/AIDS infected individuals who enrolled in the HIV Care Clinics of government health
- 6 facilities of northeast Ethiopia.
- 7 Participants: A total of 451 HIV infected adults who newly enrolled in the adult HIV Care
- 8 Clinic from July 1, 2010 with complete information were followed until May 2015.
- **Primary outcome measure:** The primary outcome was the proportion of patients diagnosed
- with TB or TB incidence rate.
- 11 Secondary outcome measure: The incidence of TB was investigated in relation to years of
- 12 follow-up
- **Results:** A total of 451 charts with complete information were followed for 1377.41 Person-
- Years (PY) of observation. The overall incidence density of tuberculosis was 8.6 per 100 person-
- year observation. Previous TB disease [Adjusted Hazard Ratio (AHR) 3.65, 95% CI 1.97-6.73],
- being bedridden [AHR 5.45, 95% CI 1.16-25.49], being underweight [Body Mass Index (BMI)
- 17 <18.5kg/m<sup>2</sup>) (AHR 2.53, 95 % CI 1.27-5.05)], taking isoniazid preventive therapy (IPT) (AHR
- 18 0.14, 95% CI 0.05-0.39), hemoglobin below 11 g/dL (AHR 2.31, 95% CI 1.35- 3.93), being in
- 19 WHO clinical stage III and IV (AHR 2.84, 95% CI 1.11, 7.27), and (AHR 3.07, 95% CI 1.08,
- 20 8.75), respectively, were significant for the incidence of tuberculosis.
- 21 Conclusion: The incidence of TB among adults living with HIV/AIDS in the first three years of
- follow-up was higher compared with that of subsequent years. Previous TB disease, no IPT, low
- 23 BMI and hemoglobin level, advanced WHO clinical stage and bedridden condition were the
- 24 determinants of the incidence of tuberculosis. Therefore, addressing the significant predictors
- and improving TB/HIV collaborative activities should be strengthened in the study setting.

# Strengths and limitations of this study

- The study which involved a five-year follow up covered longer time than other similar studies and is expected to show the long term impact of HIV on TB.
- The study attempted to show the incidence of TB and its predictors among people living with HIV (PLHIV) using a five-year retrospective data.
- The retrospective nature of the method prevented the inclusion of all possible factors that affect the incidence of tuberculosis.
- Some participants whose data were incomplete were excluded from the study because if such patients had TB they would undermine the findings of the study.
- The sample size used, due to the overall low incidence rate of TB, had limited power to provide clinically relevant conclusions for some risk factors, such as CD4 counts.
- As there was no culture confirmation of TB infections during the study, the cases in the study might be potential ones.
- Inability to address TB contacts (other family members/co-inhabitants) due to the type of study and the introduction of selection bias due to the exclusion of patients who did not use the hospitals chosen are also the limitation of the study.
- Since the study was conducted in a single region of Ethiopia, it might not indicate the actual incidence of TB in other regions of the country.

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright

#### Introduction

TB is an infectious disease caused by bacillus *Mycobacterium tuberculosis* which affects the lungs (pulmonary TB), but it can also affect other sites (extra pulmonary TB) and has remained a major global health problem. In 2015, Tuberculosis (TB) was one of the top 10 causes of death worldwide and the leading killer among HIV positive people, exceeding HIV/AIDS as a killer with infectious diseases (1). Out of the 1.4 million TB-caused deaths reported in 2015, 0.4 million occurred to HIV positive TB patients. Globally, it was estimated that there were 10.4 million TB cases, including 1.2 million among the HIV positive people (1).

Worldwide, nearly 78 million people have contracted HIV infection since the beginning of the pandemic, and close to 39 million died of AIDS-related causes for 25% of which TB was responsible (2). According to the World Health Organization (WHO) 2014 report, there were an estimated 1.1 million cases of TB co-infected with HIV (3), where the majority (90%) of the TB-HIV co-infected people were living in resource limited settings, like Ethiopia (4-6). In the African region, that has the highest TB/HIV burden; three out of four TB patients knew their HIV status. In fact, 70% of the TB patients known to be living with HIV in 2013 were started on antiretroviral therapy (ART). Sub-Saharan Africa is among the regions highly hit by the HIV epidemic, covering more than three-quarters (79%) of the burden of TB-HIV co-infections (7).

In Ethiopia, TB remains one of the leading causes of mortality and the third major cause of hospital admissions. In the last ten years, the number of new cases has increased from 55,000 to 100,000, and the rise in the number of tuberculosis cases has been due to the rapid spread of HIV infection. According to the 2011 Ethiopian Demographic and Health Survey (EDHS) report, the average prevalence of HIV in Ethiopia was 1.5%, while it was 1.8% where the study was conducted. Similarly, it was reported that the prevalence of TB was 211 per 100,000 of the population (8), and the global TB report indicated that Ethiopia ranked 10<sup>th</sup> among the 22 TB high burden countries with a TB/HIV co-infection prevalence of 15% in 2012 (6, 7). TB/HIV co-infection which constitutes an immense burden in the health system in the country is associated with diagnostic and therapeutic challenges. The dual epidemic has been draining resources and overburdening the limited health work-force (9). Hence, the Ministry of Health designed a strategy to increase the percentage of TB patients tested for HIV and vice versa. As a result, the

- 1 percentage of TB patients tested for HIV increased from 16 percent in 2007 to 92 percent in
- 2 2012, and HIV patients screened for TB from 25 percent in 2007 to 92 percent in 2012 (10).
- 3 Though HIV increases the risk of developing TB, it is not the only determinant for it. Various
- 4 reports indicated that socio-demographic (11, 12), clinical (13, 14), life style (14, 15) and
- 5 environmental (16) factors were some of the determinants of the incidence of TB infection
- 6 among HIV positive individuals. Among the clinical factors, low cluster of differentiation (CD4
- 7 count) (17-21), low hemoglobin level, diabetes and other opportunistic infections, and functional
- 8 status showed significant associations with the incidence of TB (20, 22-24). However, Isoniazid
- 9 Preventive Therapy (IPT), Antiretroviral Therapy (ART), and Co-trimoxazole Preventive
- 10 Therapy (CPT) treatments reduce the risk of TB infection among HIV positive individuals (23,
- 25, 26). In resource limited countries such as Ethiopia, where there is poor access to health care,
- very few studies are conducted on the determinants of the incidence of TB among HIV infected
- people. As a matter of fact, it is important to know the variables which are risk factors for better
- understanding the etiology of HIV/TB co-infection in the region. This can contribute to the
- development of interventions to reduce risks. Therefore, this study assessed the incidence of TB
- and its determinants among HIV positive people in northeast Ethiopia. As a second outcome, the
- study considered the incidence of TB in relation to years of follow-up.

### Methods

# Study design and setting

- 20 A five-year retrospective cohort study was conducted on HIV positive patients attending the
- 21 chronic HIV care clinics in selected government health facilities of the Afar Regional State,
- northeast Ethiopia, from July 2010 to June 2011. The region is located in the north-eastern part
- of Ethiopia and has a total population of 1,678,000 of whom only 289,000 live in urban and
- semi-urban areas (27). In the region, there are four hospitals, 40 health centers, and 15 private
- clinics actively providing services. When HIV care service was first introduced to the region in
- 26 2006, 15 public health institutions provided chronic HIV care and support to around more than
- 27 4,000 people living with HIV (PLHIV). For this study, two health centers (Awash, and Samara)
- and three hospitals (Asayta, Abala, and Dubti General) were selected based on the availability of
- 29 TB/HIV clients. These health institutions were providing chronic HIV care and follow up to
- about 85% of the patients living with HIV in the region.

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright.

# Study population and eligibility criteria

All HIV/AIDS patients aged 15 years and above and newly enrolled for HIV care in selected government health facilities of Afar Region from July 2010 to June 2011 participated in the study. These individuals, who enrolled for HIV care from July 2010 to June 2011, were followed for five years, until May 2015. Out of the total 503 people living with HIV and registered during July 2010 to June 2011 in the selected hospitals, 451 records with complete information were included in the analysis. Fifty-two records with incomplete information, like missing the date of enrollment, outcome of interest, and follow-up data were excluded. However, individual charts deleted for analysis were compared to the study groups and showed no significant baseline demographic characteristics. In addition, those who died or were lost to follow-up were considered as censored. 

## Measurements and study variables

The outcome variable in this study was the incidence rate of TB co-infection among HIV positive patients, and it was calculated using the total duration of follow-up for the whole cohort in person-year observation (PY). For individuals who did not develop TB, the duration of followup from the time of enrolment for HIV care until the end was considered as TB-free. For those who developed TB, TB-free survival time was measured from the time of enrolment in the HIV Care Program until the development of TB. An event of an incidence of TB in this study was considered as any form of TB that was not only diagnosed clinically or radio-graphically but also confirmed by laboratory examinations or by patients who have empirically started anti-TB treatment after enrollment. However, since there was no culture confirmation of TB infections during the study period, the cases in the study might be potential ones. When an individual became diagnosed with active TB, treatment was given based on the National TB Program, which was 8 months of treatment (currently 6 months). Patients taking anti-tuberculosis treatment at the time of enrollment were excluded from the study. HIV positive individuals who were lost to follow-up, transferred, died, and not diagnosed for TB until the end of the follow-up period were considered as censored. Study variables, such as age, sex, educational status, employment status, residence, religion, family size, marital status, plus clinical characteristics, like WHO clinical stage, baseline cluster of differentiation (CD4 count), bedridden functional status, history of TB along with body mass index (BMI), hemoglobin level including sociodemographic and economic characteristics were reviewed. Bedridden functional status was

- 1 measured by asking the patient whether he or she was able to perform activities of daily living or
- 2 not. If he/she said "yes", it was taken as bedridden functional status and coded '1'; otherwise,
- 3 he/she was deemed to be not bedridden functional status. In this study, CPT prophylaxis was
- 4 defined as a patient who took co-trimoxazole for longer than one month for a prophylaxis
- 5 purpose. Isoniazid preventive therapy (IPT) use was defined as a patient who took IPT for at
- 6 least 3 months. Substance use was referred to as use of at least one of the substances (alcohol,
- 7 khat, cigarettes, and illicit drugs) in an individual's life time to alter mood or behavior. Illicit
- 8 drugs were defined as psychoactive substances, like hashish, cannabis, and heroin, the
- 9 production, sale, or use of which is prohibited.

# 10 Sample size and sampling procedure

- All HIV/AIDS patients aged 15 years and above and enrolled newly into HIV care from July
- 12 2010 to June 2011 were participated in the study. Sample size was calculated using the single
- proportion formula, considering the following assumptions: 17% prevalence of TB among HIV
- positive people in Jimma, Ethiopia (28), 95% level of confidence, 3.5 margin of error, and 3.3%
- expected incomplete record (29). Finally, the minimum sample size of 458 was obtained.
- Though, 503 PLHIV were registered in the selected health facilities for chronic HIV care, a total
- of 451 patients with complete information were included in the analysis, while 52 records were
- 18 excluded because of incomplete information.
- In Afar Region, where the study was conducted, there were four hospitals, 40 health centers, and
- 20 15 private clinics providing services to the community. Out of these, two health centers (Awash
- and Samara), and three hospitals (Asayta, Abala and Dubti General) were selected based on
- 22 client flow and the availability of TB and HIV follow-up services. In these selected health
- facilities, 503 HIV positive people were newly registered from July 2010 to June 2011.
- However, people living with HIV and registered in the facilities from July 2010 to June 2011 and
- 25 had complete information were followed until May 2015.

# Data collection tool and procedure

- Nurses trained on ART collected the data by reviewing charts and using the patient chart data
- extraction format. All records of HIV/AIDS patients between July 2010 and May 2015 were
- 29 considered. Charts were retrieved by using patient medical record and ART registration numbers
- found on the database of the selected health facilities. Forms used for laboratory request, TB

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright

- 1 records, ART intake, and patient cards were reviewed. Data quality was assured by using a
- 2 pretested questionnaire and trained data collectors. Data completeness and consistency was
- 3 checked by supervisors. The data clerk and case managers assisted the data collectors by
- 4 identifying charts.

# **Data Processing and Analysis**

- 6 Extracted data were checked for completeness, coded, entered, and cleaned into EPI-INFO
- 7 version 7 and exported to SPSS version 20.0 software for further analysis. Statistical summary
- 8 measures and incidence density were calculated. Descriptive statistics were used to characterize
- 9 the socio-demographic and clinical variables. The event of interest was TB incidence. The
- incidence of TB (measured by incidence and incidence density rates) was stratified by socio-
- demographic and clinical variables. Kaplan-Meier estimates were used to describe time to event
- distributions. Log-rank tests were used to compare time-to-event across the different categories.
- Time-to-event data that the study considered and survival analysis were carried out; the cox
- 14 proportional hazards model was fitted, and a life table was used to estimate cumulative
- probabilities. The bi-variable and multivariate cox regression model was used to identify the
- predictors of the incidence of TB. Variables with p-values of less than 0.2 in the bi-variable
- analysis were considered for the multivariate cox proportional hazard model. A 95% confidence
- interval of the hazard ratio (HR) was computed, and variables with less than 0.05 p-values in the
- multivariate cox proportional hazards model were taken as significant predictors for the outcome
- variable. Moreover, basic assumptions of the cox proportional hazard model were checked using
- 21 the Schoenfield residuals test.

#### Ethical considerations

- 23 Ethical clearance was obtained from the Institutional Review Board (IRB) of the Institute of
- Public Health, the University of Gondar. A letter of permission was secured from the Afar
- 25 Regional Health Bueuro (ARHO), and a written permission letter was sent to each selected
- health facilities. In addition, confidentiality was maintained by using only unique identification
- 27 codes rather than patient names and identifications.

#### Results

# 2 Socio-demographic and clinical characteristics of PLHIV

- 3 Out of the total 503 PLHIV registered at the selected hospitals from July 2010 to June 2011, 451
- 4 records with complete information were followed until May 2015. The charts of 451 HIV/AIDS
- 5 patients with complete information were analyzed, while 52 records were excluded because they
- 6 did not contain complete information (**Figure-1**). Out of the 451 patients that remained in the
- analysis, more than half (267/59.2%) were female, and over half of the total (242/53.7%) were
- 8 26-34 years of age. The mean age ( $\pm$ SD) of the patients was 32.6 ( $\pm$ 7.5) years. Most of the
- 9 respondents, 410 (90.9%), were urban dwellers and 275 (61.0%) Muslims (**Table 1**).
- Almost half, 234 (51.9%), of the participants were self-employed. Only 76 (16.9%) had more
- than 5 family members. Almost half, 212 (47%), of the subjects never went to formal school.
- More than two-thirds (68.1%) of the patients were currently or formerly married. Of the 130
- 14 (28.8%) patients recorded as substance users, 14 (5.0%) were tobacco users, 26 (20.0%) alcohol
- 15 consumers, and 90 (75.0%) used both (**Table 1**).
- Out of the total 451 study participants with complete information for analysis, more than half
- 18 (45.4%) had a baseline WHO clinical stage I and II. The majority, 440 (97.6%), of the
- 19 participants were enrolled with working functional status. Almost half, 218 (51.7%), of the
- 20 participants were underweight (BMI less than 18.5 kg/m²), whereas more than three-quarters,
- 21 344 (76.3%), were anemic (Hgb<11g/dL). During the five year retrospective follow up, most,
- 413 (91.6%), of the participants were provided with co-trimoxazole preventive therapy (CPT),
- while only 94 (20.8%) received isoniazid preventive therapy (IPT). Similarly, nearly half, 215
- 24 (47.7%), of the respondents were initiated into ART therapy either on WHO clinical stage or
- 25 CD4 cell count. More than one-third, 170 (37.7%), of the HIV/AIDS positive people took a
- combination of Tenofovir (TDF), Lamivudine (3TC), and Efavirenz (EFV); likewise, one-fifth,
- 27 110 (24.4%), of the patients took Zidovudine (AZT), Lamivudine (3TC), and Efavirenz (EFV).
- Another one-fifth, 96 (21.3%), of the patients changed their initial regimen, 92 due to
- substitution and 4 due to switching to second line treatment for HIV. Out of the 96 HIV/AIDS
- 30 patients who changed their initial regimen, side effect and development of TB were the major
- 31 reasons for 50 (52.1%) and 29 (30.2%), respectively (**Table 1**).

Characteristics	Frequency	Percent (%)
Age in years (mean=32.6, SD=7.5)		
15-25	55	12.2
26-34	242	53.7
35-44	119	26.3
≥45	35	7.8
Sex		
Male	184	40.8
Female	267	59.2
Marital status	_0,	<u> </u>
Single	144	31.9
Married	200	44.3
Divorced	77	17.1
Widowed	30	6.7
	30	0.7
Residence	410	00.0
Urban	410	90.9
Rural	41	9.1
Religion	<b>V</b>	
Muslim	275	61.0
Orthodox	165	36.6
Others	11	2.4
<b>Educational status</b>		
Illiterate	212	47.0
Primary school	177	39.2
Above secondary	62	13.8
Family size		
1-3	216	47.9
4-5	159	35.3
≥5	76	16.8
Occupation	, 0	10.0
Self-employed	234	51.9
Governmental employed	45	10.0
	172	38.1
Non-employed	1/2	36.1
Substance use	120	20.0
Yes	130	28.8
No	321	71.2
Type of substance used		
Tobacco	14	5.0
Alcohol	26	20.0
Both tobacco and alcohol	90	75.0
On ART		
Yes	215	47.7
No	236	52.3
WHO clinical stage		
I & II	200	45.4
III	172	39.0
III IV	172 69	39.0 15.6

Bedridden			_
No No	440	97.6	
Yes	11	2.4	
CD4 cell count (cells/uL)	11	2.4	
<100	44	9.8	
100-200	124	27.5	
201-349	125	27.7	
>350	158	35.0	
BMI (kg/m <sup>2</sup> )	138	33.0	
<18.5	218	51.7	
>18.5	203	48.3	
	203	40.3	
Hgb level (g/dL) <11	344	76.3	
≥11	107	23.7	
<del>-</del>	107	23.1	
CPT use	413	91.6	
Yes	38	91.6 8.4	
No IDT was	38	8.4	
IPT use	94	20.0	
Yes		20.8	
No Little Landing	357	79.2	
Initial regimen	(5	1.4.4	
d4t-3TC-NVP	65	14.4	
AZT-3TC-EFV	89	19.7	
AZT-3TC-NVP	110	24.4	
TDF-3TC-EFV	170	37.7	
Others	17	3.8	
Previous TB disease	7.1	16.4	
Yes	74	16.4	
No	377	83.6	
Opportunistic infection (OI)	24	7.5	
Yes	34	7.5	
No	417	92.5	
Chronic illness	25	7.0	
Yes	35	7.8	
No	416	92.2	
Regimen change	0.0	20.4	
To First line	92	20.4	
To Second line	4	0.9	
Not changed	355	78.7	
Reason for change	20	20.2	
Due to TB development	29	30.2	
Due to side effect	50	52.1	
Failure of treatment	4	4.2	
Others	13	13.5	
Form of TB	0.1	<b>7</b> 6.4	
Pulmonary	91	76.4	
extra pulmonary	28	23.6	_
AZT Zidovudine: BMI Body mass inc	dex: ('I)4 ('luster of differentiation'	4. ('PT' ('o-trimovazo	٦I

AZT, Zidovudine; BMI, Body mass index; CD4, Cluster of differentiation 4; CPT, Co-trimoxazole Preventive Therapy; D4T, Stavudine; EFV, Efavirenz; Hgb, Hemoglobin; IPT, isoniazid preventive therapy; NVP, Nevirapine; OI, Opportunistic Infection; TB, Tuberculosis; TDF, Tenofovir; 3TC, Lamivudine; WHO, World Health Organization

# The incidence of TB stratified with socio-demographic and clinical characteristics

Out of the total 451 HIV/AIDS patients, 119 (26.4%) developed active TB infection during the follow-up period, while 332 were censored (40 transferred out, 13 died, 21 lost to follow-up, and 258 remained TB-negative till the end of follow-up period) (Figure-1). Therefore, the overall TB incidence rate in the five year retrospective data was 8.64 cases per 100 Person-years (PY) of observation. The incidence of patients diagnosed with TB at the end of one year was 4.9 per 100 person-year observation. The sum of the whole follow-up period for all 451 HIV/AIDS infected individuals was 1377.41 Person-years of observation. The minimum and maximum follow-up observation was 0.03 and 58.8 months, respectively. The median (IQR) follow-up period was 46.74 months of observation [IOR=15.95-52.42 months]. Females constituted more than half, 67 (56.3%), of the total TB patients. Three-quarters, 91 (76.47%), of the cases were pulmonary TB. About 68 (57.14%) of the TB incidents occurred within the first year of follow up. The incidence of TB was 105 cases and 14 cases among urban and rural dwellers, respectively. The test of equality for survival distribution for different levels of different categories was performed with Kaplan Meier, using the long rank test. The cumulative probability of TB patient survival at the end of one year, two, three, and four years was 0.77, 0.68, 0.34 and 0.10, respectively. The median survival time was 54 months (Figure-2). In terms of survival curves, there were significant variations among underweight and normal weight (p<0.002) (Figure-3); different WHO clinical stage categories (P<0.001) (**Figure-4**); anemic and non-anemic (p<0.001) (Figure-5); bedridden and otherwise (p<0.002) (Figure-6); and IPT receivers and non-receivers (P<0.0001) (Figure-7). Out of the participants who developed TB, 41 (34.5%) had previous TB disease, and 8 (6.7%) were bedridden at the time of enrollment. One hundred fifteen (96.6%) of the TB cases were not given INH prophylactic therapy. Fifty (42.0%) with incident cases of TB were enrolled with Hgb level below11g/dL (Table-2).

Table 2: The incidence of tuberculosis stratified by socio-demographic and clinical characteristics of PLHIV on HIV chronic care at selected government health facilities of Afar Regional State, July 2010 to May 2015

Characteristics         Total N(%)         TB incidence N(%)         Person-Vears observation (PY)           Vears of follow-up (median=46.74, IQR=15.95-52.42, months)         Onc year         88(19.5)         68(57.1)         35.07           Two years         41(9.0)         28(23.5)         54.73           Three years         32(7.0)         11(9.3)         76.66           Forth         89(19.8)         9(7.6)         322.67           Fifth         201(44.6)         3(2.5)         888.28           Age (years)         15-25         55(12.2)         14(11.7)         158.81           26-34         242(53.7)         63(52.9)         739.05           35-44         119(26.3)         30(25.3)         384.1           ≥45         35(7.8)         12(10.1)         95.45           Sex         8         840.51           Male         184(40.8)         52(43.7)         536.9           Female         267(59.2)         67(56.3)         840.51           Residence         1         Urban         41(9.9)         105(88.2)         1260.67           Rural         41(9.1)         14(11.8)         116.74           Marriad status         1         14(31.9)         30(25.2)	Regional State, July 201	10 to May 2015		
Vears of follow-up ( median=46.74, IQR=15.95-52.42, months)           One year         88(9.5)         68(57.1)         35.07           Two years         41(9.0)         28(23.5)         54.73           Three years         32(7.0)         11(9.3)         76.66           Forth         89(19.8)         9(7.6)         322.67           Fifth         201(44.6)         3(2.5)         888.28           Age (vears)         88.22         32.3         32.5           15-25         55(12.2)         14(11.7)         158.81           26-34         242(63.7)         63(52.9)         739.05           35-44         119(26.3)         30(25.3)         384.1           ≥45         35(7.8)         12(10.1)         95.45           Sex         840.51         840.51           Male         184(40.8)         52(43.7)         536.9           Female         267(59.2)         67(56.3)         840.51           Residence         Urban         410(90.9)         105(88.2)         1260.67           Rural         41(9.1)         14(11.8)         116.74           Marrial status         Single         144(31.9)         30(25.2)         435.14	Characteristics			
One year         88(19.5)         68(57.1)         35.07           Two years         41(9.0)         28(23.5)         54.73           Three years         32(7.0)         11(9.3)         76.66           Forth         89(19.8)         9(7.6)         322.67           Fifth         201(44.6)         3(2.5)         888.28           Age (years)         15-25         55(12.2)         14(11.7)         158.81           26-34         242(53.7)         63(52.9)         739.05           35-44         119(26.3)         30(25.3)         384.1           245         35(7.8)         12(10.1)         95.45           Sex         Male         184(40.8)         52(43.7)         536.9           Female         267(59.2)         67(56.3)         840.51           Residence         Urban         410(90.9)         105(88.2)         1260.67           Rural         41(9.1)         14(11.8)         116.74           Marrital status         Single         144(31.9)         30(25.2)         435.14           Married         200(44.3)         52(43.7)         616.07           Divorced         77(7.1)         30(25.2)         435.14           Married				(PY)
Two years				
Three years 32(7.0) 11(9.3) 76.66 Forth 89(19.8) 9(7.6) 322.67 Fifth 201(44.6) 3(2.5) 888.28 Age (years)  15-25 55(12.2) 14(11.7) 158.81 26-34 242(53.7) 63(52.9) 739.05 35-44 119(26.3) 30(25.3) 384.1 ≥45 35(7.8) 12(10.1) 95.45 Sex  Male 184(40.8) 52(43.7) 536.9 Female 267(59.2) 67(56.3) 840.51 Residence  Urban 410(90.9) 105(88.2) 1260.67 Rural 41(9.1) 14(11.8) 116.74 Marital status Single 144(31.9) 30(25.2) 435.14 Married 200(44.3) 52(43.7) 616.07 Divorced 77(17.1) 30(25.2) 184.5 Widowed 30(6.7) 7(7.9) 91.61 Educational status  Illiterate 212(47.0) 55(46.2) 683.8 Primary School 177(39.3) 49 (41.2) 510.54 Secondary and above 62(13.7) 51(2.6) 183.07 Occupation Self-employed 234(51.8) 59(49.6) 741.68 Government-employed 45(10.1) 9(7.6) 121.45 Non- employment 172(38.1) 51(42.8) 514.28 Religion Muslim 275(61.0) 70(58.8) 826.69 Orthodox 165(36.6) 47(39.5) 520.89 Others 11(2.4) 2(1.7) 29.83 Family size  1-3 216(47.9) 51(42.9) 668.68 4-5 159(35.3) 43(36.1) 484.74 ≥ 5 159(35.3) 43(36.1) 48	2		` /	
Forth 89(19.8) 9(7.6) 322.67 Fifth 201(44.6) 3(2.5) 888.28  Age (years)  15-25 55(12.2) 14(11.7) 158.81 26-34 242(53.7) 63(52.9) 739.05 35.44 119(26.3) 30(25.3) 384.1 245 35(7.8) 12(10.1) 95.45  Sex  Male 184(40.8) 52(43.7) 536.9 Female 267(59.2) 67(56.3) 840.51  Residence  Urban 410(90.9) 105(88.2) 1260.67 Rural 41(9.1) 14(11.8) 116.74  Marrial status  Single 144(31.9) 30(25.2) 435.14  Married 200(44.3) 52(43.7) 616.07  Divorced 77(17.1) 30(25.2) 184.5  Widowed 30(6.7) 7(7.9) 91.61  Educational status  Illiterate 212(47.0) 55(46.2) 683.8  Primary School 177(39.3) 49 (41.2) 510.54 Secondary and above 62(13.7) 15(12.6) 183.07  Occupation  Self-employed 234(51.8) 59(49.6) 741.68 Government-employed 45(10.1) 9(7.6) 121.45 Non- employment 172(38.1) 51(42.8) 514.28  Religion  Muslim 275(61.0) 70(58.8) 826.69 Orthodox 165(36.6) 47(39.5) 520.89 Others 11(2.4) 2(1.7) 29.83  Family size  1-3 216(47.9) 51(42.9) 668.68 4-5 159(35.3) 43(36.1) 484.74 >>5 5 76(16.8) 25(21.0) 223.99  Substance use  Yes 130(28.8) 42(35.3) 379.7	•	` ′	` /	
Fifth 201(4.6) 3(2.5) 888.28  Age (years)  15-25 55(12.2) 14(11.7) 158.81 26-34 242(53.7) 63(52.9) 739.05 35-44 119(26.3) 30(25.3) 384.1 ≥45 35(7.8) 12(10.1) 95.45  Sex  Male 184(40.8) 52(43.7) 536.9 Female 267(59.2) 67(56.3) 840.51  Residence  Urban 410(90.9) 105(88.2) 1260.67 Rural 41(9.1) 14(11.8) 116.74  Marital status  Single 144(31.9) 30(25.2) 435.14 Married 200(44.3) 52(43.7) 616.07 Divorced 77(17.1) 30(25.2) 184.5 Widowed 30(6.7) 7(7.9) 91.61  Educational status  Illiterate 212(47.0) 55(46.2) 683.8 Primary School 177(39.3) 49 (41.2) 510.54 Secondary and above 62(13.7) 15(12.6) 183.07  Occupation  Self-employed 234(51.8) 59(49.6) 741.68 Government-employed 45(10.1) 9(7.6) 121.45 Non- employment 172(38.1) 51(42.8) 510.54  Religion  Muslim 275(61.0) 70(58.8) 826.69 Orthodox 165(36.6) 47(39.5) 520.89 Orthodox 165(36.6) 47(39.5) 520.89 Orthors 11(2.4) 2(1.7) 29.83  Family size  1-3 216(47.9) 51(42.9) 668.68 4-5 159(35.3) 43(36.1) 484.74 ≥5 159(35.3) 43(36	•	, ,	` /	
Age (years)         15-25       55(12.2)       14(11.7)       158.81         26-34       242(53.7)       63(52.9)       739.05         35-44       119(26.3)       30(25.3)       384.1         ≥45       35(7.8)       12(10.1)       95.45         Sex         Male       184(40.8)       52(43.7)       536.9         Female       267(59.2)       67(56.3)       840.51         Residence         Urban       410(90.9)       105(88.2)       1260.67         Rural       41(9.1)       14(11.8)       116.74         Married       20(44.3)       52(43.7)       616.07         Divorced       77(17.1)       30(25.2)       435.14         Married       200(44.3)       52(43.7)       616.07         Divorced       77(17.1)       30(25.2)       184.5         Widowed       30(6.7)       7(7.9)       91.61         Educational status         Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07		` ′	9(7.6)	
15-25         55(12.2)         14(11.7)         158.81           26-34         242(53.7)         63(52.9)         739.05           35-44         119(26.3)         30(25.3)         384.1           245         35(7.8)         12(10.1)         95.45           Sex           Male         184(40.8)         52(43.7)         536.9           Female         267(59.2)         67(56.3)         840.51           Residence           Urban         410(90.9)         105(88.2)         1260.67           Rural         41(9.1)         14(11.8)         116.74           Married         414(31.9)         30(25.2)         435.14           Married         200(44.3)         52(43.7)         616.07           Divorced         77(17.1)         30(25.2)         435.14           Married         200(44.3)         52(43.7)         616.07           Divorced         77(17.1)         30(25.2)         184.5           Widowed         30(6.7)         7(7.9)         91.61           Educational status           Illiterate         212(47.0)         55(46.2)         683.8 </td <td></td> <td>201(44.6)</td> <td>3(2.5)</td> <td>888.28</td>		201(44.6)	3(2.5)	888.28
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$				
35-44 119(26.3) 30(25.3) 384.1 ≥45 35(7.8) 12(10.1) 95.45  Sex  Male 184(40.8) 52(43.7) 536.9 Female 267(59.2) 67(56.3) 840.51  Residence Urban 410(90.9) 105(88.2) 1260.67 Rural 41(9.1) 14(11.8) 116.74  Marital status Single 144(31.9) 30(25.2) 435.14 Married 200(44.3) 52(43.7) 616.07 Divorced 77(17.1) 30(25.2) 184.5 Widowed 30(6.7) 7(7.9) 91.61  Educational status Illiterate 212(47.0) 55(46.2) 683.8 Primary School 177(39.3) 49 (41.2) 510.54 Secondary and above 62(13.7) 15(12.6) 183.07  Occupation  Occupation  Self-employed 234(51.8) 59(49.6) 741.68 Government-employed 45(10.1) 9(7.6) 121.45 Non- employment 172(38.1) 51(42.8) 514.28  Religion  Muslim 275(61.0) 70(58.8) 826.69 Orthodox 165(36.6) 47(39.5) 520.89 Others 11(2.4) 2(1.7) 29.83  Family size  1-3 216(47.9) 51(42.9) 668.68 4-5 159(35.3) 43(36.1) 484.74 2-5 76(16.8) 25(21.0) 223.99  Substance use  Yes 130(28.8) 42(35.3) 379.7			14(11.7)	158.81
≥45	26-34	242(53.7)	63(52.9)	739.05
Sex         Male         184(40.8)         52(43.7)         536.9           Female         267(59.2)         67(56.3)         840.51           Residence         Urban         410(90.9)         105(88.2)         1260.67           Rural         41(9.1)         14(11.8)         116.74           Marital status         Single         144(31.9)         30(25.2)         435.14           Married         200(44.3)         52(43.7)         616.07           Divorced         77(17.1)         30(25.2)         184.5           Widowed         30(6.7)         7(7.9)         91.61           Educational status         Illiterate         212(47.0)         55(46.2)         683.8           Primary School         177(39.3)         49 (41.2)         510.54           Secondary and above         62(13.7)         15(12.6)         183.07           Occupation         Self-employed         234(51.8)         59(49.6)         741.68           Government-employed         45(10.1)         9(7.6)         121.45           Non- employment         172(38.1)         51(42.8)         514.28           Religion         Muslim         275(61.0)         70(58.8)         826.69	35-44	119(26.3)	30(25.3)	384.1
Male       184(40.8)       52(43.7)       536.9         Female       267(59.2)       67(56.3)       840.51         Residence       Urban       410(90.9)       105(88.2)       1260.67         Rural       41(9.1)       14(11.8)       116.74         Marital status       Single       144(31.9)       30(25.2)       435.14         Married       200(44.3)       52(43.7)       616.07         Divorced       77(17.1)       30(25.2)       184.5         Widowed       30(6.7)       7(7.9)       91.61         Educational status         Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation       Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion         Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5	≥45	35(7.8)	12(10.1)	95.45
Female         267(59.2)         67(56.3)         840.51           Residence         Urban         410(90.9)         105(88.2)         1260.67           Rural         41(9.1)         14(11.8)         116.74           Marital status         Single         144(31.9)         30(25.2)         435.14           Married         200(44.3)         52(43.7)         616.07           Divorced         77(17.1)         30(25.2)         184.5           Widowed         30(6.7)         7(7.9)         91.61           Educational status         Illiterate         212(47.0)         55(46.2)         683.8           Primary School         177(39.3)         49 (41.2)         510.54           Secondary and above         62(13.7)         15(12.6)         183.07           Occupation         Self-employed         234(51.8)         59(49.6)         741.68           Government-employed         45(10.1)         9(7.6)         121.45           Non- employment         172(38.1)         51(42.8)         514.28           Religion         Muslim         275(61.0)         70(58.8)         826.69           Orthodox         165(36.6)         47(39.5)         520.89           Oth	Sex			
Residence         Urban       410(90.9)       105(88.2)       1260.67         Rural       41(9.1)       14(11.8)       116.74         Marital status         Single       144(31.9)       30(25.2)       435.14         Married       200(44.3)       52(43.7)       616.07         Divorced       77(17.1)       30(25.2)       184.5         Widowed       30(6.7)       7(7.9)       91.61         Educational status         Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion         Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83 <td< td=""><td>Male</td><td>184(40.8)</td><td>52(43.7)</td><td>536.9</td></td<>	Male	184(40.8)	52(43.7)	536.9
Urban       410(90.9)       105(88.2)       1260.67         Rural       41(9.1)       14(11.8)       116.74         Marital status       Single       144(31.9)       30(25.2)       435.14         Married       200(44.3)       52(43.7)       616.07         Divorced       77(17.1)       30(25.2)       184.5         Widowed       30(6.7)       7(7.9)       91.61         Educational status       Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation       Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion       Wuslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(3	Female	267(59.2)	67(56.3)	840.51
Rural       41(9.1)       14(11.8)       116.74         Marital status       Single       144(31.9)       30(25.2)       435.14         Married       200(44.3)       52(43.7)       616.07         Divorced       77(17.1)       30(25.2)       184.5         Widowed       30(6.7)       7(7.9)       91.61         Educational status       Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation       Value       Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion       Wuslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size       1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74       25       76(16.8)	Residence			
Marital status         Single       144(31.9)       30(25.2)       435.14         Married       200(44.3)       52(43.7)       616.07         Divorced       77(17.1)       30(25.2)       184.5         Widowed       30(6.7)       7(7.9)       91.61         Educational status         Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Octupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion       Religion       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99	Urban	410(90.9)	105(88.2)	1260.67
Single       144(31.9)       30(25.2)       435.14         Married       200(44.3)       52(43.7)       616.07         Divorced       77(17.1)       30(25.2)       184.5         Widowed       30(6.7)       7(7.9)       91.61         Educational status         Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion         Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)	Rural	41(9.1)	14(11.8)	116.74
Married       200(44.3)       52(43.7)       616.07         Divorced       77(17.1)       30(25.2)       184.5         Widowed       30(6.7)       7(7.9)       91.61         Educational status         Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion       Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.	Marital status			
Divorced       77(17.1)       30(25.2)       184.5         Widowed       30(6.7)       7(7.9)       91.61         Educational status       Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion       Wuslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Single	144(31.9)	30(25.2)	435.14
Widowed       30(6.7)       7(7.9)       91.61         Educational status       Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion         Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Married	200(44.3)	52(43.7)	616.07
Educational status         Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion         Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Divorced	77(17.1)	30(25.2)	184.5
Illiterate       212(47.0)       55(46.2)       683.8         Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion         Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Widowed	30(6.7)	7(7.9)	91.61
Primary School       177(39.3)       49 (41.2)       510.54         Secondary and above       62(13.7)       15(12.6)       183.07         Occupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion       Secondary and above       82(6.9)       668.69         Orthodox       165(36.6)       70(58.8)       82(6.9)         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	<b>Educational status</b>			
Secondary and above       62(13.7)       15(12.6)       183.07         Occupation       Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion       Wuslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Illiterate	212(47.0)	55(46.2)	683.8
Occupation         Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion         Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Primary School	177(39.3)	49 (41.2)	510.54
Self-employed       234(51.8)       59(49.6)       741.68         Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion         Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Secondary and above	62(13.7)	15(12.6)	183.07
Government-employed       45(10.1)       9(7.6)       121.45         Non- employment       172(38.1)       51(42.8)       514.28         Religion       Wuslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Occupation			
Non- employment       172(38.1)       51(42.8)       514.28         Religion       Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Self-employed	234(51.8)	59(49.6)	741.68
Religion         Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Government-employed	45(10.1)	9(7.6)	121.45
Religion         Muslim       275(61.0)       70(58.8)       826.69         Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Non- employment	172(38.1)	51(42.8)	514.28
Orthodox       165(36.6)       47(39.5)       520.89         Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Religion			
Others       11(2.4)       2(1.7)       29.83         Family size         1-3       216(47.9)       51(42.9)       668.68         4-5       159(35.3)       43(36.1)       484.74         >5       76(16.8)       25(21.0)       223.99         Substance use         Yes       130(28.8)       42(35.3)       379.7	Muslim	275(61.0)	70(58.8)	826.69
Family size  1-3	Orthodox	165(36.6)	47(39.5)	520.89
1-3 216(47.9) 51(42.9) 668.68 4-5 159(35.3) 43(36.1) 484.74 >5 76(16.8) 25(21.0) 223.99 Substance use Yes 130(28.8) 42(35.3) 379.7	Others	11(2.4)	2(1.7)	29.83
4-5 159(35.3) 43(36.1) 484.74 >5 76(16.8) 25(21.0) 223.99 <b>Substance use</b> Yes 130(28.8) 42(35.3) 379.7	Family size		, ,	
4-5 159(35.3) 43(36.1) 484.74 >5 76(16.8) 25(21.0) 223.99 <b>Substance use</b> Yes 130(28.8) 42(35.3) 379.7	1-3	216(47.9)	51(42.9)	668.68
>5 76(16.8) 25(21.0) 223.99 <b>Substance use</b> Yes 130(28.8) 42(35.3) 379.7	4-5	159(35.3)		484.74
<b>Substance use</b> Yes 130(28.8) 42(35.3) 379.7	>5	76(16.8)	` /	223.99
Yes 130(28.8) 42(35.3) 379.7	Substance use		` /	
		130(28.8)	42(35.3)	379.7
()	No	321(71.2)	77(64.7)	997.71

Previous TB disease			
Yes	74(16.4)	41(34.5)	164.74
No	377(83.6)	78(65.5)	1212.67
Opportunistic infection (O	( )	,	
Yes	34(7.5)	19(16)	85.28
No	417(92.5)	100(84)	1292.13
Chronic illness	,	,	
Yes	35(7.8)	11(9.2)	106.28
No	416(92.2)	108(90.8)	1271.13
Bedridden	,	,	
Yes	11 (2.4)	8(6.7)	33
No	440(97.6)	111(93.3)	1356.76
BMI (kg/m <sup>2</sup> )		` ,	
<18.5	218(48.3)	75(64)	626.46
>18.5	203(45.0)	42(36)	750.95
Hgb level (g/dL)		, ,	
<11	107(23.7)	50(42.0)	233.8
≥11	344(76.3)	69(58.0)	1143.6
CD4 cell count (cells/uL)		, ,	
<100	44(9.7)	22(18.5)	84.77
100-200	124(27.5)	40(33.6)	343.72
201-349	125(27.7)	29(24.4)	384.29
>350	158(35.0)	28(23.5)	564.63
On ART			
Yes	215 (47.7)	36 (30.3)	941.70
No	236(52.3)	83(69.7)	435.71
WHO clinical stage			
I & II	210(46.6%)	36(30.3)	785.3
III	172(38.1)	59(49.6)	464.98
IV	69(15.3)	24(20.1)	187.13
Initial regimen			
d4t-3TC-NVP	65(14.4)	14(11.7)	223.56
AZT-3TC-EFV	89(19.7)	20(16.8)	296.28
AZT-3TC-NVP	110(24.4)	28(23.5)	349.17
TDF-3TC-EFV	170(37.7)	52(43.7)	461.71
Others	17(3.8)	5(4.3)	46.69
IPT use			
Yes	94(20.8)	4(3.4)	363.60
No	357(79.1)	115(96.6)	1013.81
CPT use			
Yes	413(91.6)	108(90.8)	1259.65
No	38(8.4)	11(9.2)	117.76

<sup>1</sup> AZT, Zidovudine; BMI, Body mass index; CD4, Cluster of differentiation 4; CPT, Co-trimoxazole

<sup>2</sup> Preventive Therapy; D4T, Stavudine; EFV, Efavirenz; Hgb, Hemoglobin; IPT, isoniazid preventive

therapy; NVP, Nevirapine; OI, Opportunistic Infections; TB, Tuberculosis; TDF, Tenofovir; 3TC,

<sup>4</sup> Lamivudine; WHO, World Health Organization

#### **Determinants of TB incidence**

In the bivariable cox regression analysis, marital status, family size, substance use, history of TB, baseline CD4 count, WHO clinical stage, opportunistic infection, body mass index (BMI), hemoglobin level, isoniazid preventive therapy (IPT), and functional status were found to be predictors of the incidence of tuberculosis at a p-value of less than 0.2. Consequently, these variables were subjected to multivariate cox regression analysis and previous TB disease, bed-ridden functional status, hemoglobin, BMI, IPT and advanced WHO clinical stage were found

8 statistically significant determinants of TB free survival at a p-value of less than 0.05.

Accordingly, the multivariate cox regression analysis indicated that people living with HIV (PLHIV) and had history of TB disease were 3.65 times at higher risk of developing TB at any time than to PLHIV who had no history of TB (AHR 3.65, 95% CI 1.97-6.73). PLHIV who were in bed-ridden functional status at base-line were 5.45 times at more risk of developing TB compared with PLHIV not in bedridden functional status (AHR 5.45, 95% CI 1.16-25.49). Similarly, PLHIV with baseline BMI less than 18.5kg/m² were 2.53 times at higher risk of developing TB at any time than those with BMI greater than 18.5kg/m² (AHR 2.53, 95 % CI 1.27-5.05). Individuals who took Isoniazid preventive therapy (IPT) were 86% less likely to develop TB at any time compared to those who didn't take IPT (AHR 0.14, 95% CI 0.05-0.39). PLHIV in WHO clinical stage III and IV had a greater risk of developing TB compared with WHO stage I and II (AHR 2.84, 95% CI 1.11, 7.27), and (AHR3.07, 95% CI 1.08, 8.75), respectively. The study also revealed that the incidence of TB in the first three years of follow-up was higher when compared with the other subsequent years. In addition, PLHIV who were anemic (Hgb <11g/dL) were 2.31 times at higher risk of developing TB than those with Hgb level greater than 11 g/dL (AHR 2.31, 95% CI 1.35-3.93) (Table-3).

Table 3: Cox regression analysis of the determinants of the incidence of tuberculosis among adult on chronic HIV care at selected government health facilities of Afar Regional State from July 2010 to May 2015

Event (TB) Censored           Marital status           Single         30         114         144         1.00         1.00           Married         52         148         200         1.34 (0.80-2.23)         1.26 (0.65-2.4           Divorce         30         47         77         2.43 (1.32-4.46)         1.75 (0.83-3.6           Widowed         7         23         30         1.16 (0.45-2.95)         2.42 (0.79-7.3           Family size           1-3         51         165         216         1.00         1.00           4-5         43         116         159         1.19 (0.75-1.92)         0.49 (0.25-1.3           >5         25         51         76         1.58 (0.89-2.81)         0.71 (0.35-1.7           Substance use           Yes         42         88         130         1.51 (0.96-2.37)         1.47 (0.84-2.5           No         77         244         321         1.00         1.00           Previous TB disease           Yes         41         33         74         4.76 (2.83-8.03)         3.65 (1.97-6.73           No         78         299         377         1	May, 2015						
Marital status   Single	riables			Total	CHR (95% CI)	AHR(95% CI)	
Single         30         114         144         1.00         1.00           Married         52         148         200         1.34 (0.80-2.23)         1.26 (0.65-2.4           Divorce         30         47         77         2.43 (1.32-4.46)         1.75 (0.83-3.6           Widowed         7         23         30         1.16 (0.45-2.95)         2.42 (0.79-7.3           Family size           1-3         51         165         216         1.00         1.00           4-5         43         116         159         1.19 (0.75-1.92)         0.49 (0.25-1.3           >5         25         51         76         1.58 (0.89-2.81)         0.71 (0.35-1.7           Substance use           Yes         42         88         130         1.51 (0.96-2.37)         1.47 (0.84-2.5           No         77         244         321         1.00         1.00           Previous TB disease           Yes         41         33         74         4.76 (2.83-8.03)         3.65 (1.97-6.73           No         78         299         377         1.00         1.00           Opportunistic infection (OI)		Event (TB)	Censored				
Married       52       148       200       1.34 (0.80-2.23)       1.26 (0.65-2.4 Divorce       30       47       77       2.43 (1.32-4.46)       1.75 (0.83-3.6 divided)       72 (0.83-3.6 divided)       77       2.43 (1.32-4.46)       1.75 (0.83-3.6 divided)       76 (0.83-3.6 divided)       77 (0.84-2.5)       2.42 (0.79-7.3 divided)       2.42 (0.79-7.3 divided)       78       2.42 (0.79-7.3 divided)       1.00       1.00       1.00       4.5       4.5       43       116 (0.95-1.92)       0.49 (0.25-1.3 divided)       2.5       5       25       51 (76 (0.75-1.92))       0.49 (0.25-1.3 divided)       7.5       2.5       5       5       5       5       5       1.00 (0.35-1.7 divided)       7.5       7.5       8.0 (0.95-2.31)       0.71 (0.35-1.7 divided)       7.7       2.44 (0.20-2.31)       1.47 (0.84-2.5 divided)       1.00 (0.35-1.7 divided)       1.00 (0.00 divided)							
Divorce         30         47         77         2.43 (1.32-4.46)         1.75 (0.83-3.6)           Widowed         7         23         30         1.16 (0.45-2.95)         2.42 (0.79-7.3)           Family size           1-3         51         1.65         216         1.00         1.00           4-5         43         116         159         1.19 (0.75-1.92)         0.49 (0.25-1.3)           >5         25         51         76         1.58 (0.89-2.81)         0.71 (0.35-1.7)           Substance use           Yes         42         88         130         1.51 (0.96-2.37)         1.47 (0.84-2.5)           No         77         244         321         1.00         1.00           Previous TB disease           Yes         41         33         74         4.76 (2.83-8.03)         3.65 (1.97-6.73)           No         78         299         377         1.00         1.00           Opportunistic infection (OI)           Yes         19         15         34         4.02 (1.97-8.19)         2.31 (0.98-5.45)           No         100         317         417         1.00         1.00	ıgle		114	144		1.00	
Widowed       7       23       30       1.16 (0.45-2.95)       2.42 (0.79-7.3 femily size         1-3       51       165       216       1.00       1.00         4-5       43       116       159       1.19 (0.75-1.92)       0.49 (0.25-1.3 sept.)         >5       25       51       76       1.58 (0.89-2.81)       0.71 (0.35-1.7 sept.)         Substance use         Yes       42       88       130       1.51 (0.96-2.37)       1.47 (0.84-2.5 no.)         No       77       244       321       1.00       1.00         Previous TB disease         Yes       41       33       74       4.76 (2.83-8.03)       3.65 (1.97-6.73 no.)         No       78       299       377       1.00       1.00         Opportunistic infection (OI)         Yes       19       15       34       4.02 (1.97-8.19)       2.31 (0.98-5.45)         No       100       317       417       1.00       1.00         Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.0	arried	52	148	200	1.34 (0.80-2.23)	1.26 (0.65-2.43)	
Family size  1-3	vorce	30		77	2.43 (1.32-4.46)	1.75 (0.83-3.68)	
1-3	idowed	7	23	30	1.16 (0.45-2.95)	2.42 (0.79-7.38)	
4-5	mily size						
>5     25     51     76     1.58 (0.89-2.81)     0.71 (0.35-1.7)       Substance use       Yes     42     88     130     1.51 (0.96-2.37)     1.47 (0.84-2.5       No     77     244     321     1.00     1.00       Previous TB disease       Yes     41     33     74     4.76 (2.83-8.03)     3.65 (1.97-6.73)       No     78     299     377     1.00     1.00       Opportunistic infection (OI)       Yes     19     15     34     4.02 (1.97-8.19)     2.31 (0.98-5.45)       No     100     317     417     1.00     1.00       Bedridden       Yes     8     3     11     7.90 (2.06-30.31)     5.45 (1.16-25.49)*       No     111     329     440     1.00     1.00       BMI (kg/m²)       <18.5	3		165	216		1.00	
Substance use           Yes         42         88         130         1.51 (0.96-2.37)         1.47 (0.84-2.5 No         77         244         321         1.00 <td>5</td> <td>43</td> <td>116</td> <td>159</td> <td>1.19 (0.75-1.92)</td> <td>0.49 (0.25-1.34)</td>	5	43	116	159	1.19 (0.75-1.92)	0.49 (0.25-1.34)	
Yes       42       88       130       1.51 (0.96-2.37)       1.47 (0.84-2.5 No         No       77       244       321       1.00       1.00         Previous TB disease         Yes       41       33       74       4.76 (2.83-8.03)       3.65 (1.97-6.73 No         No       78       299       377       1.00       1.00         Opportunistic infection (OI)         Yes       19       15       34       4.02 (1.97-8.19)       2.31 (0.98-5.45)         No       100       317       417       1.00       1.00         Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5		25	51	76	1.58 (0.89-2.81)	0.71 (0.35-1.76)	
No       77       244       321       1.00       1.00         Previous TB disease         Yes       41       33       74       4.76 (2.83-8.03)       3.65 (1.97-6.73)         No       78       299       377       1.00       1.00         Opportunistic infection (OI)         Yes       19       15       34       4.02 (1.97-8.19)       2.31 (0.98-5.45)         No       100       317       417       1.00       1.00         Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5	bstance use						
No       77       244       321       1.00       1.00         Previous TB disease         Yes       41       33       74       4.76 (2.83-8.03)       3.65 (1.97-6.73)         No       78       299       377       1.00       1.00         Opportunistic infection (OI)         Yes       19       15       34       4.02 (1.97-8.19)       2.31 (0.98-5.45)         No       100       317       417       1.00       1.00         Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5	es	42	88	130	1.51 (0.96-2.37)	1.47 (0.84-2.56)	
Yes       41       33       74       4.76 (2.83-8.03)       3.65 (1.97-6.73)         No       78       299       377       1.00       1.00         Opportunistic infection (OI)         Yes       19       15       34       4.02 (1.97-8.19)       2.31 (0.98-5.45)         No       100       317       417       1.00       1.00         Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5	)	77	244	321	1.00		
No       78       299       377       1.00       1.00         Opportunistic infection (OI)         Yes       19       15       34       4.02 (1.97-8.19)       2.31 (0.98-5.45)         No       100       317       417       1.00       1.00         Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5	evious TB disea	se					
Opportunistic infection (OI)         Yes       19       15       34       4.02 (1.97-8.19)       2.31 (0.98-5.45)         No       100       317       417       1.00       1.00         Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5	żs	41	33	74	4.76 (2.83-8.03)	3.65 (1.97-6.73)**	
Yes       19       15       34       4.02 (1.97-8.19)       2.31 (0.98-5.45)         No       100       317       417       1.00       1.00         Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5       75       143       218       2.01(1.29-3.12)       2.53(1.27-5.05)***         ≥18.5       42       161       203       1.00       1.00         Length of follow-up       ≤ 1 year       68       20       88       78.76 (36.7-168.9)       83.76 (33.94-206.7         2-3 years       39       34       73       26.57 (12.7-55.6)       33.81(14.12-80.96)         4-5 years       12       278       290       1.00       1.00         WHO clinical stage       1       13       172       2.52 (1.57-4.07)       2.84(1.11-7.27)**         IV       24       45       69       2.58 (1.40-4.75)       3.07(1.08-8.75)**         Hgb level (g/dL)	)	78	299	377			
Yes       19       15       34       4.02 (1.97-8.19)       2.31 (0.98-5.45)         No       100       317       417       1.00       1.00         Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5       75       143       218       2.01(1.29-3.12)       2.53(1.27-5.05)***         ≥18.5       42       161       203       1.00       1.00         Length of follow-up       ≤ 1 year       68       20       88       78.76 (36.7-168.9)       83.76 (33.94-206.7         2-3 years       39       34       73       26.57 (12.7-55.6)       33.81(14.12-80.96)         4-5 years       12       278       290       1.00       1.00         WHO clinical stage         I &II       36       174       200       1.00       1.00         III       59       113       172       2.52 (1.57-4.07)       2.84(1.11-7.27)**         IV       24       45       69       2.58 (1.40-4.75)       3.07(1.08-8.75)** <th c<="" td=""><td>portunistic infe</td><td>ection (OI)</td><td></td><td></td><td></td><td></td></th>	<td>portunistic infe</td> <td>ection (OI)</td> <td></td> <td></td> <td></td> <td></td>	portunistic infe	ection (OI)				
Bedridden         Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)	S	19	15	34	4.02 (1.97-8.19)	2.31 (0.98-5.45)	
Yes       8       3       11       7.90 (2.06-30.31)       5.45 (1.16-25.49)*         No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5	)	100	317	417	1.00	1.00	
No       111       329       440       1.00       1.00         BMI (kg/m²)         <18.5	dridden						
BMI (kg/m²) <18.5 75 143 218 2.01(1.29-3.12) 2.53(1.27-5.05)** ≥18.5 42 161 203 1.00 1.00  Length of follow-up ≤1 year 68 20 88 78.76 (36.7-168.9) 83.76 (33.94-206.7 2-3 years 39 34 73 26.57 (12.7-55.6) 33.81(14.12-80.96 4-5 years 12 278 290 1.00 1.00  WHO clinical stage I &II 36 174 200 1.00 1.00  III 59 113 172 2.52 (1.57-4.07) 2.84(1.11-7.27)** IV 24 45 69 2.58 (1.40-4.75) 3.07(1.08-8.75)**  Hgb level (g/dL)	es	8	3	11	7.90 (2.06-30.31)	5.45 (1.16-25.49)**	
<18.5	)	111	329	440	1.00	1.00	
≥18.5 42 161 203 1.00 1.00  Length of follow-up  ≤1 year 68 20 88 78.76 (36.7-168.9) 83.76 (33.94-206.7 2-3 years 39 34 73 26.57 (12.7-55.6) 33.81(14.12-80.96) 4-5 years 12 278 290 1.00 1.00  WHO clinical stage I &II 36 174 200 1.00 1.00  III 59 113 172 2.52 (1.57-4.07) 2.84(1.11-7.27)** IV 24 45 69 2.58 (1.40-4.75) 3.07(1.08-8.75)**  Hgb level (g/dL)	$MI (kg/m^2)$						
Length of follow-up       ≤ 1 year       68       20       88       78.76 (36.7-168.9)       83.76 (33.94-206.7)         2-3 years       39       34       73       26.57 (12.7-55.6)       33.81(14.12-80.96)         4-5 years       12       278       290       1.00       1.00         WHO clinical stage         I &II       36       174       200       1.00       1.00         III       59       113       172       2.52 (1.57-4.07)       2.84(1.11-7.27)**         IV       24       45       69       2.58 (1.40-4.75)       3.07(1.08-8.75)**         Hgb level (g/dL)	8.5	75	143	218	2.01(1.29-3.12)	2.53(1.27-5.05)**	
≤ 1 year 68 20 88 78.76 (36.7-168.9) 83.76 (33.94-206.7 2-3 years 39 34 73 26.57 (12.7-55.6) 33.81(14.12-80.96 4-5 years 12 278 290 1.00 1.00 WHO clinical stage I &II 36 174 200 1.00 1.00 III 59 113 172 2.52 (1.57-4.07) 2.84(1.11-7.27)** IV 24 45 69 2.58 (1.40-4.75) 3.07(1.08-8.75)** Hgb level (g/dL)	8.5	42	161	203	1.00	1.00	
2-3 years 39 34 73 26.57 (12.7-55.6) 33.81(14.12-80.96) 4-5 years 12 278 290 1.00 1.00  WHO clinical stage I &II 36 174 200 1.00 1.00 III 59 113 172 2.52 (1.57-4.07) 2.84(1.11-7.27)** IV 24 45 69 2.58 (1.40-4.75) 3.07(1.08-8.75)**  Hgb level (g/dL)	ngth of follow-u	ıp					
2-3 years 39 34 73 26.57 (12.7-55.6) 33.81(14.12-80.96) 4-5 years 12 278 290 1.00 1.00  WHO clinical stage I &II 36 174 200 1.00 1.00 III 59 113 172 2.52 (1.57-4.07) 2.84(1.11-7.27)** IV 24 45 69 2.58 (1.40-4.75) 3.07(1.08-8.75)**  Hgb level (g/dL)	l year	68	20	88	78.76 (36.7-168.9)	83.76 (33.94-206.7)**	
WHO clinical stage         I &II       36       174       200       1.00       1.00         III       59       113       172       2.52 (1.57-4.07)       2.84(1.11-7.27)**         IV       24       45       69       2.58 (1.40-4.75)       3.07(1.08-8.75)**         Hgb level (g/dL)       45       69       2.58 (1.40-4.75)       3.07(1.08-8.75)**		39	34	73	26.57 (12.7-55.6)	33.81(14.12-80.96)**	
I &II     36     174     200     1.00     1.00       III     59     113     172     2.52 (1.57-4.07)     2.84(1.11-7.27)**       IV     24     45     69     2.58 (1.40-4.75)     3.07(1.08-8.75)**       Hgb level (g/dL)	5 years	12	278	290	1.00	1.00	
III 59 113 172 2.52 (1.57-4.07) 2.84(1.11-7.27)** IV 24 45 69 2.58 (1.40-4.75) 3.07(1.08-8.75)** <b>Hgb level (g/dL)</b>	•	ge					
IV 24 45 69 2.58 (1.40-4.75) 3.07(1.08-8.75)** <b>Hgb level (g/dL)</b>	lΙΣ	36	174	200	1.00	1.00	
Hgb level (g/dL)		59	113	172	2.52 (1.57-4.07)	2.84(1.11-7.27)**	
		24	45	69	2.58 (1.40-4.75)	3.07(1.08-8.75)**	
	gb level (g/dL)					,	
		50	57	107	3.49 (2.20-5.55)	2.31(1.35-3.93)**	
$\geq 11$ 69 275 344 1.00 1.00	1	69	275	344	1.00	1.00	
CD4 count (cells/uL)		ıL)					
<100 22 24 44 4.64 (2.26-9.52) 1.14(0.46-2.82)	00	22	22	44	4.64 (2.26-9.52)	1.14(0.46-2.82)	
100-200 40 84 124 2.21 (1.27-3.85) 1.29(0.66-2.57)	0-200	40	84	124	,	1.29(0.66-2.57)	
201-349 29 96 125 1.40 (0.78-2.51) 0.99(0.49-1.99)		29	96				
≥350 28 130 158 1.00 1.00 1.00					,	,	
ĪPT							
		4	90	94	0.09 (0.03-0.26)	0.14 (0.05, 0.39)**	
No 115 242 357 1.00 1.00			242	357			

<sup>\*\*</sup> Variable significant at p-value less than 0.05

BMI, Body mass index; CD4, Cluster of differentiation 4; Cells/ul, cells per microliter (ul); Hgb, Hemoglobin; g/dl, grams (g) per decilitre (dL); OI, Opportunistic Infection; IPT, isoniazid preventive 

therapy; TB, Tuberculosis; WHO, World Health Organization

#### **Discussion**

TB and HIV remain the major public health problems in many parts of the world. Ethiopia is among the TB high burden countries with an estimated annual incidence of 211 cases per 100,000 people and a prevalence of 224 cases per 100,000 (30).

In this study, the overall incidence of TB among PLHIV was 8.64 cases per 100 person-year (PY) observation. This finding is similar to those reported from Gondar and Assela, Ethiopia, which are 7 and 7.9 cases, respectively, per 100 person-year (PY) observations (31, 32). The finding is consistent with that of a study in Tanzania and other Sub-Saharan countries with incidence ranging from 7.6-8.2 per 100 person-year observation (PY) (33, 34). However, the incidence density of TB in this study is higher than those of studies conducted in Korea, Israel, and Malaysia (35-37). The lower incidence of TB in the latter studies compared with this one might be due to the availability of better preventive, diagnostic, and treatment setups and strategies for controlling TB in such countries when compared with our study setting. In addition, low health care coverage, high burden of HIV, and the fact that the study setting is so unprivileged might explain the difference. Furthermore, late enrollment at health facilities due to late presentation of HIV infected people at health facilities, increases the progression of latent infection to active TB after HIV chronic care. It was noted that individuals with late presentation might get new infections or IRIS after initiation into highly active antiretroviral therapy (HAART), and Immune Reconstitution Inflammatory Syndrome (IRIS) related TB is commonly seen within the first six months of initiation into HAART (38). Similarly, it was revealed that the incidence of TB is significantly associated with the length of follow-up year. It was reported that the incidence of TB decreased as the years of follow-up increased, and a higher incidence of TB was reported in the first three of follow-up years compared with the other subsequent years.

Out of the determinants of the incidence of TB infection in the multivariate cox regression analysis, the study revealed that previous TB disease, using IPT, bedridden functional status, low hemoglobin level, advanced WHO staging (III and IV), years of follow-up, and low BMI were

found to be significantly associated with the incidence of TB. Individuals who had history of TB

2 disease had greater risk of developing TB compared with those who had no history of TB

treatment. Poor compliance with anti-TB treatment at the first episode, reactivation or re-

infection of individuals with the existing diminished immunity might be the reasons for higher

incidence of TB among individuals with history of TB infection. This finding is consistent with

those of studies conducted in Uganda, Malaysia, and Israel (36, 37, 39).

8 PLHIV who took Isoniazid preventive therapy (IPT) were found to be protective of the incidence

9 of TB. Individuals who took Isoniazid preventive therapy (IPT) were 86% less likely to develop

TB at any time compared to those who didn't take IPT (AHR=0.14, 95% CI: 0.05-0.39). This

might be due to the role of IPT in reducing the incidence of TB among people living with HIV.

The finding is consistent with those of studies in Ethiopia, South Africa, and Brazil (40-42). In

spite of this fact, poor uptake, ambiguity, and fear of drug resistance might contribute to no-IPT

use.

Similarly, in this study, patients' functional status at baseline was found to be the predictor of TB

17 incidence. Patient bedridden functional status at baseline was 5.45 times at higher risk of

developing TB than individuals with working functional status at baseline. This might be due to

the fact that debilitated patients will be prone to malnutrition, and lack of physical activity

exposes them to many diseases, including TB. This finding is in line with those of other studies

21 conducted in Ethiopia (16, 31, 43).

Out of the anthropometric variables, HIV patients who were underweight (BMI <18.5 kg/m²)

were 2.53 times at higher risk of developing TB compared to individuals with BMI≥18.5 kg/m².

25 This finding was consistent with that of a study done in Tanzania (44), Ethiopia, and South

Africa (33, 45). The possible explanations might be that a low BMI category is a proxy indicator

of malnutrition, and malnutrition in HIV patients is associated with increased catabolic activity,

infection, loss of appetite, and decreased intake, which further increase the risk of developing

opportunistic infections such as tuberculosis.

Furthermore, this study found that patients with Hgb level of <11 g/dL at base-line were 2.31

times at higher risk of developing TB than those with Hgb level  $\ge 11$  at base-line. Hematologic

complications were risk factors for the incidence of TB among PLHIV. This finding is

concordant with those of studies conducted in Ethiopia, Uganda, Tanzania, and South Africa (44-

- 1 47). The possible explanation might be malnutrition, side effects of medications, opportunistic
- 2 infections, and advanced stage of the disease. Undiagnosed TB could explain low Hgb level at
- 3 early enrollment.
- 4 The other important result which was found to have a significant association with the incidence
- of TB was advanced clinical staging (III & IV). PLHIV with advanced WHO staging (III and
- 6 IV), respectively had 2.84 and 3.07 times higher risk of developing TB compared with people in
- 7 stages I & II. The finding corresponded to those of studies conducted in Nigeria (48), South
- 8 Africa (49), and Gambia (50). This might be due to the fact that once patients get into late stages;
- 9 the immunity protective capacity will be minimal, making them predisposed to tuberculosis
- infection. Something worth mentioning as well is that TB is one of the defining factors of AIDS
- that categorizes patients who use HIV/AIDS clinics in Ethiopia into late WHO clinical staging.

#### Limitations of the study

- 13 Though the study did its best to indicate the incidence and predictors of tuberculosis among
- 14 PLHIV using a five-year retrospective data, it was not free from limitations. The retrospective
- 15 nature of the study limited the inclusion of all possible factors that could affect the incidence of
- tuberculosis. Variables such as housing condition and household income were some of the
- plausible factors that were not measured in this study. For some risk factors, such as CD4 count,
- 18 the sample size limited the power to provide clinically relevant conclusions because of the
- overall low incidence rate of TB. Inability to conduct culture confirmation (the gold standard
- 20 method) is another limitation of the study. Inability to address TB contacts (other family
- 21 member/co-inhabitant) and introduction of selection bias due to the exclusion of patients who did
- 22 not use the selected hospitals is the other drawback. Since the study was conducted in a single
- 23 region of Ethiopia, it might not indicate the actual incidence of TB in other regions of the
- 24 country.

#### Conclusion

- The overall incidence of TB among PLHIV was found to be comparable with those of similar
- 27 studies in Ethiopia. However, it was higher in the first year of follow-up than it was in the
- 28 subsequent years. HIV infected individuals with history of TB disease, not using IPT,
- underweight status (BMI<18.5kg/m<sup>2</sup>), bedridden functional status, being anemic (Hgb<11g/dL),
- advanced WHO stage (III &IV), and short duration of follow-up were determinants of the

- 1 incidence of TB among PLHIV. Therefore, our study suggested early screening and diagnosis
- 2 among high risk PLHIV such as those in bed-ridden functional status, underweight
- 3 (BMI<18.5kg/m<sup>2)</sup>, and anemic (Hgb <11g/dL). In addition, providing IPT to PLHIV without
- 4 active TB and intensified TB case screening for those with advanced WHO stage is highly
- 5 recommended. In addition, emphasis should be given to those with shorter follow-ups.
- 6 Therefore, attention to PLHIV and prompt diagnosis and treatment of TB are recommended.
- 7 Furthermore, prospective studies need to include all factors that influence the risk of TB among
- 8 PLHIV. Since our study was conducted in a single region of Ethiopia, collaborative projects that
- 9 can include several regions of the country are recommended to give a more balanced view of the
- incidence of TB and potential risk factors in HIV-infected patients.
- 11 List of abbreviations

- 12 AHR, Adjusted hazard ratio; AIDS, Acquired immune deficiency syndrome; ART, Anti-
- 13 Retroviral Therapy; BMI, Body mass index; CD4, cluster of differentiation 4; CI, Confidence
- 14 interval; CPT, Cotrimoxazole prophylaxis therapy; EDHS, Ethiopian Demographic health
- survey; HIV, Human immune deficiency; HAART, Highly active anti retro viral therapy; Hgb,
- Hemoglobin; INH, Isoniazid; IQR, Inter quartile range; IPT, Isoniazid preventive therapy; IRIS,
- 17 Immune reconstitution inflammatory syndrome; PLHIV/AIDS, People living with HIV/AIDS;
- 18 PY, person-year observation; TB, tuberculosis; WHO, World health organization
- 19 Competing interests
- The authors declare that they have no conflict of interest.
- 21 Funding
- No specific fund was obtained for this study.
- 23 Data sharing statement
- 24 All data supporting our findings will be shared upon request.
- 25 Authors' contributions
- AA, DM and MKY involved in the conception, design, data collection, analysis and report
- 27 writing. DM, AMS, FB, and MKY assisted with the design, approved the proposal with some
- 28 revisions, participated in data analysis and manuscript preparation. All authors read and
- approved the final manuscript.

### Acknowledgement

- We would like to extend our thanks to Afar Regional Health Beauro for permission to conduct
- the study and providing the necessary preliminary information during the study. We are indebted
- to data collectors and supervisors without whom this project wouldn't have gone so far.

#### References

- World Health Organization. Global tuberculosis report 2016. World Health Organization: Geneva, 1. 2016.
- World Health Organization/HIV/AIDS JUNPo. World AIDS Day 2014 Report-Fact sheet. 2.
- Geneva, Switzerland. 2014.
- 3. World Health Organization. Global tuberculosis report 2013. World Health Organization; 2013.
- World Health Organization. Global tuberculosis control 2009: World Health Organization; 2009. 4.
- 5. World Health Organization. Global tuberculosis control 2009: epidemiology, strategy, financing.
- Geneva, Switzerland: World Health Organization, 2009. 2011.
- Zumla A, George A, Sharma V, Herbert RHN, of Ilton BM, Oxley A, et al. The WHO 2014 global tuberculosis report—further to go. The Lancet Global Health. 2015;3(1):e10-e2.
- World Health Organization. Global Tuberculosis Report 2013. World Health Organization:
- Geneva, 2013. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656\_eng.pdf.
- Demographic E. Health Survey (2011) Addis Ababa. Ethiopia and Calverton, Maryland, USA:
- Central Statistical Agency and ICF International. 2012.
- Pawlowski A, Jansson M, Sköld M, et al.. Tuberculosis and HIV co-infection. PLoS Pathog. 9. 2012;8(2):e1002464.
- Health EMo. Ethiopian Federal Ministry of Health/Ethiopian Health & Nutrition Research Institute National. TB/HIV surveillance report. 2012.
- Batista JdAL, Maruza M, de Alencar Ximenes RA, et al. Incidence and risk factors for tuberculosis in people living with HIV: cohort from HIV referral health centers in Recife, Brazil. PloS
- one. 2013;8(5):e63916.
- Jagodziński J, Zielonka TM, Błachnio M. Socio-economic status and duration of TB symptoms in 12.
- males treated at the Mazovian Treatment Centre of Tuberculosis and Lung Diseases in Otwock.
- Pneumonol Alergol Pol. 2012;80(6):533-40.
- Wilkinson D. Drugs for preventing tuberculosis in HIV infected persons. The Cochrane Library. 13.
- 2000.
- Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in 14. adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001270.
- Alvi A, Rizwan M, Sunosi RA, et al. Does khat chewing increases the risk of Mycobacterium
- tuberculosis infection by macrophage immune modulation? Medical hypotheses. 2014;82(6):667-9.
- Kibret KT, Yalew AW, Belaineh BG, et al. Determinant factors associated with occurrence of
- tuberculosis among adult people living with HIV after antiretroviral treatment initiation in Addis Ababa, Ethiopia: a case control study. PloS one. 2013;8(5):e64488.
- Amoakwa K, Martinson NA, Moulton LH, et al. Risk Factors for Developing Active Tuberculosis After the Treatment of Latent Tuberculosis in Adults Infected With Human
- Immunodeficiency Virus. Open forum infectious diseases; 2015: Oxford University Press.
- Bendayan D, Littman K, Polansky V. Active tuberculosis and human immunodeficiency virus co-
- infection in Israel: a retrospective study. The Israel Medical Association journal: IMAJ. 2010;12(2):100-3.
- 19. Hwang J-H, Choe PG, Kim NH, et al. Incidence and risk factors of tuberculosis in patients with human immunodeficiency virus infection. Journal of Korean medical science. 2013;28(3):374-7.

- 20. Méda ZC, Sombié I, Sanon OW, et al. Risk factors of tuberculosis infection among HIV/AIDS patients in Burkina Faso. AIDS research and human retroviruses. 2013;29(7):1045-55.
- Metcalfe JZ, Porco TC, Westenhouse J, et al. Tuberculosis and HIV co-infection, California, USA, 1993–2008. Emerg Infect Dis. 2013;19(3):400-6.
- Ibrahim J. Tuberculosis: an eight year (2000-2007) retrospective study at the University of
- Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia. Southeast Asian Journal of Tropical Medicine and Public Healt. 2010;41(2).
- Maro I, Lahey T, MacKenzie T, et al. Low BMI and falling BMI predict HIV-associated
- tuberculosis: a prospective study in Tanzania. The International Journal of Tuberculosis and Lung Disease. 2010;14(11):1447-53.

- Nantha YS. Influence of diabetes mellitus and risk factors in activating latent tuberculosis
- infection: A case for targeted screening in Malaysia. Med J Malaysia. 2012;67(5):467-72.
- Assebe LF, Reda HL, Wubeneh AD, et al. The effect of isoniazid preventive therapy on incidence
- of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study. BMC public health. 2015;15(1):1.
- Okwera A, Mafigiri DK, Guwatudde D, et al. Level of understanding of co-trimoxazole use
- among HIV infected, recurrent pulmonary tuberculosis suspects at a national referral tuberculosis clinic in
- Kampala, Uganda: a qualitative analysis. African health sciences. 2015;15(1):49-57.
- Ethiopia Central Statistical Agency. Report of Centeral statistical agency., 2014.
- Gudina EK, Gudissa FG. Prevalence of tuberculosis in HIV in Ethiopia in early HAART era: 28.
- Retrospective analysis. The Pan African medical journal. 2013;14.
- Melkamu H, Seyoum B, Dessie Y. Determinants of tuberculosis infection among adult HIV
- positives attending clinical care in western Ethiopia: a case-control study. AIDS research and treatment. 2013;2013.
- 30. World Health Organization. WHO Global TB report 2014.
- 31. Addis Alene K, Nega A, Wasie Taye B. Incidence and predictors of tuberculosis among adult
- people living with human immunodeficiency virus at the University of Gondar Referral Hospital,
- Northwest Ethiopia. BMC Infect Dis. 2013;13:292.
- Abebe A, Etana B, Tsadik M, et al. Assessing the Effect of Highly Active Anti-Retroviral
- Treatment and Associated Factors on Incidence of Tuberculosis among Adult HIV Positive Individuals in
- Assela, Ethiopia. J Health Med Informat. 2014;5(156):2.
- Liu E, Makubi A, Drain P, et al. Tuberculosis incidence rate and risk factors among HIV-infected 33.
- adults with access to antiretroviral therapy. Aids. 2015.
- Haraka F, Glass TR, Sikalengo G, et al. A Bundle of Services Increased Ascertainment of
- Tuberculosis among HIV-Infected Individuals Enrolled in a HIV Cohort in Rural Sub-Saharan Africa.
- PLoS One. 2015;10(4):e0123275.
- Hwang JH, Choe PG, Kim NH, et al. Incidence and risk factors of tuberculosis in patients with 35.
- human immunodeficiency virus infection. J Korean Med Sci. 2013;28(3):374-7.
- Syed Suleiman SA, Ishaq Aweis DM, Mohamed AJ, et al. Role of diabetes in the prognosis and
- therapeutic outcome of tuberculosis. Int J Endocrinol. 2012;2012:645362.
- Mor Z, Lidji M, Cedar N, et al. Tuberculosis Incidence in HIV/AIDS Patients in Israel, 1983-37.
- 2010. PLoS One. 2013;8(11).
- Namale PE, Abdullahi LH, Fine S, et al. Paradoxical TB-IRIS in HIV-infected adults: a
- systematic review and meta-analysis. Future Microbiol. 2015;10:1077-99.
- Amuha MG, Kutyabami P, Kitutu FE, et al. Non-adherence to anti-TB drugs among TB/HIV co-
- infected patients in Mbarara Hospital Uganda: prevalence and associated factors. Afr Health Sci. 2009;9
- Suppl 1:S8-15.
- Assebe LF, Reda HL, Wubeneh AD, et al. The effect of isoniazid preventive therapy on incidence
- of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort
- study. BMC Public Health. 2015;15:346.

- 41. Dowdy DW, Golub JE, Saraceni V, et al. Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model. J Acquir Immune Defic Syndr.
- 2014;66(5):552-8.
- Wood R, Bekker LG. Isoniazid preventive therapy for tuberculosis in South Africa: an assessment of the local evidence base. S Afr Med J. 2014;104(3):174-7.
  - Fekadu S, Teshome W, Alemu G. Prevalence and determinants of Tuberculosis among HIV
- infected patients in south Ethiopia. The Journal of Infection in Developing Countries. 2015;9(08):898-904.
- 44. Maro I, Lahey T, MacKenzie T, et al. Low BMI and falling BMI predict HIV-associated tuberculosis: a prospective study in Tanzania. Int J Tuberc Lung Dis. 2010;14(11):1447-53.
- Melkamu H, Seyoum B, Dessie Y. Determinants of Tuberculosis Infection among Adult HIV
- Positives Attending Clinical Care in Western Ethiopia: A Case-Control Study. AIDS Res Treat.
- 2013;2013:279876.
- Kerkhoff AD, Wood R, Cobelens FG, et al. Resolution of anaemia in a cohort of HIV-infected
- patients with a high prevalence and incidence of tuberculosis receiving antiretroviral therapy in South
  - Africa. BMC Infect Dis. 2014;14:3860.
- Kerkhoff AD, Wood R, Cobelens FG, et al. The predictive value of current haemoglobin levels 47.
- for incident tuberculosis and/or mortality during long-term antiretroviral therapy in South Africa: a cohort
- study. BMC Med. 2015;13:70.
- Akanbi MO, Achenbach CJ, Feinglass J, et al. Tuberculosis after one year of combination
- antiretroviral therapy in Nigeria: a retrospective cohort study. AIDS research and human retroviruses.
- 2013:29(6):931-7.
- Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long 49.
- term incidence and risk factors in a South African cohort. Aids. 2005;19(18):2109-16.
- Hill PC, Jackson-Sillah D, Donkor SA, et al. Risk factors for pulmonary tuberculosis: a clinic-
- based case control study in The Gambia. BMC Public Health. 2006;6(1):156.

# Figure legends

- Figure 1: Flow chart showing selection of HIV/AIDS people at selected Governmental health
- facilities in Northeast Ethiopia, July 2010 to May, 2015
- Figure 2: Kaplan Meier curve of TB survival proportion of HIV/AIDS people at selected
- Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015
- Figure 3: Kaplan Meier survival curve of TB patients based on the BMI category among PLHIV
- at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015
- Figure 4: Kaplan Meier survival curve of TB patients based on the WHO stage among PLHIV at
- selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015
- Figure 5: Kaplan Meier survival curve of TB patients based on hemoglobin level among PLHIV
- at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015
- Figure 6: Kaplan Meier survival curve of TB patients based on the bed-ridden functional among
- PLHIV at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015
- Figure 7: Kaplan Meier survival curve of TB patients based on IPT use among PLHIV at
- selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015




Figure 1: Flow chart showing selection of HIV/AIDS people at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015




Figure 2: Kaplan Meier curve of TB survival proportion of HIV/AIDS people at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015

325x420mm (300 x 300 DPI)




Figure 3: Kaplan Meier survival curve of TB patients based on the BMI category among PLHIV at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015

325x420mm (300 x 300 DPI)




Figure 4: Kaplan Meier survival curve of TB patients based on the WHO stage among PLHIV at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015

325x420mm (300 x 300 DPI)




Figure 5: Kaplan Meier survival curve of TB patients based on hemoglobin level among PLHIV at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015




Figure 6: Kaplan Meier survival curve of TB patients based on the bed-ridden functional among PLHIV at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015

BMJ Open: first published as 10.1136/bmjopen-2017-016961 on 6 February 2018. Downloaded from http://bmjopen.bmj.com/ on April 9, 2024 by guest. Protected by copyright.




Figure 7: Kaplan Meier survival curve of TB patients based on IPT use among PLHIV at selected Governmental health facilities in Northeast Ethiopia, July 2010 to May, 2015

routinely collected health data.

v				RECORD items 5	
Title and abstrac	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
		(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	<ul> <li>Study design is indicated in the title and abstract sections (page 1 line-2 OR on page-2 line-4)</li> <li>Abstract section is informative and is indicated in page-2</li> </ul>	RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included.  RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract.  RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	The type of data which was retrospective cohort is given in the title and the abstract section (pages 1&2)  The geographical region (northeast Ethiopia) is mentioned in the title and abstract sections (pages 1 & 2)
Introduction				<u>9</u>	
Background rationale	2	Explain the scientific background and rationale for the investigation being reported	<ul> <li>Background/Introd uction section is presented on page-4</li> <li>Rationale of the study is mentioned on page-5 lines 13-</li> </ul>	rotected by copyright.	

				en	
			18	2017-0	
Objectives	3	State specific objectives, including any prespecified hypotheses	Objectives of the study are indicated on page-5 lines 17-20. In addition, it is also clearly mentioned in the abstract section on page-2 lines 13-16.	16961 on 6 February 2018. Downloaded	
Methods				<u>0</u> 0.	
Study Design	4	Present key elements of study design early in the paper	• Study design is found on page 5 lines 23-24.	from http://bi	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Study setting is stated on page-5 line 21 to page-6 line 2.	njopen.bmj.com/ c	
Participants	6	(a) Cohort study - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study - Give the eligibility criteria, and the sources and methods of selection of participants	Study population and eligibility criteria are found on page-6 lines 4- 13	RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in details. If this is not possible, an explanation should be provided.  RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.  RECORD 6.3: If the study involved linkage of databases, consider use of a	<ul> <li>The methods of data collection are on page 7</li> <li>The flow diagram indicating how the study subjects are selected is presented in figure 1.</li> </ul>

BMJ Open

 Page 32 of 37

		(b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed Case-control study - For matched studies, give matching criteria and the number of controls per case		flow diagram or other graphical display to demonstrate the data kinkage process, including the number of individuals with linked data at each stage.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.	<ul> <li>Measurement and study variables are presented on page-6, lines 14 to page -7 line-6</li> </ul>	RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported an explanation should be provided.
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement).  Describe comparability of assessment methods if there is more than one group	Data collection     tool and     procedure is     located on page-7     lines 22-30	m http://bmjopen.bmj.co
Bias	9	Describe any efforts to address potential sources of bias		m/ on
Study size	10	Explain how the study size was arrived at	Sample size     calculation and     procedure is     described on page-     7 lines 7-14	April 9, 2024 by guest.
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why		Protected by copyright
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to	Data processing     and analysis is     found on page-8,  p://bmjopen.bmj.com/site.	

			<b>→</b>	
Data access and cleaning methods  Linkage	examine subgroups and interactions (c) Explain how missing data were addressed (d) Cohort study - If applicable, explain how loss to follow-up was addressed Case-control study - If applicable, explain how matching of cases and controls was addressed Cross-sectional study - If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses	Data access and cleaning is found on page-7 lines 22-27	RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.  RECORD 12.2: Authors should provide information on the data geaning methods used in the study.  RECORD 12.3: State whether the study	<ul> <li>How the authors accessed data is stated in the data collection procedure (page-7)</li> <li>Information on data coding, entering and cleaning is given in the data processing and analysis sub-sections (page-8, lines 1-17)</li> <li>The study</li> </ul>
Linkage	••		The one 12.3. State whether the study	- The study
			included person-level, institutional-	

BMJ Open

 Page 34 of 37

					level, or other data linkage across two or more databases. The nethods of linkage and methods of hage quality evaluation should be provided.		setting is on page 5 lines 21 to page 6 lines 1-2
Results					<u>б</u>		
Participants	13	(a) Report the numbers of individuals at each stage of the study (e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram	•	Number of participants included in this study is indicated on page-8 lines 27-28 Flow diagram representing how study participants are presented on figure-1.	RECORD 13.1: Describe in detail the selection of the persons included in the study ( <i>i.e.</i> , study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagrams.	•	A flow diagram indicating the eligibility of study participants for the study is presented in a graph 1.
Descriptive data	14	(a) Give characteristics of study participants ( <i>e.g.</i> , demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time ( <i>e.g.</i> , average and total amount)	•	Descriptive data, including the socio-demographic and clinical factors are located from pages 8-11	bmj.com/ on April 9, 2024 by guest. Pr		
Outcome data	15	Cohort study - Report numbers of outcome events or summary measures over time  Case-control study - Report numbers in each exposure category, or summary measures of exposure  Cross-sectional study - Report		The outcome data (incidence of TB) is on pages 12-14	rotected by copyright.		

				en-:
		numbers of outcome events or summary measures		2017-01
Main results	16	(a) Give unadjusted estimates and, if applicable, confounderadjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	The adjusted estimates with 95% confidence interval are reported on page 16	16961 on 6 February 2018. Downloaded from http
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	None	://bmjopen.bi
Discussion		1		ا <u>ئے</u> : ۰۰
Key results	18	Summarise key results with reference to study objectives	The discussion section is presented on pages 17-19	om/ on April 9, 20;
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	The limitation of the study is pointed out on page 19 lines 12-22	RECORD 19.1: Discuss the implications of using data that were not created or collected to a swer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of	The conclusion section is on page 19 line 23 to page tp://bmiopen.bmi.com/site	byright.

BMJ Open

 Page 36 of 37

-						
		analyses, results from similar studies, and other relevant evidence	20 lines 1-9		017-01696	
Generalisability	21	Discuss the generalisability (external validity) of the study results	Since the study was conducted in a setting where more than 85% of HIV/AIDS patients are enrolled, we can generalize the finding to northeast Ethiopia		81 on 6 February 2018 Downlos	
Other Informatio	n					
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	<ul> <li>Funding information is on page 20 lines 20-</li> <li>21</li> </ul>		d from http://bmior	
Accessibility of protocol, raw data, and programming code			Data sharing statements are on page 20 lines 22- 23	RECORD 22.1: Authors information on how to a supplemental information study protocol, raw data, programming code.	cess any a such as the	Data collection procedure is on page-7 and data sharing statement is on page 24.

\*Reference: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Længan SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECOR) Statement. *PLoS Medicine* 2015; in press.

<sup>\*</sup>Checklist is protected under Creative Commons Attribution (<u>CC BY</u>) license.